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Abstract 
 
 
 Over 1.2 million Americans are currently living with a traumatic spinal cord injury (SCI). 
Despite the need for effective therapies, there are currently no proven effective treatments that 
can improve recovery of function in SCI patients. Many therapeutic compounds have shown 
promise in preclinical models of SCI, but all of these have fallen short in clinical trials.  
 P-glycoprotein (Pgp) is an active transporter expressed on capillary endothelial cell 
membranes at the blood-spinal cord barrier (BSCB). Pgp limits passive diffusion of blood-
borne drugs into the CNS, by actively extruding drugs from the endothelial cell membrane. Pgp 
can become pathologically up-regulated, thus greatly impeding therapeutic drug delivery 
(‘multidrug resistance’). Importantly, many drugs that have been evaluated for the treatment of 
SCI are Pgp substrates. We hypothesized that Pgp-mediated drug resistance diminishes the 
delivery and efficacy of neuroprotective drugs following SCI. 
 We observed a progressive, spatial spread of Pgp overexpression within the injured spinal 
cord. To assess Pgp function, we examined spinal cord uptake of systemically-delivered 
riluzole, a drug that is currently being evaluated in clinical trials as an SCI intervention. Blood-
to-spinal cord riluzole penetration was reduced following SCI in wild-type but not Pgp-null 
rats, highlighting a critical role for Pgp in mediating spinal cord drug resistance after injury. 
Others have shown that pro-inflammatory signaling drives Pgp up-regulation in cancer and 
epilepsy. We have detected inflammation in both acutely- and chronically-injured spinal cord 
vii 
 
tissue. We therefore evaluated the ability of the dual COX-/5-LOX inhibitor licofelone to 
attenuate Pgp-mediated drug resistance following SCI. Licofelone treatment both reduced 
spinal cord Pgp levels and enhanced spinal cord riluzole bioavailability following SCI. Thus, 
we propose that licofelone may offer a new combinatorial treatment strategy to enhance spinal 
cord drug delivery following SCI.  
 Additionally, we assessed the ability of licofelone, riluzole, or both to enhance recovery of 
locomotor function following SCI. We found that licofelone treatment conferred a significant 
improvement in hindlimb function that was sustained through the end of the study. In contrast, 
riluzole did not improve functional outcome. We therefore conclude that licofelone holds 
promise as a potential neuroprotective intervention for SCI.  
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Spinal Cord Injury:  Prevalence, Consequences, and Clinical Management 
 Spinal cord injury (SCI) can be fundamentally described as an event causing damage to the 
spinal cord, resulting in partial to complete loss of neurological function below the level of 
injury. SCI is a particularly devastating form of trauma for which no proven effective treatment 
is yet available; as a result, the majority of SCI patients suffer from lifelong paralysis and other 
functional impairments. Recently, the impact of SCI in the United States has been found to be 
greater than previously thought. In 2009, the Christopher & Dana Reeve Foundation’s Paralysis 
Resource Center published the largest, most comprehensive study of SCI and paralysis 
statistics in the U.S. in history (1). This report, the result of an exhaustive survey of more than 
33,000 American households, revealed that approximately 1,275,000 individuals (0.4% of the 
U.S. population) are currently living with SCI; a startlingly high figure compared to a previous 
estimate of 262,000 (2). Most cases of SCI result from accidental trauma; the most commonly 
reported causes of SCI are work-related accidents (28%), motor vehicle accidents (24%), and 
sporting or recreation accidents (16%) (1). The majority of injuries (80.8%) are sustained by 
males, and the average age at injury is 40.2 years (2). Notably, the cost of SCI is substantial, 
both to the individual—the estimated lifetime cost of SCI to a 25-year old patient is $3,273,270 
(2) —and to society. The financial burden incurred by SCI on the American health care system 
amounted to $40.5 billion in 2009, a figure that continues to grow (1).  
 SCI most often occurs when a ballistic insult to the spinal column results in a contusion 
and compression to the spinal cord (3, 4). However, SCI can also result from other forms of 
trauma such as penetrating injuries from stab or gunshot wounds, or non-traumatic events such 
as cancer, infection, or ischemia. SCI can be classified as solid cord injury, laceration, 
contusion/cavity-type injury, or massive compression (5). Furthermore, injury may occur at any 
level of the spinal cord, from the first cervical level to the conus medullaris and cauda equina. 
For these reasons, the resulting neurological deficits can vary dramatically from patient to 
patient. It is also partially because of its pathological diversity that SCI remains such a 
challenging condition for which to develop effective therapeutic treatments.  
 The physiological impact of SCI depends upon a number of factors. The location of injury 
largely determines the degree of function retained by the patient, with injuries to more rostral 
regions of the spinal cord typically resulting in the greatest degree of functional impairment 
(Fig. 1.1). An individual’s level of injury is determined by diagnostic imaging, such as MRI  
3 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
(On previous page) 
 
Figure 1.1.  Anatomy and innervation of the human spinal cord. (a) The human spinal cord 
is approximately 42-45 cm in length, and about 1 cm in diameter. The spinal cord is divided 
into 8 cervical segments (C1-C8), 12 thoracic segments (T1-T12), 4 lumbar segments (L1-L5), 
5 sacral segments (S1-S5), and 1 coccygeal segment (Co1). The spinal cord proper ends at 
approximately between vertebral levels L1 and L2, and is succeeded by the conus medullaris 
(L2-L5) and cauda equina (S1-S5). Spinal nerve roots at levels C7 and above exit the vertebral 
column above the corresponding vertebral body, and spinal nerve roots below C7 exit below 
the corresponding vertebra (6). (b) Dermatomes, the areas of skin innervated by each individual 
spinal nerve [adapted from (7)]. (Note that the face and head are innervated by the twelve 
cranial nerves, rather than the spinal nerves.) Injury to the spinal cord results in loss of 
sensation at and below the dermatome innervated by the spinal nerve at that level, as well as 
loss of motor control of muscles innervated by spinal nerves at and below the level of injury. 
(c) Cross-section of the spinal cord. Neuronal cell bodies are located in the gray matter, and 
ascending and descending axonal fiber tracts are located in the white matter. The central canal 
is filled with cerebrospinal fluid and extends the full length of the spinal cord. SCI can lead to a 
condition called syringomyelia, in which obstruction of the central canal results in the 
formation of a fluid-filled cyst (syrinx) which can cause adverse neurological effects. 
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and/or CT, in combination with a comprehensive neurological evaluation (3). SCI patients with 
high cervical injuries may lose function in all four limbs (tetraplegia). Patients receiving 
injuries above cervical level 5 (C5) often lose diaphragm function, thus forcing the patient to 
rely on a mechanical ventilator to breathe. Approximately 55% of injuries to the spinal cord 
occur at cervical levels, whereas injuries to the thoracic, lumbar, or sacral spinal cord levels are 
evenly distributed with each representing about 15% of all injuries (3). Injuries to more caudal 
spinal cord locations are generally associated with an improved prognosis compared to cervical 
SCI. However, injuries below cervical levels can still result in loss of sensory and motor 
function in the trunk and legs (paraplegia), bowel and bladder incontinence, and sexual 
dysfunction.  
 Severity of injury is the largest predictor of an SCI patient’s functional outcome (8). The 
majority of injuries are termed ‘incomplete’, with some degree of sensory or motor function 
retained below the level of injury; in a ‘complete’ injury, no below-level movement or feeling 
is retained at all (2). To assess the severity of injury, the patient undergoes neurological testing 
in which the degree of above- and below-level sensory function and muscle strength are 
evaluated. Injury severity is diagnosed according to the assessment criteria of the American 
Spinal Injury Association (ASIA) Impairment Scale (AIS)1 (7). According to AIS 
classification, a patient categorized as ASIA A has sustained a complete SCI, whereas a patient 
receiving an ASIA D or -E rating retains a relatively high level of function below the 
neurological level of injury (See APPENDIX A for ASIA Standards for Neurological 
Classification of SCI Worksheet). The specific functional deficits resulting from an injury to 
the spinal cord are determined by the particular motor and sensory pathways that are damaged 
(Fig. 1.2). Anatomically, a complete injury affects all ascending and descending spinal tracts, 
though not necessarily as a result of a complete spinal cord transection, with no axons 
traversing the injury site. A complete SCI can also result from chronic spinal cord compression  
                                                          
1
 While the ASIA Spinal Cord Injury Classification system has now been widely adopted as the standard 
motor and sensory assessment scheme for SCI patients, there also exist other functional ranking systems 
including the Modified Benzel Classification (9), the Walking Index for Spinal Cord Injury (WISCI) 
(10), and the Spinal Cord Injury-Functional Ambulation Inventory (SCI-FAI) (11). Additionally, the 
AIS does not score outcome measures such as bowel, bladder, and sexual function or degree of 
independence. Functional deficits of this nature may be assessed by rating systems such as the Spinal 
Cord Independence Measure (SCIM) (12), the Barthel Index (13), or the ASIA Autonomic Standards 
Assessment Form (APPENDIX A). 
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Figure 1.2.  Organization of spinal motor and sensory pathways. Cartoon depicting a cross 
section of the spinal cord, with the locations of select white matter spinal tracts and gray matter 
neuron pools highlighted and labeled (14). Left half illustrates the location of the lower motor 
neuron pools of the ventral horn (dark blue), and the sensory neurons of the dorsal horn (dark 
pink). Flexed arm cartoon in ventral horn illustrates the flexor-extensor rule: motor neurons 
innervating flexor muscles (e.g., biceps) are located more dorsal to those innervating extensor 
muscles (e.g., triceps); as well as the proximal-distal rule: motor neurons innervating distal 
muscles (hands) are located laterally, and motor neurons that innervate proximal muscles 
(shoulders) are located medially. Right half depicts the major descending motor pathways 
(light blue) and ascending sensory pathways (light pink) of the spinal cord white matter 
columns. The corticospinal tract (CST) is comprised of fibers originating from cortical motor 
neurons and synapsing on lower motor neurons of the ventral horn (dark blue). Fibers of the 
lateral corticospinal tract (90% of CST axons) control the distal musculature, including fine 
control of the hands and fingers, and the ventral corticospinal tract (remaining 10% of CST 
axons) carries fibers that innervate proximal musculature. The ventral spinocerebellar tract 
conveys information about joint position (proprioception) to the cerebellum, and plays an 
important role in coordination. The lateral spinothalamic tract is a major conduit for pain and 
temperature sensation. The dorsal column of the spinal cord contains the fasciculus gracilis and 
fasciculus cuneatus, which transmit fine touch, vibration, and proprioceptive information from 
spinal levels below and above spinal level T6, respectively. Orientations of human silhouettes 
indicate neuronal layering, in which fibers within a tract (or neurons in a pool) are organized in 
layers corresponding to the order in which fibers are added to or exit the tract along the rostral-
caudal axis. 
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or ischemia due to loss of blood supply, and in these cases function can be recovered by 
removing decompression or reperfusion, respectively (15). In contrast, an incomplete SCI only 
partially damages the spinal cord at the level of injury, damaging some spinal tracts and sparing 
others. Incomplete injuries may be described as one of five ‘classical’ clinical syndromes (Fig. 
1.3), collections of common functional deficits attributed to generally similar patterns of 
damage to spinal cord tracts (7). For example, unilateral damage to the spinal cord generally 
leads to loss of ipsilateral motor function and contralateral sensory function, similar to that 
observed following lateral hemisection in Brown-Séquard syndrome (See Fig. 1.3 for a 
description of this syndrome). However, spinal injuries are highly heterogeneous, and an 
individual’s degree of functional impairment is always assessed on a case-by-case basis. The 
ASIA grading system is at best a rough classification of injury severity, and a patient’s ASIA 
score upon initial evaluation is not a reliable predictor of his or her recovery trajectory2. In 
general, in SCI patients with incomplete injuries, the extent of function that is eventually 
recovered is inversely proportional to the severity of injury; in other words, the greater the 
initial neurological deficit, the less function the patient can expect to regain (17). 
 
Physiological Consequences of Spinal Cord Injury 
 Perhaps the most recognizable functional deficit resulting from SCI is paralysis, which 
results from damage to the descending spinal motor tracts and/or lower motor neurons of the 
spinal cord. Paralysis is one of the principal factors affecting quality of life for the majority of 
SCI patients. According to the 2009 Christopher & Dana Reeve Foundation’s Paralysis 
Resource Center report, 48% of individuals with paralysis resulting from SCI report “a lot of 
difficulty” or “complete inability” moving (1). The degree of motor function lost due to SCI 
depends on the spinal motor pathways affected by injury. For example, damage to the lateral 
corticospinal tract (CST), the major motor pathway allowing fine motor control of the 
extremities, will impact an individual’s ability to perform tasks requiring manual dexterity,  
                                                          
2
 This is particularly true due to the effects of spinal shock, a transient phenomenon occurring in the first 
days to weeks following injury to the spinal cord. Spinal shock may be defined as a reduction or 
absence of spinal reflexes below the injury level that are gradually recovered (16). The precise etiology 
and physiological significance of spinal shock are not yet clear. 
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Figure 1.3.  Clinical syndromes associated with incomplete spinal cord injury. The 
American Spinal Injury Association (ASIA) has described five clinical syndromes commonly 
exhibited by patients with an incomplete SCI (7). Each of these conditions can be identified by 
its set of common functional deficits; in each syndrome, a conserved pattern of tissue damage 
results in a unique array of neurological symptoms due to the organization of fiber tracts in the 
spinal cord. The most common of these, central cord syndrome (left), is often a result of 
hyperextension injury. This condition is characterized by significant muscle weakness in the 
arms and hands (upper limbs) with a smaller degree of impairment in the legs and feet (lower 
limbs). The functional deficits in central cord syndrome are due to neuronal layering in the 
spinal cord gray matter.  Anterior cord syndrome (middle) results most often from a loss of 
blood supply from the anterior spinal arteries, which supply the anterior two-thirds of the spinal 
cord. This type of injury spares the dorsal spinal columns, thus preserving below-level sense of 
light touch and proprioception; however, below-level motor function and at- and below-level 
pain and temperature sensation is lost. Brown-Séquard syndrome (right) results from a lateral 
hemisection of the spinal cord, resulting in 1) loss of below-level motor control, proprioception, 
and sense of vibration on the ipsilateral side, 2) contralateral loss of below-level pain and 
temperature sensation, and 3) total at-level sensory loss on both sides (resulting from at-level 
sensory fiber decussation). Not pictured: Cauda equina syndrome, which results from damage 
to the lower motor neurons of the lumbosacral nerve roots, causing flaccid paralysis of lower 
limb muscles and loss of bowel and bladder reflexes; conus medullaris syndrome, damage to 
the conus medullaris (L1-L2), which results in similar functional deficits to cauda equina 
syndrome. 
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such as writing, picking up a fork, or carrying out personal hygienic routines. This type of 
functional impairment can be devastating, as it dramatically decreases a person’s degree of 
independence and quality of life. In a 2004 survey in which tetraplegic SCI patients ranked the 
abilities that would most dramatically improve their quality of life if regained, 48.7% rated 
regaining arm and hand function as most important, in comparison, only 7.8% of respondents 
ranked regaining walking ability as most important (18).  
 Following damage to spinal motor tracts, spared parallel descending pathways can recover 
a modest degree of lost motor function, generally for coarse, voluntary movements. 
Approximately 41% of SCI patients experience some degree of spontaneous neurological 
recovery within the first year following injury (19). However, fine motor control cannot be 
recovered unless spared CST axons undergo compensatory sprouting (20), or severed CST 
axons regenerate across the lesion (21), to a sufficient enough extent to have a significant 
functional impact. Despite limited functional recovery, the lack of extensive regenerative CST 
growth following injury generally results in permanent loss of fine control of the extremities 
(6). Restoring even partial function to tetraplegic patients is therefore a highly desirable goal, 
and the development of novel therapies to promote CST regeneration remains a major objective 
in SCI research (22).  
  SCI can also affect the autonomic nervous system; depending on the type of injury, a 
patient may experience bowel, bladder, and sexual dysfunction. In fact, regaining sexual 
function was ranked as the highest priority by the greatest percentage of surveyed SCI 
paraplegics (26.7%), followed closely by improved bowel and bladder function and eliminating 
autonomic dysreflexia (18%) (18). Neurogenic bladder resulting from SCI can perhaps be best 
understood as “failure to store” and/or “failure to empty” urine due to dysfunction of the 
urinary sphincters (23). Complications resulting from neurogenic bladder are injury-specific 
but very frequently lead to upper and lower urinary tract infections, which usually plague the 
SCI patient throughout his or her lifetime. Bowel dysfunction resulting from SCI is also 
complex and depends on the type of injury. Patients may suffer from debilitating constipation 
as well as the humiliation of accidental bowel incontinence (24). Individuals with impaired 
bowel function must follow personalized bowel management regimens, which can be 
incredibly time-consuming and difficult to manage (23). Moreover, approximately 36% of 
those living with SCI require assistance with bowel care, a socially agonizing experience that 
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can severely detract from quality of life (25). Men with SCI commonly experience erectile and 
ejaculatory dysfunction as well as infertility (26), whereas female SCI patients may suffer from 
impaired sexual arousal and anorgasmia (27). The most potentially life-threatening 
complication of SCI is autonomic dysreflexia, a condition that can occur in patients with 
injuries above spinal cord level T6, the location of the splanchnic outflow (a major sympathetic 
output) (28). In autonomic dysreflexia, strong, below-level afferent sensory input, such as tight 
clothing, an overfilled bladder, or an ingrown toenail, is unable to travel past the spinal lesion 
site, and as a result it stimulates neurons in the sympathetic ganglia. The major reflex 
sympathetic response that results causes a sudden, significant vasoconstriction below the level 
of SCI; this response runs unopposed by the parasympathetic system which lies above the level 
of injury. The exaggerated, hyperreflexive sympathetic response is characterized by extreme 
hypertension, bradycardia, sweating, headaches, and anxiety (29). If the sensory stimulus is not 
removed, the sympathetic reflex response will continue to increase in the presence of persistent 
input; this can lead to seizures, hemorrhage, and death (28). 
 In addition to these serious consequences of SCI, patients also frequently suffer from 
uncontrolled muscle spasticity (29), chronic neuropathic pain (30), and a systemic 
inflammatory response that impacts peripheral organs including the lungs and kidneys (31), 
liver (32), bladder (33), and testes (34). A recent clinical study reported that the majority of 
acute traumatic SCI patients experience multiple organ failure (35). Life expectancy of SCI 
patients varies with severity of injury, age at injury, and time since sustaining the injury; 
however, life expectancy for those with SCI is universally lower than that for uninjured persons 
(2). Currently, the causes of death that most greatly impact life expectancy for SCI patients are 
pneumonia, septicemia and pulmonary embolism (2). Clearly, the field of translational SCI 
research is an area with multiple unmet needs for therapeutic intervention. 
 The culmination of the myriad of complications experienced by SCI patients is a 
dramatically reduced quality of life. SCI is a complex condition that profoundly impacts not 
only multiple aspects of physical health, but psychological and social well-being as well. 
Researcher Kim D. Anderson of the University of California Reeve-Irvine Research Center 
summarizes the difficulties faced by those living with SCI: 
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What constitutes quality of life? That is a very subjective question because people 
value different things. After a spinal cord injury, many things are lost …. Being 
paralyzed is so much more than not being able to walk. Physiologically, there are 
severe impairments in bladder, bowel, cardiac, respiratory, sensory, and sexual 
function. Socially, relationships are difficult to maintain, and reintegration into 
society is quite challenging. Financially, initial and long-term medical costs are 
extremely burdening and, unfortunately, large proportions of people living with 
paralysis are not able to return to full-time work and, thus, are dependent upon state 
and federal assistance. Psychologically, the loss of a “normal” life can be devastating 
for months or years depending upon the person, and this can result in further 
physiological, social, and financial problems. All of these issues factor in definitions 
of the quality of life. [emphasis added] (18)  
 
Clinical Management of Spinal Cord Injury 
 SCI is a form of acute trauma that must be managed in a careful, timely, and judicious 
manner in order to optimize patient outcome. Surgical intervention is needed to remove 
fractured bone or disc fragments compressing the spinal cord tissue (decompression) and to 
realign and stabilize the vertebral column (36). Though the optimal timing for surgical 
decompression has been debated, it is currently believed that surgery should ideally be 
performed between 8 and 24 hours after SCI (37). Once in the clinic, most acute SCI patients 
are first subjected to a comprehensive preoperative evaluation, unless decompressive surgery is 
deemed emergent (38). This evaluation includes a medical history, complete neurological 
sensory and motor evaluation, assessment of autonomic and cardiovascular dysfunction, 
laboratory blood tests, electrocardiogram, and diagnostic imaging (39). In addition, there is a 
considerable possibility that the trauma producing SCI has also resulted in injury to other vital 
organs, e.g., the brain or liver; thus, a full physical evaluation must be performed. Such 
thorough medical evaluations are critical in determining outcome due to the potential 
importance of systemic factors, for example, hemodynamic stability, on spinal cord perfusion 
(39). Following preoperative evaluation, the patient may be administered medications such as 
antibiotics, anxiolytics, or agents to promote gastrointestinal (GI) motility, depending on the 
circumstances. After spinal surgery, the median length of acute-care hospitalization for an SCI 
patient is about twelve days (2). 
 There are currently no proven effective, FDA-approved interventions that can improve 
functional outcome if administered to an acute SCI patient. However, if patients meet the 
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inclusion criteria for a currently enrolling clinical trial, they may be presented with the option 
of receiving an experimental treatment. Due to some clinical studies demonstrating modest 
functional improvement if administered within eight hours of injury, many hospitals have 
historically administered high-dose methylprednisolone sodium succinate (MPSS), a synthetic 
anti-inflammatory corticosteroid, for acute SCI patients (19). However, the use of MPSS has 
now dramatically declined due to the considerable negative side effects associated with high-
dose steroids, as well as mounting criticism surrounding the clinical trials reporting its 
therapeutic benefits (40, 41). A 2006 survey revealed that only 24% of spinal surgeons believed 
MPSS improved patient outcome and that in fact, most surgeons continued to administer the 
drug primarily out of a fear of litigation (42). 
 For SCI patients with incomplete, sub-acute (weeks) or chronic (months) injuries, physical 
rehabilitation may be a useful tool to improve functional recovery. Studies of body weight-
supported treadmill training indicate that gait rehabilitation produces a modest improvement in 
patients with chronic SCI (43). The average patient with a motor incomplete SCI generally 
spends between five and six weeks in a clinical rehabilitation unit subsequent to leaving an 
acute care facility (2). After completing rehab, however, SCI patients are far from finished with 
medical care. During the chronic phase of injury, a plethora of medical complications may 
arise; each year, 30-50% of all individuals with SCI will be readmitted to the hospital (2). 
These patients are at particularly high risk for complications such as urinary tract infections, 
respiratory disease, pressure sores, and circulatory problems, all of which can be life-
threatening if untreated (2). In addition, SCI patients will likely require regular follow-up 
medical care; for example, to assess efficacy of pain and spasticity medications, to evaluate 
whether adjustments need to be made to bladder or bowel programs, and to receive routine 
neurological and psychological evaluations. As a result, the lifetime cost of SCI-associated 
medical care can be as high as $4 million (2). 
 
Experimental Models of Spinal Cord Injury 
 The inherent complexity of the molecular and cellular pathophysiology of SCI requires the 
use of experimental animal models in SCI research. These in vivo models are critical tools for 
evaluating the effects of experimental treatments on complex physiological processes like 
axonal regeneration, and examining clinically relevant outcome measures such as locomotor or 
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neurosensory function. Since human SCI is a highly heterologous condition with many 
variables affecting outcome, selection of the appropriate experimental model can be 
challenging for SCI researchers. Furthermore, the myriad of anatomical, behavioral, and 
pathophysiological differences between humans and laboratory animals can limit experimental 
studies in a variety of ways. Regardless, experimental animal models are invaluable in the 
ongoing search for effective new therapies for SCI (6). 
 The most common cause of SCI in human patients is contusion and/or compression injury 
(4), and a variety of animal models have been developed to approximate human contusion 
injury pathology (44). One of the most frequently used models is the weight-drop model of 
SCI, such as the NYU Spinal Cord Injury Device (45), which entails dropping a calibrated 
weight from a defined height onto the exposed spinal cord, resulting in a rapid and controlled 
displacement of spinal cord tissue (45, 46). Another common contusion injury model utilizes a 
mechanical impactor, such as the Ohio State University Electromechanical Spinal Cord Injury 
Device (47) or the Infinite Horizon Spinal Impactor Device (48), to deliver a rapid force-
controlled contusion to the exposed spinal cord. A review of the various experimental 
contusion/compression injury models emphasizes the importance of consistency in force and 
displacement parameters in producing reproducible histological and behavioral outcomes (49). 
Though spinal contusion injury models are frequently used due to their approximation of 
human spinal contusion pathology, models of spinal cord transection and hemisection are also 
frequently utilized in SCI research. In an experimental transection model, the spinal cord is 
completely severed via a scissor or blade; in a hemisection model, either the dorsal or lateral 
half of the spinal cord is incised at one or more spinal levels (47). Though complete transection 
of the spinal cord is a relatively rare occurrence in humans, these models have a particular 
utility for investigating the mechanisms of SCI pain (50), regeneration of CST axons (51, 52), 
or to kindle a more hospitable environment for the introduction of therapeutic stem cells, which 
can be sensitive to the high levels of inflammation associated with contusion/compression 
injuries (47, 52-54). Dorsal hemisection models are useful for the study of discrete lesions of 
motor or sensory pathways; this type of injury usually leaves gray matter intact, allowing the 
researcher to assess the suitability of gray versus white matter for regenerative or plastic growth 
(47). Lateral hemisection models are suitable for assessing the ability of spared pathways on 
the contralateral uninjured half of the spinal cord to sprout and/or contribute to recovery of 
function (47). 
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  Experimental animals are also useful for modeling injuries that produce different types of 
neurological deficits. Contusion/compression models can be tailored to produce mild, 
moderate, or severe injuries, which are associated with increasing degrees of impairment in 
neurological and motor recovery (55). Additionally, selecting the location of injury in animal 
models allows the experimenter to examine specific behavioral outcome measures. Cervical 
SCI models result in loss of fine motor control and ability to perform tasks requiring forelimb 
dexterity, while preserving normal hindlimb function (6). Models of cervical injury are 
frequently utilized to investigate the efficacy of treatment on CST regeneration by examining 
performance in fine motor tasks. In contrast, thoracic injury models produce hindlimb 
functional deficits, and as such are best suited for evaluating parameters such as locomotor 
recovery and the development of neuropathic pain (56). Whereas animals with cervical injuries 
of sufficient severity can lose their ability to ambulate and feed, animals with thoracic injuries 
retain full use of the forelimbs and can still perform these functions. Because of the 
significantly greater amount of post-operative animal care needed with cervical injury models, 
thoracic injury models are generally more practical to the researcher. 
 The vast majority of experimental SCI studies utilize rats and mice. The advantages of 
rodent models, aside from the relatively low cost and ease of experimentation, include the 
abundance of reproducible rodent SCI models, the relative homogeneity of genetic background 
and the ease of genetic manipulation, and the wealth of sensitive behavioral assessments 
developed for mice and rats. Rodent models are useful in optimizing the parameters of delivery 
for, or assessing the potential harmful side effects of, a novel or exploratory therapy (57). 
Rodents have been used extensively to assess the potential neuroprotective benefits of novel 
treatments for SCI, and rodent studies have also led to great gains in knowledge of the 
pathophysiology of SCI. However, there are key disadvantages to relying upon rodent models. 
First, there are key differences in the pathophysiology of SCI between mice, rats, and humans 
(6, 58-60). For example, the cellular inflammatory process exhibited by rats is different than 
that of humans, and is better modeled using nonhuman primates (61). Perhaps the most obvious 
disadvantage is the discrepancy between the nervous systems of rodents and humans, both in 
size and in the anatomy of neural networks (6). Large animals offer an advantage in that axonal 
regeneration must occur over a larger distance within the spinal cord, similar to humans (57). 
Additionally, because neuroanatomical tract distribution is different in bipeds and quadrupeds, 
15 
 
the regenerative growth and locomotor recovery of bipedal nonhuman primates following SCI 
are more clinically relevant than those of quadrupedal rodents (6, 61). 
 It is clear that rodent models alone are inadequate for assessing the safety and efficacy of 
novel therapies. Treatments exhibiting efficacy in rodents must subsequently be validated in 
large animal models, such as pigs or nonhuman primates, before translation to clinical trials. 
Recently, Levine and colleagues have pointed to the naturally occurring canine disorder of 
thoracolumbar intervertebral disk herniation as a useful model of large animal SCI, providing 
an alternative to nonhuman primates for the validation of therapies (62). Other models of large 
animal SCI, such as pigs (63) and felines (64), have also historically been used in experimental 
research studies. Ultimately, the choice of experimental animal utilized must be based on a 
careful consideration of many factors, including the nature of the research question being 
investigated or the intervention being tested, and the suitability of the animal model in 
addressing those questions. 
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Molecular and Cellular Pathophysiology of Spinal Cord Injury 
 Contusion injury, such as that occurring when a fractured disc impinges into the spinal 
cord tissue secondary to fracture-dislocation or burst fracture of the spinal column, represents 
the most common type of SCI (3). This type of traumatic SCI is characterized by a biphasic 
pattern of injury (Fig. 1.4). The immediate mechanical insult (primary injury) is a direct result 
of acute contusion and/or compression of the spinal cord tissue by displaced disc or bone 
fragments. Immediately, there is disruption of the vasculature causing hemorrhage, substantial 
cell death within the gray matter due to both the actual mechanical force of impact as well as 
ischemic insult, generation of a necrotic epicenter of injury, and mechanical shearing of axons 
in the white matter (3, 6, 65). The primary insult to the spinal cord sets into motion a 
prolonged, expanding wave of secondary injury, which can best be described as a cascade of 
pathological cellular and molecular processes that contribute to further tissue death and 
degeneration during sub-acute and chronic injury (6). A central goal of current SCI research is  
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Figure 1.4.  Timeline of pathological secondary injury processes following spinal cord 
injury. (a) Cartoon depiction of an uninjured spinal cord, illustrating the presence of normal, 
healthy myelinated axons and gray matter. (b) Traumatic injury to the spinal cord results in an 
immediate death of neurons in the gray matter, thereby generating a necrotic epicenter of 
injury. This cell death is caused by both force of impact to the cell bodies, and hemorrhagic and 
ischemic insult due to mechanical disruption of the microvasculature. The large blood vessels 
on the spinal cord surface are more resistant to physical damage as a result of contusion injury. 
However, disruption of the spinal cord blood supply via occlusion of the spinal arteries leads to 
gray matter infarction, and subsequent reperfusion of the ischemic tissue results in the 
generation of cytotoxic free radicals, exacerbating injury (65). The mechanical force of the 
primary injury also instantly severs axonal fibers within the white matter of the cord; however, 
the primary injury causes considerably more damage to the gray matter with relative sparing of 
the peripheral white matter. Within minutes, activated microglia accumulate at the site of injury 
and begin to secrete cytotoxic factors including pro-inflammatory cytokines (66). (c) In the 
days to weeks following SCI, secondary injury processes continue to shape pathological 
changes to the injured spinal cord. Within hours, there is a massive invasion of neutrophils 
from the bloodstream, producing free radicals and pro-inflammatory cytokines. The first few 
days to weeks after injury are characterized by: accumulation of activated microglial cells and 
invasion of peripheral macrophages/monocytes that also secrete pro-oxidative and pro-
inflammatory factors; healing of the damaged BSCB; axonal degeneration; and proliferation of 
glial cells that begin to form the glial scar (67). (d) Several weeks to months post-SCI, there is 
deposition of components of the extracellular matrix that cause inhibition of axonal 
regeneration. During this time, the glial scar also stabilizes around the cystic cavity that forms 
at the epicenter, presenting an additional barrier to regrowth of axons. Demyelination and 
degeneration of axons in and surrounding the injury site cause the spinal cord to atrophy due to 
loss of white matter volume (68). Furthermore, there is T cell invasion and chronic macrophage 
activation in the injured cord that may last months to years (69, 70).  
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to develop a better understanding of the complex pathophysiology of secondary injury, in order 
to identify and target the molecular mechanisms contributing to cell death (71). 
 The earliest aspects of the secondary injury cascade can be largely attributed to a massive 
influx of cytotoxic substances into the spinal cord tissue in the minutes to hours following 
injury, a direct result of the cellular damage and vascular disruption caused by the primary 
insult (65). Early events in the initial pathological cascade include extracellular accumulation 
of excitotoxic neurotransmitters, oxidative stress resulting from free radical formation and lipid 
peroxidation, ionic imbalance, edema formation, and an infiltration of immune cells that secrete 
cytotoxic factors such as cytokines and chemokines, free radicals, pro-inflammatory lipid 
mediators, and proteases (65, 71). Each of these in turn activates downstream intracellular 
signaling pathways, resulting in further cell death and demyelination in the acutely injured 
spinal cord (68). Diffusible factors such as cytokines also serve to recruit additional immune 
cells into the injured cord for days to weeks following injury, thus perpetuating the secondary 
injury pathology further. Furthermore, inflammation mediates a progressive opening of the 
blood-spinal cord barrier (BSCB), allowing inflammatory immune cells and cytotoxic factors to 
permeate into the cord (72). These pathological events are not simply confined to the acute 
phase; apoptosis, demyelination, BSCB breakdown, and axonal degeneration have been shown 
to continue into the chronic phase, weeks to months following SCI (73-76). Clearly, the process 
of secondary injury is extraordinarily complex, and as such is not fully understood.  
 Many drug compounds that have been evaluated as potential therapeutics for preclinical 
and clinical SCI are intended to target the early components of secondary injury, with the goal 
of attenuating the destructive cascade as early as possible and protecting the spinal cord from 
further secondary injury-induced damage (77). One such drug, riluzole, is a neuroprotective 
compound that has to date been evaluated in nine experimental studies as a potential SCI 
intervention (78-86), and is currently being evaluated in a Phase I clinical trial as an acute 
intervention for human SCI patients (87). Riluzole exerts an anti-glutamatergic effect by both 
blocking voltage-sensitive Na+ channels and attenuating Ca2+-dependent presynaptic glutamate 
release, thus protecting neurons against excitotoxic cell death (88, 89). Interest in riluzole as a 
treatment for SCI originated because of the central role of excitotoxicity in early secondary 
injury, as well as the fact that riluzole is already FDA-approved for treatment of the 
neurodegenerative disease amyotrophic lateral sclerosis (ALS), thus making it a highly 
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translatable drug for clinical SCI studies (89). Other neuroprotective compounds that have been 
evaluated in SCI clinical trials include MPSS (90), the neuronal membrane component 
monosialoganglioside GM-1 (91), and the tetracycline antibiotic minocycline (77). 
Unfortunately, clinical trials in SCI patients have thus far failed to produce any statistically 
significant functional improvements, with the dubious exception of MPSS3 (96). Despite the 
failure to translate neurological benefits in preclinical studies to human SCI patients, preclinical 
evaluation of neuroprotective compounds continues to push forward in the hope of finding a 
novel effective therapy.  
 
Role of Inflammation in Spinal Cord Injury Pathophysiology  
 Inflammation is the endogenous, multifaceted physiological response to injury or disease, 
and it encompasses a host of molecular and cellular processes with complex, diverse effects on 
the different tissues and organ systems in the body (97). Inflammation is one of the major 
forces in the secondary injury cascade, and as such, plays a central role in the 
pathophysiological processes that occur in the acutely injured spinal cord (98). Components of 
the molecular and cellular inflammatory response drive a host of adverse pathological events 
following SCI, such as cell death (98), disruption of the BSCB (72), generation of the glial scar 
(99, 100), and sensitization of neural pathways leading to neuropathic pain (30). For this 
reason, attenuating inflammation following SCI has been viewed as a promising therapeutic 
strategy for decades, and to date researchers continue to investigate the efficacy of anti-
                                                          
3
 The clinical studies leading to the widespread of the steroid MPSS as an acute SCI intervention are 
controversial (40, 92). This is chiefly due to the fact that those studies reporting its neurological benefits 
exhibited statistical significance only when subjected to extensive post-hoc analysis. NASCIS I, a large, 
randomized multicenter clinical trial (1979-1984), showed no benefit of acutely (<12 hours post-SCI) 
administered MPSS over the opioid antagonist drug naloxone or placebo in improving neurological 
outcome up to one year post-injury (93). A subsequent study, NASCIS II (19, 94), was conducted to 
evaluate the efficacy of a much higher dose of MPSS for acute SCI. NASCIS II, like NASCIS I, failed 
to show any overall neurological improvement in patients receiving MPSS. However, a post hoc 
analysis detected a small gain in functional outcome of a small subgroup of patients who received the 
drug 3-8 hours post-injury. As a direct result of this finding, the high-dose MPSS infusion tested in 
NASCIS II quickly became a standard of care for acute SCI in many clinical settings throughout the 
world, despite the failure of subsequent clinical studies to replicate these findings (92). Today, MPSS is 
widely considered to be ineffective for improving function in acute SCI patients; moreover, the harmful 
side effects of high-dose steroid treatment actually make MPSS a dangerous clinical approach for acute 
SCI (40, 41, 95). 
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inflammatory treatment as a neuroprotective intervention for SCI. However, the cellular 
inflammatory response is also extraordinarily complex, and paradoxically, it alters the local 
environment in ways that both foster and discourage regenerative regrowth (101). 
  Injury to the spinal cord invokes a complex cellular response involving several different 
immune cell types. There is an invasion of peripheral circulating immune cells (i.e., 
neutrophils, dendritic cells, and macrophages) into the injured spinal cord, as well as 
widespread activation of resident microglial cells (102). The major activities of these immune 
cells include phagocytosis of cellular debris, presentation of degraded peptides to helper T-
lymphocytes, secretion of pro-inflammatory cytokines, chemokines, and growth factors, and 
free radical production (102). The dual nature of the effect of inflammation in the injured spinal 
cord microenvironment becomes apparent upon examining the multifaceted role of activated 
microglia (103). Following injury, activated microglial cells release factors, such as glial cell 
line-derived neurotrophic factor and transforming growth factor-beta1 (TGF-beta1), that 
promote neurite growth and survival (104). In contrast, these cells also produce pro-
inflammatory cytokines and reactive oxygen species (ROS) that promote neuronal cell death 
and secrete proteoglycans that are inhibitory to neurite growth (66). These diverse functions of 
microglia and other immune cell types underlie the complexity of the inflammatory response 
and its duality in promoting both tissue damage and repair after SCI.  
 Historically, much attention has been focused on the potential of immunosuppressive 
therapies to improve functional recovery after SCI, an initiative that has been largely motivated 
by the desire to combat immune cell-mediated tissue damage in the injured spinal cord (102). 
However, as more information has been gained about the intricate forces contributing to tissue 
damage and tissue repair following SCI, it has become increasingly apparent that more targeted 
therapies must be developed. These therapies must be able to attenuate the destructive effects 
of the cellular immune response, such as secretion of cytotoxic factors, while preserving the 
processes that enhance repair and regrowth, such as clearance of cellular debris and secretion of 
growth factors. This type of therapeutic goal will be achieved by specifically inhibiting the 
intracellular signaling cascades that mediate tissue-destructive effects within the injured spinal 
cord; one particularly important target is pro-inflammatory signaling. One of the hallmarks of 
the acute inflammatory response after SCI is the oxidative metabolism of arachidonic acid  
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Figure 1.5.  Phospholipase A2 activation and oxidative arachidonic acid metabolism 
mediate secondary neuronal injury in the injured spinal cord. Injured spinal cord tissue is 
an environment rich in neuroinflammation and excitotoxicity. Under these conditions, high 
levels of pro-inflammatory cytokines, reactive oxygen species (ROS), and excitatory amino 
acids lead to activation of the lipolytic enzyme phospholipase A2 (PLA2). When PLA2 becomes 
activated, it hydrolyzes membrane-bound phospholipids into the free polyunsaturated fatty 
acid, arachidonic acid (AA), which in turn is metabolized by cyclooxygenase (COX-1/2) and 5-
lipoxygenase (5-LOX) enzymes into the potent pro-inflammatory mediators, the prostaglandins 
and the leukotrienes, respectively. These bioactive eicosanoids, along with ROS produced via 
oxidative AA metabolism, contribute to further neuronal injury and tissue damage within the 
injured spinal cord. This pro-inflammatory cascade is a major and destructive component of the 
secondary injury process following SCI. Pharmacotherapies targeting multiple elements of this 
signaling network have been evaluated extensively in preclinical and clinical SCI studies. 
These include the PLA2 inhibitor GM1 ganglioside, COX inhibitors such as ibuprofen and 
naproxen, the 5-LOX inhibitor zileuton, as well as the cysteinyl leukotriene (CysLT) receptor 
antagonist montelukast. 
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(AA). This cascade is triggered by the activation of the phospholipase A2 (PLA2) family of 
lipolytic enzymes (Fig. 1.5). The PLA2 family contains the isoforms cytosolic PLA2 (cPLA2), 
Ca2+-independent PLA2 (iPLA2) and secretory PLA2 (sPLA2), and each are activated 
differentially by Ca2+ and/or phosphorylation (105). All classes of PLA2 isoforms are known to 
be expressed in the spinal cord, though their individual roles following injury have yet to be 
fully understood (106). It is known that PLA2 activation begins within a few minutes after SCI 
and sets into motion a variety of downstream events promoting inflammation and oxidative 
stress, thus exacerbating neuronal injury and spread of secondary pathology (107). Thus, PLA2 
and its downstream effectors are critical elements driving the acute SCI pathological cascade, 
making them a major target for neuroprotective therapies. 
 PLA2 activation, one of the earliest events in the neuroinflammatory process following 
SCI, is induced largely by activated microglia that accumulate at the site of injury within 
minutes (108). These activated microglia secrete free radicals and pro-inflammatory cytokines 
such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), resulting in 
increased neuronal PLA2 expression and activation (105, 107). Excitatory amino acids, released 
by cellular membrane damage upon injury, further induce PLA2 activation (105). Activated 
PLA2 exerts a hydrolytic activity on membrane phospholipids within the injured tissue, 
releasing the polyunsaturated omega-6 fatty acid, AA. The enzymes cyclooxygenase (COX)-1 
and COX-2, and 5-lipoxygenase (5-LOX), which are also stimulated by SCI (108, 109), 
catalyze rate-limiting steps in the conversion of AA into the bioactive eicosanoids, 20-carbon 
lipids that are potent mediators of inflammation and secondary injury. High levels of ROS are 
also produced during this process of oxidative AA metabolism. These free radicals contribute 
to further neuronal damage, exacerbate the cellular inflammatory response, and promote 
upstream PLA2 activation, thus perpetuating the secondary injury cascade (107).  
 Because the PLA2 pro-inflammatory signaling network plays such an early and central role 
in SCI secondary pathology, various groups have evaluated the therapeutic potential of 
inhibiting PLA2 family members. Michael-Titus and colleagues demonstrated that inhibiting 
both cPLA2 and iPLA2 enzyme activity shortly following SCI in rats conferred some 
neuroprotection (110). In addition, there is much preclinical evidence indicating the 
neuroprotective benefits of the gangliosides, inhibitors of intracellular PLA2 (111), though 
clinical studies examining the efficacy of gangliosides for acute SCI have not seen therapeutic 
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benefits in human patients (91). Until recently the specific contributions of the different PLA2 
isoforms to SCI pathology have been unclear. López-Vales et al. demonstrated that in mice, 
blocking all three PLA2 isoforms actually inhibits recovery; interestingly, the cPLA2 GIVA 
isoform was shown to exert a tissue-protective effect (106). These findings demonstrate that a 
deeper understanding of the divergent roles of PLA2 isoforms within the injured spinal cord is 
needed in order to develop more effective, targeted therapies. In fact, the majority of 
investigations have not focused on PLA2, but rather on the therapeutic potential of targeting 
downstream components of this network, such as COX signaling.  
 
Cyclooxygenase and Lipoxygenase in Spinal Cord Injury 
 COX-1 and COX-2 are the rate-limiting enzymes in the biological pathway converting AA 
into the prostanoids—the prostaglandins, thromboxanes, and prostacyclin (Fig. 1.6). Activity of 
COX-1 and -2 is inhibited by classical non-steroidal anti-inflammatory drugs (NSAIDs), a class 
of nonselective COX inhibitors that includes such commonly used drugs as aspirin and 
ibuprofen (112). Structurally and functionally, COX-1 and -2 are very similar, both catalyzing 
the stepwise conversion of AA into the prostaglandins PGG2/PGH2 (112). The crucial 
distinction between these two enzymes lies in their tissue-specific expression. COX-1 is 
expressed constitutively in most tissues, whereas the inducible isoform COX-2 is not usually 
detectable in most normal tissue (though it is constitutively expressed in some tissues under 
normal conditions (113)) but rather is expressed predominantly by immune cells, such as 
activated macrophages, under inflammatory conditions. Thus, COX-1 activity plays a variety of 
normal homeostatic roles in various tissues of the body, but the induction of COX-2 activity is 
usually a strong indicator of the pathophysiological inflammatory response (112, 114).  
 The prostanoids are synthesized directly from the COX product PGH2 via the activity of 
different enzymes, and are ubiquitously expressed throughout the body. The prostanoids have 
diverse physiological functions, e.g., protection of the gastric mucosa, controlling menstruation 
and parturition, and maintaining normal kidney function; during disease pathophysiology, they 
also play central roles in the inflammatory process (115, 116). In the central nervous system 
(CNS), COX-derived prostanoids have been shown to be strong contributors to the pathological 
processes of a host of neurodegenerative diseases and neurological insults (117). COX  
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Figure 1.6.  Cyclooxygenase enzymes generate prostanoids from arachidonic acid. 
Cyclooxygenase (COX) enzymes, COX-1 and COX-2, both catalyze the conversion of 
arachidonic acid (AA) into prostaglandin G2 (PGG2), then PGH2. Prostaglandin synthases 
convert PGH2 into the prostaglandins PGD2, PGE2, and PGF2. PGH2 can be shunted into the 
thromboxane (TXA2) pathway via thromboxane synthase activity, or it be converted into 
prostacyclin (PGI2) by prostacyclin synthase. Non-steroidal anti-inflammatory drugs (NSAIDs) 
block COX-1/2 activity, thus inhibiting production of the pro-inflammatory prostaglandins, 
mediators of inflammatory pain and arthritis (112). 
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signaling is central in pain transmission in the spinal cord, both under normal physiological 
conditions as well as during pathophysiological pain states following SCI (118-120). The 
specific contribution of COX signaling to secondary SCI pathology has long been a subject of 
investigation. It has been demonstrated that increased spinal cord COX-2 expression (121) and 
prostanoid synthesis (122) occur from very early after injury. Studies utilizing treatment with 
NSAIDs or COX-2-specific inhibitors prior to injury (119, 123-128) or shortly following injury 
(121, 129-137) have largely detected improvement in neurological and histological outcome in 
animal models of SCI. Of these preclinical studies, the drug that has been most frequently 
evaluated is indomethacin, a nonselective COX inhibitor (77). However, the clinical relevance 
of the findings is dubious; relatively few studies of indomethacin’s efficacy have reported 
behavioral outcome, and most utilized pre-treatment or very early treatment during an 
unrealistic window of efficacy. According to Kwon and colleagues (77), greater potential may 
lie in ibuprofen, which has demonstrated neurological benefits even when administered up to a 
week following SCI (136). 
 The lipoxygenase (LOX) family of enzymes is parallel to the COX pathway in the 
oxidative AA metabolism signaling network. The LOX family is comprised of 5-LOX, 12-
LOX, and 15-LOX, all of which catalyze the conversion of AA into bioactive eicosanoids (Fig. 
1.7). The 12-LOX and 15-LOX pathways produce the lipoxins, which are unique among the 
lipid mediators in that they exert anti-inflammatory action (138) and, interestingly, appear to 
play a role in attenuating inflammatory pain within the spinal cord (139). 5-LOX, however, 
catalyzes the rate-limiting step in the conversion of AA into the pro-inflammatory leukotrienes: 
leukotriene B4 (LTB4) and the cysteinyl leukotrienes (CysLTs). The leukotrienes have long 
been recognized for their fundamental role in promoting and sustaining inflammation, 
especially in asthma and the allergic response (140). As such, drugs such as the 5-LOX 
inhibitor zileuton and the CysLT receptor antagonist montelukast are commonly used in the 
clinical treatment of asthma and bronchial constriction.  
 Though the potential role of lipoxins in SCI has not yet been explored, it is now known 
that the leukotrienes are important mediators in the secondary pathogenesis of SCI. 
Experimental studies have revealed that LTB4 levels are increased within the injured spinal 
cord in the hours to days following SCI (141, 142). Genovese and colleagues have shown that  
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Figure 1.7.  Lipoxygenase enzymes catalyze conversion of arachidonic acid into the pro-
inflammatory leukotrienes and the anti-inflammatory lipoxins. Arachidonic acid (AA), 
freed by PLA2 hydrolysis of membrane phospholipids, is metabolized by 5-lipoxygenase (5-
LOX) and the 5-lipoxygenase-activating protein (FLAP) into 5-hydroperoxyeicosatetraenoic 
acid (5-HPETE). 5-HPETE is reduced to 5-hydroxyeicosatetraenoic acid (5-HETE), and then 
converted by 5-LOX to leukotriene A4 (LTA4). Via the activity of LTA4 hydrolase, LTA4 is 
converted into the pro-inflammatory lipid mediator, leukotriene B4 (LTB4). LTB4 is a potent 
chemoattractant mediating leukocyte infiltration into the spinal cord and aggravating the 
secondary injury process. Via glutathione-S-transferase II activity in cells such as mast cells, 
LTA4 can also be converted into leukotriene C4 (LTC4), a member of the cysteinyl leukotriene 
(CysLT) family. LTC4 can then be converted to the other two CysLTs, leukotrienes D4 (LTD4) 
and -E4 (LTE4), by the enzymes gamma-glutamyl transpeptidase and dipeptidase, respectively 
(143). 15-lipoxygenase (15-LOX), expressed in leukocytes, produces the anti-inflammatory 
lipoxins, which promote processes such as vasorelaxation and inhibition of polymorphonuclear 
cell infiltration through the vascular endothelium (138). 
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5-LOX knockout mice exhibit reduced neutrophil infiltration, neuronal death, and axonal 
degeneration after SCI compared to wild-types; additionally, they found that these mice have 
improved motor function following SCI (144). In a subsequent study, the same  
group showed similar histological and functional improvements with zileuton and montelukast 
treatment, specifically revealing the importance of the CysLTs in driving SCI pathology (142). 
Recently, Saiwai et al. demonstrated that interaction between LTB4 and its receptor, the 
leukocyte-specific LTB4 receptor 1 (BLT1), promotes the infiltration of neutrophils, 
macrophages, and microglia into the injured spinal cord within the first week following SCI 
(145). Importantly, blocking the LTB4-BLT1 axis reduced secondary pathophysiologies 
including neuronal death and white matter loss, and enhanced motor recovery. Together, these 
studies reveal that both LTB4 and CysLT signaling mediate secondary SCI pathology early 
after injury.  
 
Pharmacological Inhibition of COX and 5-LOX Activity 
 COX inhibition has been extensively evaluated as a potential neuroprotective therapy for 
acute SCI, but there are multiple complications with the clinical use of COX inhibitors. The 
first-generation COX inhibitors, the classical NSAIDs, nonselectively inhibit COX-1 and COX-
2; common over-the-counter drugs such as aspirin and ibuprofen belong to this class of drugs, 
and each inhibits COX-1 and -2 at approximately equal potency. Though these drugs are very 
widely used to treat inflammatory pain, long-term or high-dose NSAID use is associated with 
adverse side effects. About 1% of chronic NSAID users experience GI complications such as 
ulcers and GI bleeding (112) and acute renal failure (113). Because of the potential severity of 
these side effects, NSAIDs are implicated in almost half of all drug-related medical 
emergencies (146). These side effects have been largely attributed to the inhibitory action of 
NSAID treatment on normal physiological COX-1 activity, which is necessary for protection of 
gastric and renal tissues (113). In 1988, it was discovered that the inducible COX-2 isoform is 
the primary COX enzyme responsible for inflammatory pain, thus opening the door for a new 
approach to anti-inflammatory treatment (112). The COX-2-specific inhibitors, the coxibs, 
were developed in the 1990s as a novel solution to sidestep GI irritation while still maintaining 
therapeutic efficacy comparable to classical NSAIDs (147). The coxibs have indeed 
demonstrated improved GI tolerability over NSAIDs in clinical trials (148). However, 
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subsequent studies have found that COX inhibitors—most notably, rofecoxib (Vioxx)—can 
cause a dramatic increase in potentially fatal cardiovascular side effects including heart attack, 
stroke, and thrombosis (149). As a result, rofecoxib was pulled off the market in 2004, and to 
date there has been relatively little progress in the development of safer COX inhibitors with 
enhanced tolerability (149). 
  Based on the findings that both COX and 5-LOX signaling contribute to the secondary 
pathology of SCI (121, 142), one may speculate that inhibiting the COX arm of AA 
metabolism alone may be an insufficient strategy by which to attenuate inflammation in the 
acutely injured spinal cord. Rather, dual blockade of both COX and 5-LOX pathways may be 
crucial in order to overcome the potent inflammation that drives vascular disruption, cell death, 
and a host of other destructive processes early after SCI. Lending support to this idea is the 
finding that AA can be “shunted” into one arm of AA metabolism when the other is blocked, 
effectively compensating for pharmacological inhibition of one pathway by increasing AA flux 
through the other pathway. An example of the AA shunt can be found in the phenomenon of 
aspirin-induced asthma. In this condition, treatment of asthmatic patients with NSAIDs acutely 
exacerbates the symptoms of asthma (150), primarily due to COX inhibition promoting 
formation of leukotrienes in the lungs (151). Further evidence for the concept of an AA shunt 
can be found in studies of lung cancer, a disease for which it is known that the prostanoids and 
leukotrienes both exert pro-tumorigenic effects (152). Ye and colleagues showed that 
pharmacological COX-2 inhibition decreased levels of the COX product PGE2, but actually 
increased LTB4 levels, in cigarette smoke-induced colonic adenomas (153). Notably, they 
found that dual inhibition of COX-2 and 5-LOX inhibited tumor growth more effectively than 
either COX-2 inhibition or 5-LOX inhibition alone, illustrating a synergistic effect of 
simultaneously blocking both pathways (153). Furthermore, clinical studies of heavy cigarette 
smokers found that one month of treatment with the COX-2 inhibitor celecoxib suppressed 
PGE2 but markedly increased LTB4 levels in the alveolar macrophages of smokers’ lungs (154, 
155). As a result of these findings, dual COX/5-LOX inhibition has been suggested as an 
effective prophylactic for lung cancer prevention with efficacy superseding that of COX or 5-
LOX inhibition alone (152). Together, this data demonstrates that COX inhibition can lead to a 
shunt of AA metabolism toward the 5-LOX pathway, increasing production of the pro-
inflammatory leukotrienes, which paradoxically enhances the inflammatory response (156). 
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 It is because of both of these undesirable effects of COX inhibition—the marked increase 
in GI, renal, and cardiovascular side effects, as well as the shunting of AA through the pro-
inflammatory 5-LOX pathway—that a new strategy in anti-inflammatory therapy has received 
increasing attention in the last decade. The approach of dual COX and 5-LOX inhibition has 
gained popularity because of the benefits of increased anti-inflammatory potential (compared to 
classical anti-inflammatory drugs), as well as its demonstrated utility in blocking the 
development and progression of cancer, in which both COX and 5-LOX products promote 
cancer cell growth and survival (157). The dual-acting COX/5-LOX inhibitor that has been 
most extensively studied in human clinical trials is licofelone, which has now successfully 
passed Phase III clinical trials for osteoarthritis (158). Licofelone is a competitive inhibitor of 
COX-1, COX-2, and 5-LOX enzymes and blocks formation of the pro-inflammatory 
prostanoids and leukotrienes, while exhibiting improved GI tolerability compared to classical 
NSAIDs such as naproxen (158, 159). Importantly, licofelone does not inhibit the 12-LOX or 
15-LOX pathways, which synthesize the anti-inflammatory lipoxins (160) (Fig 1.7), as 
previous generations of COX/LOX inhibitors have done (161). In addition, studies have shown 
that treatment with licofelone is neuroprotective and improves behavioral outcome in 
experimental models of Huntington’s disease (162, 163) and Parkinson’s disease (164). These 
findings strongly suggest a potential neuroprotective role of licofelone treatment for other 
neurological disorders.  
 In summary, experimental studies have found that COX and 5-LOX activity are both 
detrimental to neurological outcome following SCI, and as a result it is thought that early 
inhibition of these pathways should produce neuroprotective, beneficial effects in SCI. 
However, to date no one has performed an extensive evaluation of the neuroprotective 
properties of combined COX/5-LOX inhibition in an acute SCI model. Due to the recent 
clinical advancement of dual COX/5-LOX inhibitors such as licofelone, which confer 
neuroprotective benefits while exhibiting reduced side effects versus classical anti-
inflammatory drugs, a combined anti-inflammatory therapeutic approach for acute SCI may 
therefore be a promising, novel therapeutic strategy. 
 
§ 
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The Blood-Spinal Cord Barrier, P-glycoprotein, and Drug Resistance 
 The BSCB is the specialized system of capillary endothelial cells (ECs) and associated 
structures that serves the important function of limiting the diffusion of substances between the 
bloodstream and the spinal cord tissue (Fig. 1.8) (165, 166).  The BSCB is similar to the blood-
brain barrier in its composition and functionality; however, there are key differences between 
the two barrier systems, and as such the BSCB should be considered as distinct and separate 
from the blood-brain barrier (166). One major distinction is that BSCB permeability is 
moderately higher than that of its counterpart in the brain (166), probably because of relatively 
lower expression of some tight junction and adherens junction proteins (167). Compared to the 
blood-brain barrier, which has been a topic of frequent investigation, much remains to be 
understood about BSCB properties under normal physiological or pathological conditions. 
 BSCB dysfunction following traumatic SCI has been extensively studied by assessing its 
permeability to tracer molecules of various sizes. Intravascular delivery of low molecular 
weight, fluorescently-labeled tracers, albumin-binding dyes, and contrast agents such as 
gadolinium allows BSCB function to be assessed both histologically (168-170) and via 
functional imaging techniques such as dynamic contrast-enhanced MRI (DCE-MRI) (171, 
172). Using these techniques, it has become evident that an extended time course of BSCB 
disruption takes place following trauma to the spinal cord. The mechanical force of injury 
instantly compromises the integrity of the BSCB, and the secondary injury cascades appear to 
contribute to a biphasic pattern of barrier breakdown over the days to weeks following SCI 
(72). Roughly, peak disruption occurs early after injury, barrier properties are re-established by 
2-4 weeks post-SCI (173-176), and a secondary disruption appears to occur in the weeks to 
months following injury, with gradual restoration of barrier integrity (177). In addition, loss of 
BSCB integrity is not limited to the initial site of injury, but spreads along the axis of the spinal 
cord, likely due to factors such as oxidative stress that are associated with the spread of 
secondary injury pathology (72, 173). Unfortunately, a cohesive understanding of the BSCB 
response to SCI still remains elusive, in large part because of the literature’s considerable 
variability in SCI models used, time windows analyzed, and size of vascular tracers utilized.  
 The changes in the BSCB underlying increased permeability after SCI include 
compromised tight junctional integrity and increased vesicular transcellular transport (166, 
178). These morphological changes are thought to be largely driven by the sustained release of  
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Figure 1.8.  The blood-spinal cord barrier. Illustration depicting the components of the 
blood-spinal cord barrier (BSCB), the system of microvascular structures that tightly regulates 
the flow of substances between the bloodstream and spinal cord. Capillaries within the spinal 
cord are composed of endothelial cells (ECs) that lack cell membrane fenestrations and 
pinocytic vacuoles, thus preventing transcellular diffusion of molecules (179). Instead, a variety 
of active transporters are expressed on the luminal and adluminal EC membranes, allowing 
selective transport of substances in and out of the cell. Tight junctions (TJ) between ECs 
restrict the paracellular passage of substances. The basal lamina is composed of a layer of 
extracellular matrix which is maintained by the other cells of the BSCB; it engulfs capillary 
ECs as well as pericytes, which are cells that associate with the outer wall of the capillary. 
Pericytes function as regulators of EC proliferation, migration, and differentiation (166). The 
outermost component of the BSCB is comprised of the endfoot processes of astrocytes. These 
processes secrete factors that maintain the barrier properties of the BSCB, but are not actually 
involved in directly limiting molecular diffusion (166). 
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pro-oxidative and pro-inflammatory factors by infiltrating immune cells (166, 180, 181). Active 
transport at the BSCB is a sophisticated system allowing for the selective uptake and efflux by 
ECs of a very large variety of endogenous and exogenous compounds, thus greatly influencing 
BSCB permeability to specific substrates. Despite the central role that transporter systems play 
in a large number of neurological diseases (182-188), SCI-associated changes in BSCB 
selective transport has not been extensively studied. It has been shown that differential EC 
expression of glucose-1 transporter (Glut-1) following injury is closely linked to blood vessel 
permeability (189). Additionally, several studies have demonstrated acute and chronic changes 
in expression of glutamate transporters (190-192) and the water transport channels, aquaporins 
(193, 194) after SCI. However, there is one particular class of BSCB transporters that is known 
to play a significant role in several CNS pathologies, but which has not yet been characterized 
in SCI—the ATP-binding cassette (ABC) transporters. 
 
P-glycoprotein: Multidrug Efflux Transporter 
 The ABC transporter superfamily is among the largest and oldest classes of proteins 
known. Members of this family of transmembrane proteins share a conserved domain structure, 
each possessing two nucleotide-binding domains (the active sites for ATP hydrolysis), and two 
substrate-binding domains (195, 196). All ABC transporters share a common function of 
translocation of substrates from one side of the lipid bilayer to the other, though the incredible 
variability in substrate recognition and the diverse expression patterns of these proteins give 
them an extraordinary range of biological functions (182). ABC transporters are evolutionarily 
ancient; expressed in bacteria and archaebacteria, they serve a vital function in the active 
import of nutrients, peptides, ions, and vitamins (195). In mammals, this family of transporters 
functions in the transport of both endogenous and xenobiotic substrates between different 
biological compartments, and are particularly important for the function of blood-tissue barriers 
(197). Many ABC transporter family members are expressed at the blood-CNS barriers where 
they have important roles in maintaining homeostasis in the brain and spinal cord, and are also 
implicated in various disease pathologies (182, 198). 
 P-glycoprotein (Pgp, ABCB1/MDR1) is one of the most extensively characterized ABC 
transporters. Pgp is a 170-kDa, 12-transmembrane glycoprotein expressed on cell membranes 
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of a variety of cell and tissue types. Its fundamental mechanism of action is to extrude 
substrates against their concentration gradients from within the cell membrane to the 
extracellular space, using the energy from ATP hydrolysis. The crystal structure of Pgp was 
recently solved (199), revealing the structural basis for the transporter’s substrate binding and 
efflux activity (Fig. 1.9). Pgp can exist in two fundamental conformations: 1) an “inward facing  
conformation”, in which a large, open cytoplasmic pocket allows the binding of two ATP 
molecules from the cytosol and one molecule of substrate from the inner leaflet of the cell 
membrane; 2) an “outward facing conformation”, assumed via an ATP hydrolysis-powered 
conformational shift, which exposes the substrate-binding domain to the extracellular space, 
thus releasing the substrate (199). 
 Pgp is expressed in several tissues of the body, where its efflux transport activity allows it 
to serve a variety of functions. In the intestinal epithelium, Pgp regulates drug absorption (200); 
in hepatocytes, it regulates excretion of bile salts (201); it regulates renal clearance of drugs in 
the kidney (202). Pgp is expressed on the luminal membrane of capillary ECs of the blood-
brain- and blood-spinal cord barriers, where it limits the blood-to-CNS penetration of various 
substances (203). Pgp is also expressed in the blood-testis barrier (204), blood-placental barrier 
(205), and the retinal pigment epithelium (206). The ability of one single transporter protein to 
perform such a wide range of biological actions is due to a remarkably broad substrate 
specificity (203). Pgp possesses a promiscuous binding pocket, with an upper half rich in 
hydrophobic and aromatic residues, and a lower half with charged and polar residues; it is this 
domain that enables Pgp to bind such hundreds of compounds with dramatically different 
structures and sizes (199). Pgp is able to bind several types of endogenous substrates, e.g., bile 
salts (201), endogenous opioid peptides (207), oxidized lipids (208), somatostatin and 
substance P (209), endogenous steroid hormones (210), beta amyloid peptide (211), and 
platelet-activating factor (212). Furthermore, Pgp also recognizes a staggering variety of 
xenobiotic substrates, including the therapeutic drugs colchicine, taxol, paclitaxel, phenytoin, 
rapamycin, ivermectin, glucocorticoids, cyclosporin A, dexamethasone, digoxin, and HIV 
protease inhibitors, to name a few (203). This substrate promiscuity equips Pgp with the ability 
to serve a highly protective “gatekeeper” function at the blood-CNS barriers, limiting the CNS 
entry of a multitude of potentially cytotoxic compounds (213). This protective function, 
however, is a double-edged sword—it is precisely because of Pgp’s strict “gatekeeping” 
activity that it is now recognized as a major obstacle to therapeutic drug delivery (214).  
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Figure 1.9.  Mechanism of P-glycoprotein-mediated active transport. Cartoon depicting the 
conformational change of P-glycoprotein (Pgp) which occurs during efflux transport of 
substrates. (a) Pgp is a 12-transmembrane glycoprotein with two large intracellular domains. In 
the inward-facing conformation of Pgp, its two structurally similar halves form a large internal 
pocket which allows access to the cytoplasm and the inner leaflet of the membrane. Substrate 
(blue) originating from the extracellular space diffuses into the lipid membrane and enters 
directly from the inner leaflet into Pgp’s substrate binding pocket (green). Substrate binding 
stimulates binding of one ATP molecule to each of Pgp’s two nucleotide-binding domains. (b) 
(View rotated 90°) ATPase activity is thought to cause a dimerization of the nucleotide-binding 
domains, thus shifting Pgp to the outward facing conformation, and releasing bound substrate 
into the extracellular space. It is through this drug efflux transport activity that Pgp expressed at 
the BSCB limits drug penetration from bloodstream to spinal cord tissue. Illustration is based 
on crystal structure of Pgp from Aller et al. (199). 
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 Pgp is notorious for the phenomenon of multidrug resistance (MDR), for which it received 
its original genetic nomenclature, MDR1 (215). Pgp was first described in colchicine-resistant 
tumor cells (216), and it has since become well established that overexpression of Pgp causes 
simultaneous cross-resistance to chemotherapeutics in multiple types of cancer (217, 218). As a 
result, a major goal of current oncology research is overcoming Pgp-mediated MDR in order to 
improve the efficacy of cancer therapy (219, 220). More recently, it has become recognized that 
pathological Pgp overexpression also presents a significant impediment to the therapeutic 
treatment of CNS diseases4. Several preclinical studies have detected altered brain Pgp 
expression in models of epilepsy (221, 222), cerebral ischemia (223), ALS (224, 225), and 
Alzheimer’s disease (226). In addition, clinical studies have shown altered brain Pgp 
expression and activity in patients with Parkinson’s disease (227-229), Alzheimer’s disease 
(230), seizure (231), schizophrenia (232), and HIV encephalitis (233). In neurological diseases 
where Pgp is overexpressed at the blood-brain barrier, delivery of therapeutic drugs to the brain 
can be dramatically impaired. It is therefore evident that Pgp-mediated pharmacoresistance is a 
barrier to the effective treatment of not only cancer, but multiple neurological diseases, and it 
must be overcome in order to improve treatment of these disorders. 
 There are a variety of pharmacological Pgp inhibitors available; however, the use of these 
inhibitors to combat Pgp-mediated pharmacoresistance has been historically difficult due to 
low tolerability, pharmacokinetic interactions with chemotherapeutics, and cross-interactions 
with other ABC transporters (220). Recently, some have suggested that rather than directly 
inhibiting Pgp activity, modulating Pgp expression by targeting the intracellular mechanisms 
that drive its up-regulation may be a more effective strategy to overcome drug resistance (187, 
214, 234).  Whether it is disease-associated pathophysiological mechanisms, or the 
pharmacological compounds used to treat the disease itself, which drives Pgp overexpression in 
neurological diseases largely remains unclear. According to in vitro studies in brain capillaries, 
ABCB1 gene expression in the CNS can be up-regulated by pro-inflammatory mediators (e.g., 
TNF-α, endothelin-1, and PGE2), oxidative stress, or nuclear receptors (198, 214). However, to 
date relatively few studies have examined the mechanisms of Pgp regulation in clinically 
relevant animal models. Some important insight can be gained from the work of Potschka and 
                                                          
4
 In this dissertation, the term “pathological Pgp overexpression” will be used to indicate Pgp up-
regulation and/or overexpression driven by pathological, disease-associated mechanisms. 
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colleagues, who have characterized the molecular mechanisms responsible for Pgp 
overexpression in drug-resistant epilepsy (221). Through their studies, they have formulated a 
model describing how seizure activity induces Pgp overexpression via a glutamate-signaling 
cascade involving COX-2 and the prostaglandin E receptor 1 (EP1) (Fig. 1.10) (222, 235). 
Notably, Potschka et al. have demonstrated that treatment with the COX-2 inhibitor celecoxib 
counteracted seizure-induced Pgp overexpression and enhanced therapeutic brain delivery of 
the anti-epileptic drug phenytoin in rats (236). These promising findings may lead the way 
toward a simple strategy to overcome resistance to therapeutic drug delivery for epileptic 
patients. Such a strategy could also have potential for the attenuation of drug resistance in CNS 
pathologies with shared pathological characteristics such as glutamate toxicity or 
neuroinflammation.  
 Interestingly, Milane et al. have recently demonstrated that mice expressing mutant 
SOD1—a commonly used model of the neurodegenerative disease ALS—overexpress Pgp in 
the brain and exhibit decreased brain concentrations of systemically administered riluzole 
(224). Though this group has not yet isolated the pathway(s) underlying this phenomenon, it is 
tempting to speculate that signaling through the glutamate/COX-2/PGE2 axis is a likely 
candidate, since glutamate excitotoxicity is a major component of ALS pathology (237). In 
addition, several groups have shown that COX inhibition is also effective in attenuating Pgp-
mediated MDR in various cancer cell lines (238-241), suggesting that COX-mediated pro-
inflammatory signaling may even be a universal pathway by which Pgp becomes pathologically 
overexpressed.  
 
A Potential Role for P-glycoprotein in Spinal Cord Injury 
 In 2000, Bernards and colleagues (242) were the first to acknowledge the potential role of 
Pgp in limiting therapeutic delivery of methylprednisolone to the spinal cord. Systemic, high-
dose MPSS is fraught with side effects (e.g., pneumonia and sepsis) that can seriously threaten 
the health of an already critical acute SCI patient, which is one of the major reasons why MPSS 
use for acute SCI has dramatically declined (40, 95). Koszdin et al. demonstrated that in the 
pig, spinal cord bioavailability of MPSS is dramatically lower following i.v. administration 
compared to intrathecal injection, an observation that they speculated was due to Pgp efflux  
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Figure 1.10.  Model of P-glycoprotein transcriptional activation by seizure activity in the 
brain. Seizure activity in the brain releases glutamate into the extracellular space, activating 
NMDA receptors on endothelial cells (222). NMDA receptor activation allows Ca2+ influx into 
the cell, triggering PLA2 activation and AA release (105). COX-2 oxidative metabolism of AA 
yields production of the pro-inflammatory prostaglandin PGE2, which in turn activates the 
downstream endothelial EP1 receptor (222, 235, 244). Potschka (2010) suggests that the 
transcription factor nuclear factor-kappaB (NF-kB) is a likely transcriptional activator of 
ABCB1 in this scenario, based on evidence that COX-2 signaling in the brain can induce NF-
kB activation (245, 246). Figure from: Heidrun Potschka, Targeting regulation of ABC efflux 
transporters in brain diseases: A novel therapeutic approach, Pharmacology & Therapeutics, 
Volume 125, Issue 1, January 2010, Pages 118-127. Reprinted with permission (234). 
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activity (242). Subsequently, Bernards (243) found that MPSS bioavailability in the pig spinal 
cord could be increased by treating with the Pgp inhibitor cyclosporin-A. The authors proposed 
that inhibiting Pgp activity could reduce the therapeutic dose of MPSS for SCI patients and 
consequently the harmful peripheral side effects of high-dose glucocorticoid treatment (242, 
243). These are significant findings, as they are the first (and only) studies to propose that Pgp 
might decrease the efficacy of therapeutic intervention for SCI. Nevertheless, whether Pgp 
becomes pathologically overexpressed in the injured spinal cord, and whether SCI patients 
become resistant to treatment, are topics that have not yet been investigated. Braughler and Hall 
performed a series of studies in the early 1980s in which they analyzed MPSS levels in injured 
cat spinal cord (247-250). However, most of these studies only reported measurements taken 
within hours of a single large bolus; the authors did not perform longitudinal assessments of 
spinal cord MPSS levels in a 24-hour continuous, high-dose treatment paradigm such as that 
utilized in the National Acute Spinal Cord Injury Study (NASCIS) II (94). To date, no group 
has yet performed an experimental study examining spinal cord resistance to systemic drug 
treatment following SCI. 
 Development of drug resistance in the injured spinal cord could have potential to impact 
the therapeutic efficacy of drugs other than MPSS as well. Significantly, several drugs that 
have been evaluated as potential SCI interventions, in addition to drugs that are used clinically 
for the treatment of pain in SCI patients, are known Pgp substrates, and thus susceptible to Pgp-
mediated drug resistance (TABLE 1.1). This list includes riluzole, a drug that is currently being 
evaluated in a clinical trial as an acute SCI intervention (87). Because Milane and colleagues 
have recently shown that Pgp-mediated drug resistance hampers riluzole treatment in ALS 
(224), it is reasonable to speculate that shared pathological mechanisms (i.e., glutamate 
excitotoxicity, inflammation, and oxidative stress) could underlie a similar phenomenon in SCI. 
Pgp-mediated drug resistance in SCI patients would have dramatic implications, with the 
capacity to impact not only the current riluzole clinical trial, but the efficacy of other 
neuroprotective drugs for SCI, as well as the treatment of patients with chronic SCI pain and 
spasticity. Despite decades of intensive research, there are no effective therapies that can 
improve functional recovery in SCI patients. Thus, the prospect of multidrug resistance 
following injury to the spinal cord is a potentially major obstacle to treatment that must be 
investigated.
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Drug Preclinical Evidence of Therapeutic Benefits for SCI Clinical Trials and/or Clinical Use 
Evidence that P-glycoprotein 
Activity Affects Therapeutic Efficacy 
and/or CNS Disposition 
Methylprednisolone 
sodium succinate 
(MPSS) 
MPSS exhibits neuroprotective 
effects in preclinical models 
of acute SCI (Young and 
Bracken, 1992; Tator, 1996, 
1998; Zeidman et al., 1996; 
Amar and Levy, 1999) 
NASCIS I: No benefit of MPSS over naloxone 
or placebo (Bracken et al., 1985) 
NASCIS II:  Post-hoc analysis detected modest 
neurological improvement in a subset of 
patients receiving MPSS 3-8 h post-injury 
(Bracken et al., 1990, 1992); subsequently 
criticized due to questionable  statistical 
analysis and lack of clinically significant 
functional outcome measures (Tator, 2006; 
Hurlbert and Hamilton, 2008) 
NASCIS III: No significant difference in motor 
recovery or FIM with 24-h or 48-h MPSS 
treatment (Bracken et al., 1998) 
The clinical use of MPSS for acute SCI has 
greatly declined, as the evidence suggesting 
harmful medical side effects of high-dose 
MPSS is more consistent than evidence 
suggesting its therapeutic benefit (Hawryluk  
et al., 2008) 
Methylprednisolone is a Pgp substrate 
(Saitoh et al., 1998) 
Intravascular delivery of MPSS results 
in lower spinal cord bioavailability 
than intrathecal delivery in pigs; Pgp 
knockout mice have increased spinal 
cord penetration of i.p. MPSS 
(Koszdin et al., 2000) 
Pgp inhibition with cyclosporin-A 
increased CSF levels of i.v.-delivered 
MPSS in the pig (Bernards, 2006) 
Minocycline 
Neuroprotective effects for 
acute SCI (Lee et al., 2003; 
Stirling et al., 2004; Festoff 
et al., 2006; Yune et al., 
2007) 
Attenuated neuropathic pain in 
SCI rats (Marchand et al., 
2009) 
Phase I/II trial, Minocycline and Perfusion 
Pressure Augmentation in Acute Spinal 
Cord Injury  (NCT00559494) (University of 
Calgary, 2007- [cited 2012 Mar 13]) 
Current status:  Currently recruiting 
Minocycline is a substrate and inhibitor 
of Pgp (Milane et al., 2007) 
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(Continued from previous page)
Riluzole 
 
Neuroprotective effects for 
preclinical models of acute 
SCI (Fehlings and Agrawal, 
1995; Schwartz and Fehlings, 
2001, 2002; Wang et al., 
2004) 
Reversed neuropathic pain 
behavior in SCI rats (Hama 
and Sagen, 2010) 
Attenuated spastic muscle 
activity in rats (Kitzman, 
2009) 
Phase I trial, Safety of Riluzole in Patients 
with Acute Spinal Cord Injury 
(NCT00876889) (The Methodist Hospital 
System, 2009- [cited 2012 Feb 29]) 
Current status:  Ongoing, but not recruiting 
participants 
Riluzole is a Pgp substrate (Milane et 
al., 2007) 
Pgp overexpression in the mSOD1 
mouse brain decreases brain 
concentrations of i.p.-delivered 
riluzole (Milane et al., 2010) 
Nimodipine 
Improved spinal cord axonal 
function and blood flow in 
preclinical SCI models 
(Fehlings et al., 1989) 
Phase III RCT (France) (Petitjean et al.,  1998):  
Compared to MPSS and placebo, no 
difference detected between groups (study 
likely underpowered) 
Blind RCT (France) (Pointillart et al., 2000):  
Compared to MPSS, no neurological 
differences detected between groups 
Nimodipine is a Pgp substrate (Zhang 
et al., 2003) 
Lamotrigine - 
Lamotrigine is used clinically as a pain 
treatment in SCI patients (Baastrup and 
Finnerup, 2008; Wiffen et al., 2011) 
Lamotrigine is a Pgp substrate 
(Potschka et al., 2002; Luna-Tortos 
et al., 2008) 
Amitriptyline - 
Amytriptyline is used clinically as a pain 
treatment in SCI patients (Baastrup and 
Finnerup, 2008) 
Amitriptyline is a Pgp substrate (Uhr  
et al., 2000) 
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TABLE 1.1.  Several drugs that have been evaluated for the treatment of spinal cord injury 
are substrates of P-glycoprotein. Abbreviations: FIM, functional independence measure; 
NASCIS, North American Spinal Cord Injury Study; RCT, randomized controlled trial. 
References are listed in bibliography (19, 40, 82, 85, 87, 93, 94, 224, 225, 242, 243, 251-279). 
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CHAPTER 2 
Materials & Methods 
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Animals and Surgeries 
 All applicable institutional and governmental regulations concerning the ethical use of 
animals were followed during the course of this research. This study was carried out in strict 
accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The animal protocol used in this study was 
approved by The University of Texas Health Science Center Institute for Animal Care and Use 
Committee. All efforts were made to minimize suffering and distress. 
 
Animals 
 Adult female Sprague-Dawley rats weighing 250-300 g were used for Pgp immunoblot 
studies (See Chapter 3). Adult male Sprague-Dawley rats weighing 250-300 g were used for all 
remaining studies. All wild-type Sprague-Dawley rats were purchased from Harlan 
Laboratories (Houston, Texas). 
Transgenic mice: Adult female mdr1a/b constitutive double knockout mice (FVB.129P2-
Abcb1atm1BorAbcb1btm1Bor N12) and wild-type mice (FVB.129P2) were purchased from 
Taconic (Germantown, New York).  
Transgenic rats: Four-week-old male mdr1a knockout rats (SD-Abcb1atm1sage) were 
purchased from SAGE Labs (St. Louis, Missouri).  
 
Spinal Cord Injury Surgery 
 All surgical procedures were performed on animals that were deeply anesthetized with a 
ketamine cocktail [ketamine (80 mg/kg), xylazine (10 mg/kg), acepromazine (0.75 mg/kg)] at a 
dose of 0.01 ml/kg body weight. Spinal cord injury surgeries were performed as previously 
described (48). Incisions were made on the animals’ dorsal skin and overlying muscles and the 
vertebral column was exposed. A laminectomy was performed at thoracic level 10 (T10) and 
the vertebral column was stabilized using forceps that grasp the ventral surface of the lateral 
spinous processes at vertebral levels T9 and T11. Using an Infinite Horizon Spinal Impactor 
Device (Precision Systems and Instrumentation, LLC, Fairfax Station, VA), moderate 
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contusion/compression injuries were delivered to the T10 spinal cord using 150 kdynes of force 
with a 1 s dwell. Immediately following injury, the overlying muscles were sutured and the 
skin was securely closed using stainless steel wound clips. 
 
Post-Operative Animal Care 
 Beginning on the day of surgery, animals received Baytril injections (2.5 mg/kg s.c., b.i.d.) 
for 10 days to prevent post-operative infections. Beginning on post-operative day one (DPI 1), 
animals’ bladders were manually expressed 2-3 times daily until control of bladder function 
was completely regained. To minimize pain, animals received buprenorphine injections (0.02 
mg/kg s.c., b.i.d.) for one week following surgery. To prevent dehydration, animals received 
0.9% saline (3-5 ml s.c.) daily for five days following surgery.  
 
Exclusion Criteria 
 To maximize reproducibility of results, spinal cord-injured animals were excluded from 
this study if the force of impact to the spinal cord fell outside a range between 150 and 175 
kdynes, a criterion that is consistent with previous studies (48). Additionally, injured animals 
exhibiting an open field locomotor score greater than two on DPI 1 were also excluded. 
 
Drug Treatment 
 Licofelone (Santa Cruz Biotechnology) was suspended in 0.5% carboxymethylcellulose in 
0.9% saline (vehicle) to a final concentration of 50 mg/ml, and administered to animals via oral 
gavage (100 mg/kg). Riluzole (Sigma-Aldrich) was dissolved in ethanol to a concentration of 
50 mg/ml, and this stock solution was stored at -20°C for up to 3 months. Riluzole stock 
solution was diluted with vehicle to a final working concentration of 2.5 mg/ml, and 
administered to animals (8 mg/kg i.p.). All working drug solutions were prepared fresh daily.  
 
Behavioral Assessments 
Open Field Locomotor Testing 
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 Animals’ locomotor function was examined using the Basso, Beattie and Bresnahan (BBB) 
open field locomotor scale (280). This test is a sensitive measure of multiple aspects of 
hindlimb function that is commonly used to assess locomotor recovery following SCI. Animals 
were allowed to acclimate to the open field testing environment (a 40”-diameter plastic wading 
pool) in groups of four for 10 minutes daily until they ceased to exhibit fear-associated 
behavior (e.g., crouching, cowering away from the examiner, vocalizing) and displayed signs 
of comfort (e.g., grooming, accepting treats from the examiner’s hand, exhibiting continuous 
locomotion and exploration). No further acclimation to the testing environment was performed. 
Baseline testing began once the examiner felt confident that all animals were comfortable in the 
testing environment. Animals were placed into the open field and allowed to freely explore for 
a period of 4 minutes. Two independent observers scored each hindlimb using a scoring sheet 
(Fig. 2.1). Hindlimb BBB scores were rated using the 21-point BBB open field rating scale 
(APPENDIX B), and inter-rater reliability was confirmed. For each animal, the locomotor scores 
for both hindpaws were averaged to produce one score per test session. Animals were tested 
once prior to receiving SCI surgery (baseline measurement) and again on post-operative days 1, 
2, 3, 5, 7, 10, 14, 21, 28, 35, and 42. BBB data did not pass the Shapiro-Wilk normality test (p 
< 0.05) and therefore nonparametric statistical analysis was chosen to analyze the effects of 
treatment on BBB scores. For each individual time point, BBB scores were analyzed using a 
nonparametric Kruskal-Wallis test followed by a Dunn’s post-test.   
 
Photobeam Activity System 
 A photobeam activity system (PAS) (San Diego Instruments, San Diego, California) was 
employed to study multiple measures of locomotion and overall activity. PAS chambers were 
made up of 16” x 16” x 16” Plexiglas enclosures, equipped with interlocking infrared 
photobeam emitters and receptors spaced at regular intervals. Animal movement (“activity 
data”) in the PAS chamber is monitored by infrared light beam breaks. The PAS stores a 
sequential list of data, recording when each beam was broken, including X-Y location, serial 
number, and timestamp, on the computer analyzer. The analyzer allows the viewer to develop a 
dynamic view of several aspects of spontaneous activity, including: total activity, total 
ambulatory activity, total fine movement, time at rest, number of rearing events and the amount 
of time spent rearing.  
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Figure 2.1.  BBB scoring sheet. Hindlimb locomotor function was rated systematically using 
this scoring sheet. Both hindlimbs were rated and assigned an individual BBB score using the 
BBB locomotor rating scale (See APPENDIX B). Abbreviations: DPO, days post-operation; 
plantar Pl., plantar placement of the paw; toe clear., toe clearance during swing of the 
hindlimb; W/O supp., without weight support; W supp., with weight support. Scoring sheet 
obtained with permission from the authors of: A Sensitive and Reliable Locomotor Rating 
Scale for Open Field Testing in Rats, D. Michele Basso, Michael S. Beattie, Jacqueline C. 
Bresnahan, Journal of Neurotrauma. February 1995: 1-21. (280) 
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 To avoid behavior specific to a novel environment, animals were allowed to acclimate to 
the PAS chambers for a 15-minute period on the day before baseline testing. During testing, 
animals were individually placed in PAS chambers, and the tester immediately left the room. 
PAS testing was performed in a dark environment during the dark cycle (in the evening), to 
encourage maximum animal activity. Each PAS chamber was cleaned with Cavicide medical 
disinfectant (Kerr) between tests in order to eliminate olfactory cues. PAS testing was 
performed once prior to receiving SCI surgery (“Baseline”) and again on post-operative days 7, 
14, 21, 28, 35, and 42.  All session activity was recorded over a 20-minute period and exported 
in tabular format. All PAS data was analyzed using two-way repeated measures ANOVA, 
followed by a Bonferroni post-test. The following parameters were assessed: 
 Distance, speed, and rest time:  Distance of movement (cm), average movement speed 
(cm/s), and time spent at rest (s) over the testing period were calculated. A “rest” period 
was defined as a period of 2.0 seconds or more with no beam breaks. 
 Fine movement and ambulatory movement:  The PAS software differentiated between 
ambulatory movement (continual locomotion over several beam breaks) and fine 
movement (movement without displacement, which indicates grooming, head movements, 
and other stereotypical behaviors). Ambulatory movement was defined as the distance 
(cm) of movement over the testing period. Fine movement was defined as the total distance 
(cm) of beam breaks attributed to small movements confined to an area of ≤2 x 2 beams 
following a minimum resting delay of 0.5 s (281). 
 Rearing events and rearing time:  Number of rearing events was determined automatically 
by the PAS by calculating the number of events breaking upper-level photobeams. We also 
extrapolated the cumulative time spent by animals in the rearing position, which has been 
suggested to be more indicative of a rat’s rearing ability/endurance (281).  
 
Tissue Processing 
 All animals were deeply anesthetized with Beuthanasia (390 mg/ml pentobarbital sodium, 
50 mg/ml phenytoin sodium) (75 mg/kg i.p.). For all of the following experiments (except 
microarray and qRT-PCR studies, for which perfusion was not performed), animals were 
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transcardially perfused with ice-cold saline. Tissue was then harvested, immediately snap-
frozen on either dry ice or liquid nitrogen, and stored at -80°C.  
 
Microarray Analysis 
 Spinal cord tissue from T10 was harvested immediately following sacrifice and snap-
frozen in liquid nitrogen. Total RNA from spinal cord tissue was isolated using the mirVana 
miRNA Isolation Kit (Ambion). RNA was applied to RatRef 12 whole genome arrays 
(Illumina). Arrays were hybridized, washed and scanned by The University of Texas Medical 
School Microarray Core Laboratory. Data was analyzed with Illumina BeadStudio software. 
Group data was compared by Student’s t test. All microarray experiments were performed in 
collaboration with Dr. Meredith Moore in The University of Texas Medical School, 
Department of Neurosurgery. 
 
Quantitative Real-Time PCR 
 DNase-treated total RNA, isolated as above, was reverse transcribed using the High 
Capacity Reverse transcriptase kit (Ambion). The cDNA was amplified in the presence of gene 
specific primers and fluorescent probes with TaqMan Fast Universal reagents (Applied 
Biosystems, Inc.). abcb1b (Rn01529260_m1) expression was examined and the housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (gapdh, Rn01775763_g1) was used as an 
internal control. Expression levels of abcb1b were normalized to gapdh expression levels. Data 
collection and Ct analysis was performed with a StepOne Plus real-time thermocycler and 
associated software (Applied Biosystems, Inc.). Data was analyzed by one-way ANOVA, 
followed by the Student-Newman-Keuls post test. All qRT-PCR experiments were performed 
in collaboration with Dr. Meredith Moore in The University of Texas Medical School, 
Department of Neurosurgery. 
 
Immunohistochemistry 
 For all immunohistochemical procedures, frozen spinal cord tissue was cryosectioned in 
the coronal plane to a thickness of 10 µm. Sections were directly mounted to gelatinized slides, 
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air dried, and post-fixed in 4% paraformaldehyde at 4°C for 15 minutes, then in 1:2 acetic acid: 
methanol solution at -20°C for 10 minutes.  
DAB Staining 
 Following post-fixation, sections were washed 3X for 10 minutes in tris-buffered saline 
(TBS, 10 mM Tris, pH 8.0; 150 mM NaCl), then incubated for 30 minutes in H2O2 buffer 
(0.6% H2O2 in TBS) at room temperature. Sections were washed 2X for 10 minutes in TBS, 
then blocked with blocking-permeabilization buffer (BPB) (5% normal horse serum in TBS, 
0.1% Triton-X-100) for 1 hour. Sections were then incubated in BPB containing primary 
antibody (1:250 mouse monoclonal anti-P-glycoprotein C219, Calbiochem) for 2 hours at room 
temperature, then washed 3X for 10 minutes in TBS. Samples were incubated in BPB 
containing 1:200 biotinylated anti-mouse IgG antibody (Vector Labs) for 3 hours at room 
temperature, then washed 3X for 10 minutes in TBS. Samples were processed with the 
Vectastain ABC Kit (Vector Labs), and immunoreactivity was then visualized by incubation in 
diaminobenzidine (DAB) solution. Samples were counter-stained with hematoxylin to visualize 
nuclei. Sections were dehydrated, mounted, and coverslipped with Fluoromount-G (Fisher).  
Immunofluorescence 
 Following post-fixation, sections were washed 3X for 10 minutes in TBS, then non-
specific IgG was blocked with 5% normal serum for 1 hour. Sections were then incubated in 
TBS containing primary antibodies against P-glycoprotein (1:250 mouse monoclonal anti-P-
glycoprotein C219, Calbiochem), GFAP (1:1000 rabbit polyclonal, Dako), von Willebrand 
factor (1:1500 rabbit polyclonal, Sigma-Aldrich), ED2/CD163 (1:750 mouse monoclonal, 
Serotec), or 5-lipoxygenase (1:1000 goat polyclonal, Novus Biologicals) overnight at 4ºC on a 
rotating shaker. Sections were washed 3X for 10 minutes in TBS, and incubated with Alexa 
Fluor conjugated secondary antibodies (1:500, Invitrogen) for 3 hours. Sections were washed, 
dried, and coverslipped with Fluoromount-G. 
 For all immunohistochemical experiments, labeled sections were imaged using an 
Olympus BX61 wide-field upright microscope with fluorescence optics with a SPOT Flex 
microscope digital camera. Every sixth section in series was chosen for histological analysis.  
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Immunoblotting 
 Tissue samples were homogenized in Tissue Protein Extraction Reagent (T-PER, Thermo 
Scientific) containing protease inhibitor cocktail tablets (Complete Mini, Roche) using an 
electric tissue homogenizer. Lysate was centrifuged at 14,000 x g for 30 minutes at 4°C, and 
the supernatant was removed and stored at -80°C. Protein concentration of samples was 
determined using a Pierce BCA Protein Assay (Thermo Scientific), using bovine serum 
albumin as the standard. Approximately 50-100 µg of tissue lysate was resolved onto 
polyacrylamide Tris-HEPES-SDS gels (Thermo Scientific) under reducing conditions. HeLa 
cell lysate (Santa Cruz Biotechnology) was used as a positive control for immunodetection of 
Pgp. Equality of loading was confirmed by Coomassie Brilliant Blue staining of gels. Proteins 
were transferred to Immobilon-FL PVDF membranes (Millipore) using a semi-dry transfer 
apparatus. For Pgp detection, transfer buffer was prepared without methanol to optimize large 
protein transfer efficiency. Following transfer, non-specific antigens were blocked by 
incubation in Odyssey Blocking Buffer (LI-COR Biosciences) for 1 hour at 4°C. Blots were 
then incubated in blocking buffer containing primary antibodies at the following 
concentrations:  
P-glycoprotein (C219):  1:250 mouse monoclonal, Calbiochem (#513710) 
Mdr-1 (D-11):  1:100 goat polyclonal, Santa Cruz Biotechnology (#sc-55510) 
Beta-actin:  1:20,000 mouse monoclonal, Abcam (#ab6276) 
     1:20,000 rabbit polyclonal, Abcam (#ab8227) 
Cyclooxygenase-1:  1:200 mouse monoclonal, Cayman Chemical (#160110) 
Cyclooxygenase-2:  1:200 rabbit polyclonal, Cayman Chemical (#160126) 
5-Lipoxygenase:  1:250 mouse monoclonal, BD Biosciences (#610694) 
 Membranes were incubated in primary antibodies at room temperature for 1 hour, or at 4°C 
overnight. Blots were then washed in TBS containing 0.1% Tween-20 (TBST), 5X for 5 
minutes, then incubated in blocking buffer containing species-specific IRDye-conjugated 
infrared secondary antibodies (1:500, LI-COR Biosciences). Blots were imaged using the 
Odyssey Infrared Imaging System (LI-COR Biosciences). This detection method has the 
advantages of high sensitivity of detection and increased signal-to-noise ratio over 
chemiluminescence, as well as capability to detect two different antigens on the same blot 
simultaneously. Band intensity was quantified using Odyssey software (LI-COR), and data was 
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analyzed using one-way ANOVA followed by the Student-Newman-Keuls post test (when 
more than two groups were compared), or by Student’s t test (when two groups were 
compared). 
 
Enzyme-Linked Immunosorbent Assay 
 A 1.5-cm piece of spinal cord tissue spanning the epicenter of injury was harvested, snap-
frozen in liquid nitrogen, and stored at -80°C. Homogenization buffer (0.1 M phosphate, pH 
7.4, 1 mM EDTA, 10 µM indomethacin; 1 ml per 100 mg tissue) was added and tissue was 
homogenized on ice using a Polytron homogenizer. For detection of PGE2 only, a purification 
step was performed using a PGE2 Affinity Sorbent Kit (Cayman Chemical Co., Ann Arbor, 
MI). PGE2, LTB4, and CysLT levels were quantified using the appropriate EIA kits (Cayman 
Chemical). All samples were prepared and analyzed in triplicate, and absorbance at 405 nm 
was read in a Model 680 Microplate Reader (Bio-Rad). Standard curves were generated and 
sample concentrations were determined using Cayman EIA data analysis worksheets 
(www.caymanchem.com/analysis/eia). Data was analyzed by one-way ANOVA followed by 
the Student-Newman-Keuls post test. ELISA experiments for chronic spinal cord samples were 
performed in collaboration with Dr. Henry Strobel in The University of Texas Medical School, 
Department of Biochemistry and Molecular Biology. 
 
Metabolomic Profiling 
 Six hours following the final drug treatment, animals were sacrificed and tissue was 
immediately harvested and snap-frozen in liquid nitrogen. A 10-mm segment of spinal cord 
tissue encompassing the lesion site was utilized for metabolomic analysis. Unbiased 
metabolomic profiling of spinal cord samples from uninjured and chronic SCI rats was 
performed using liquid-/gas chromatography coupled to mass spectrometry (LC/GC-MS) as 
previously described (282). At the time of publication, the metabolomics platform is capable of 
detecting approximately 2,400 named metabolites, of which 257 metabolites were detected 
within this study. A data normalization step was performed to correct variation resulting from 
instrument inter-day tuning differences. Each compound was corrected in run-day blocks by 
registering the medians to equal one (1.00) and normalizing each data point proportionately 
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(termed the “block correction”). Following log2 transformation and imputation with minimum 
observed values for each compound, Welch’s two-sample t test was used to identify 
biochemicals that differed significantly between two groups. Lists of biochemicals that 
achieved statistical significance (p ≤ 0.05), as well as those approaching significance (0.05 < p 
< 0.10), are given in TABLES 4.1 & 4.2. An estimate of the false discovery rate (Q value) was 
calculated to take into account the multiple comparisons that normally occur in metabolomic-
based studies; as Q values were reasonable for p ≤ 0.05, no Q value cutoff was established for 
this study. Outliers were defined as 1.5*(inter-quartile range) and removed from analyses. Heat 
maps of metabolomics data (Figs. 4.7, 4.8, & 4.10a) were generated using the open-source 
software package MultiExperiment Viewer version 4.7.3, part of the TM4 Microarray Software 
Suite (Dana-Farber Cancer Institute, Boston) (283). Scaled, imputed, log2-transformed data 
was used to generate heat maps and to perform clustering analysis. Pearson distances (1-r, 
where r is the Pearson correlation coefficient) were used as the pairwise distance between 
individual replicates for hierarchical clustering by biochemical. 
 
High-Performance Liquid Chromatography 
 All reagents used for HPLC experiments were HPLC-grade (ChromaSolv, Sigma-Aldrich). 
Riluzole stock solutions (1 mM) were prepared by dissolving riluzole in 1:1 H2O:CH3OH. 
Stock solutions were stored for up to 3 months at -20°C. Serial dilutions of riluzole stock 
solutions were prepared and known amounts of riluzole were injected onto the HPLC system in 
the following quantities: 0.05, 0.1, 0.5, 1, and 2 nmoles. A calibration curve was generated 
using Empower 3 Chromatography Data Software program (Waters) (Fig. 2.2). The R2 value 
obtained for the riluzole calibration curve was 0.998. 
Tissue Extraction of Riluzole 
 Animals were dosed with riluzole, and sacrificed 2 hours later. Animals were transcardially 
perfused with ice-cold saline, and spinal cords were immediately harvested, rinsed, and snap-
frozen on dry ice.  
Spinal cord riluzole extraction:  A 1.5-cm segment of spinal cord tissue centered around 
the lesion site was homogenized, and riluzole was extracted with ethyl acetate as 
previously described (284). Samples were re-suspended in 100 µl mobile phase buffer.   
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Figure 2.2.  HPLC chromatograph and calibration curve for riluzole. Known amounts of 
riluzole were injected onto the HPLC system, generating a series of chromatographic peaks that 
were integrated to produce a calibration curve (inset). AU, absorbance units. 
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Plasma riluzole extraction:   Whole blood was obtained by cardiac puncture immediately 
following sacrifice, and plasma was recovered by centrifugation at 1,300 x g for 10 min at 
4°C. Plasma samples were diluted 1:2 in 0.01 M phosphate buffer, pH 7.4 and riluzole was 
recovered via solid-phase extraction as previously described (285). Samples were re-
suspended in 75 µl mobile phase buffer and filtered through Millex-GV4 0.22 µM 
membranes (Millipore) before injection onto the HPLC system. 
High-Performance Liquid Chromatography Separation and Analysis 
 The HPLC system consisted of a Waters 515 HPLC pump, a Waters 996 Photodiode Array 
Detector, and a CI-10B integrator (LDC Analytical). Separation was achieved through a 
ZORBAX Extend-C18 column (4.6 x 150 mm) (Agilent Technologies) with a 20-mm ODS 
pre-column (Custom LC, Inc.). The mobile phase consisted of 68% CH3OH and 32% of [1% 
TEA in H2O, adjusted to pH 3.2 with H3PO4]. The flow was isocratic with a constant flow rate 
of 0.5 ml/min. The sample injection volume was 100 µl (spinal cord samples) or 75 µl (plasma 
samples). Absorbance was continuously monitored at a wavelength of 254 nm. Riluzole peaks 
(retention time = ~9 minutes) were identified and integrated at 264 nm, and quantified using 
previously run calibration curves. Naïve spinal cord and plasma samples were spiked with 0.5 
nmoles riluzole and extracted, then analyzed by HPLC to determine percent recovery of 
riluzole (63.2% in spinal cord; 76.4% in plasma). Riluzole concentrations in spinal cord 
samples were normalized to plasma concentrations to obtain a spinal cord/plasma ratio for each 
animal. Riluzole concentrations were analyzed by one-way ANOVA followed by the Student-
Newman-Keuls post test.  
 
Statistical Analysis 
 All statistical analysis was performed using SigmaPlot 11 (Systat Software, Inc., Chicago, 
Illinois) or GraphPad Prism 5. Student’s t test was used for comparisons between two groups. 
For comparisons among more than two groups for parametric data, one-way ANOVA followed 
by the Student-Newman-Keuls post test was used. Multiple-group, repeated-measures 
comparisons of parametric data were performed using a two-way repeated measures ANOVA, 
followed by appropriate multiple comparisons tests. Nonparametric data (BBB scores) were 
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compared across groups using a Kruskal-Wallis test followed by a Dunn’s post-test. p values < 
0.05 were considered statistically significant. 
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CHAPTER 3 
Assessment of P-glycoprotein Expression and Function 
Following Spinal Cord Injury in the Rat 
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Background 
 It has long been known that treatment with chemotherapeutic drugs can induce 
overexpression of Pgp in multiple types of cancer, conferring tumor cells with simultaneous 
cross-resistance to multiple cytotoxic chemotherapeutic compounds (286-288). This 
phenomenon, known as multidrug resistance, is a major obstacle to the efficacy of cancer 
therapy, and identifying new avenues to circumvent this obstacle remains a chief priority in the 
field of oncology research (289, 290). More recently, several preclinical and clinical studies 
have shown that in neurological diseases characterized by high levels of excitotoxicity, 
oxidative stress, and inflammation in the brain, Pgp can become pathologically overexpressed 
at the blood-brain barrier (223, 224, 235, 244). As a consequence, it is now acknowledged that 
Pgp overexpression presents a formidable obstacle to effective CNS drug delivery in patients 
suffering from neurological diseases (214).   
 Pgp expression and function in the healthy and diseased brain has been a subject of much 
investigation over the last few decades. Despite this, relatively few groups have focused on the 
role of Pgp drug efflux activity in the BSCB. Bernards and colleagues have drawn attention to 
Pgp efflux activity as a barrier to penetration of systemically-delivered methylprednisolone into 
spinal cord tissue in SCI patients (242, 243). They emphasized that the high dose of MPSS 
needed to approach therapeutic spinal cord levels is associated with harmful peripheral side 
effects that might be avoided by circumventing Pgp efflux activity. However, whether Pgp 
undergoes pathological up-regulation following SCI, as has been observed in other 
neuroinflammatory conditions, has not yet been addressed. If multidrug resistance does develop 
in the spinal cord following traumatic injury, then Pgp may present an even more 
insurmountable barrier to effective delivery of neuroprotective drugs than previously 
speculated (243). 
 
Specific Aims  
1. A central feature of multidrug resistance in neurological diseases is overexpression of 
Pgp at the blood-brain barrier (234). Previous work has shown that the BSCB undergoes 
multiple structural and functional alterations after traumatic SCI (72, 168, 173, 291); 
however, Pgp expression at the BSCB in response to SCI has not yet been investigated. 
61 
 
We therefore sought to assess the temporal and spatial expression profiles of Pgp within 
the spinal cord following SCI. 
2. The functional consequence of pathological Pgp overexpression at the blood-brain 
barrier is reduced brain penetration of blood-borne drugs such as riluzole (224). 
Therefore, we anticipated that Pgp overexpression within the injured spinal cord would 
also correspond with reduced spinal cord drug bioavailability. We investigated this 
possibility by evaluating spinal cord concentrations of systemically-delivered riluzole 
during acute and sub-acute phases of SCI, and using transgenic mdr1a-/- rats to delineate 
the role of Pgp in conferring spinal cord drug resistance5. 
 
Results 
Expression of ABC Transporter Genes Following Spinal Cord Injury 
 In humans, there is only one Pgp gene product that confers multidrug resistance—MDR1 
(292). Rodents express two 90% homologous isoforms, Mdr1a (Abcb1a) and Mdr1b (Abcb1b), 
and both confer multidrug resistance (293). The distinction between the expression patterns of 
these two isoforms is somewhat unclear. It has been reported that only the Mdr1a gene product 
is expressed in rodent brain capillary endothelial cells under normal conditions (294, 295) and 
loss of mdr1a gene expression results in heightened CNS sensitivity to drugs (296). Schinkel 
and colleagues demonstrated that the accumulation of digoxin (a Pgp substrate) in the brains of 
mdr1a/1b-/- mice was only slightly greater than that of mdr1a-/- mice (295). However, other 
studies have reported an increased expression of both mdr1a and mdr1b genes in mouse brain 
capillary endothelial cells in response to inflammatory lipopolysaccharide (LPS) treatment 
(245), which is accompanied by an increase in Pgp protein expression and activity (297). The 
differential regulation of both Mdr1a and Mdr1b gene products under pathological conditions is 
unclear, but their considerable functional redundancy suggests that both may play a role in 
multidrug resistance under neuroinflammatory conditions. 
 Microarray analysis was performed to detect changes in expression of ABC transporter 
genes within the T10 spinal cord at one week after SCI (n = 6) compared to uninjured controls 
                                                          
5
 The term drug resistance is used in this dissertation to indicate a reduction in the spinal cord 
penetration of drug from the plasma following systemic (i.v. or i.p. delivery) of that drug. 
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(n = 6) (TABLE 3.1). Microarray data revealed differential expression of several ABC 
transporter genes within the lesion site of animals one week after injury. Of these family 
members, abcb1b, encoding the Mdr1b isoform of Pgp, exhibited the most dramatic up-
regulation with ten-fold higher expression levels compared with controls (+10.05-fold, p < 
0.001)6. Among other family members exhibiting up-regulation was abcb4 (mdr2), a selective 
transporter of phosphatidylcholine, expression of which was increased substantially in injured 
tissue (+6.07-fold, p < 0.001).  
 
TABLE 3.1.  Differential expression of ABC transporter genes 7 days following spinal cord 
injury. DNA microarray gene expression data for ABC transporter family members at 7 days 
following SCI in the rat T10 spinal cord. Gene expression is represented as fold change versus 
uninjured control levels (0 indicates no change in expression versus controls). Up-regulated 
genes are highlighted in green and down-regulated genes are highlighted in red. abcb1b (bold) 
encodes rat P-glycoprotein. All gene expression data included in this table are p < 0.01 versus 
uninjured controls.  
                                                          
6
 The Illumina microarray chip used in this study did not contain a probe against abcb1a.  
63 
 
 We also detected significantly decreased expression of several ABC transporter family 
members during acute SCI. Genes exhibiting the most prominent down-regulation included 
abcc2, encoding the multidrug resistance-associated protein 2 (MRP2), (-13.92-fold, p < 
0.001), and abcd2, encoding the adrenoleukodystrophy-related protein (ALDRP), (-5.54-fold, p 
< 0.001). Like Pgp, MRP2 is expressed on the luminal membrane of brain capillary endothelial 
cells and possesses broad substrate specificity, contributing to efflux of drugs and other 
compounds (298). ALDRP does not contribute to multidrug resistance, but its dysfunction is 
implicated in the neuroinflammatory disease adrenoleukodystrophy (299). It is possible that 
more than one member of the ABC transporter family, for which we have observed differential 
expression after SCI, may play a role in the pathophysiology and/or treatment of SCI. For this 
study, we chose to focus specifically on investigating Pgp, largely due to its extensively 
described role in a variety of diseases including cancer and several neurodegenerative diseases 
(224, 227, 230, 300). 
 To corroborate our microarray data and assess whether Pgp undergoes SCI-induced up-
regulation at the transcriptional level, we next performed quantitative real time PCR (qRT-
PCR) analysis of abcb1b gene expression (Fig. 3.1). Our results revealed a twelve-fold increase 
in the lesion site of rats 7 days post-SCI (RQ = 9.10 ± 0.67, n = 3) compared with expression in 
uninjured controls (0.76 ± 0.12, n = 4). Moreover, we observed that abcb1b gene expression 
was also increased three-fold in the T10 cord of rats 8 months post-SCI (2.60 ± 0.24, n = 5) 
compared to age-matched, uninjured controls (0.87 ± 0.077, n = 5). These findings suggest that 
Pgp transcription is increased not only in the acutely-injured spinal cord, but in the chronic 
phase of injury as well. 
 
Expression of P-glycoprotein Within the Injured Spinal Cord 
 Pgp expression in the brain is restricted to the luminal membrane of capillary endothelial 
cells; although one group has reported Pgp expression in the membranes of astrocyte foot 
processes (301-304), their observations have not been replicated and thus remain dubious 
(203). We therefore examined the localization of Pgp expression in rat spinal cord tissue. In the 
wild-type, uninjured rat, Pgp immunoreactivity was restricted to spinal cord blood vessel 
endothelial cells, and was not observed on astrocytes (Fig. 3.2). Immunohistochemical staining  
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Figure 3.1.  Expression of abcb1b is increased during acute and chronic spinal cord 
injury. qRT-PCR gene expression data for T10 spinal cord tissue from rats 7 days and 8 
months post-SCI, versus age-matched, uninjured control expression levels. RQ, relative 
quantity of abcb1b expression (fold change). All data are mean ± s.e.m. *, p < 0.001 versus 
uninjured, age-matched controls. 
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Figure 3.2.  P-glycoprotein expression is localized to blood vessels in the intact spinal 
cord. (a) Coronal spinal cord section with Pgp immunoreactivity in green. Cartoon indicates 
field of view (red-bounded box). Scale bar = 250 µm. (b) Pgp immunoreactivity co-localizes 
with the endothelial marker von Willebrand factor (vWF), but not with the astrocytic marker 
glial fibrillary acidic protein (GFAP). Scale bar = 100 µm. 
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Figure 3.3.  P-glycoprotein is expressed on the luminal surface of spinal cord blood 
vessels. Pgp immunoreactivity (brown) is localized to the luminal surface of capillary 
endothelial cells in the intact spinal cord (arrowhead). Nuclei are stained blue. Scale bar = 10 
µm. 
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also revealed strong Pgp localization on the luminal surface of capillary endothelial cells in the 
spinal cord (Fig. 3.3), consistent with previous reports (305). We did not observe localization 
of Pgp immunoreactivity in any other cell types. To evaluate whether different cell types might 
also express Pgp following SCI, we also examined Pgp immunoreactivity in the spinal cord 
lesion site 7 days after injury (Fig. 3.4). We did not observe co-localization with macrophages 
(Fig. 3.4a) or astrocytes (Fig. 3.4b) at this time point; rather, Pgp expression still appeared to 
be restricted to capillary endothelial cells. 
 
Figure 3.4.  P-glycoprotein expression is localized to blood vessels 7 days following spinal 
cord injury. Pgp immunoreactivity (green) co-localizes with blood vessel endothelial cell 
markers within the spinal cord lesion site one week post-SCI. (a) Pgp co-localizes with spinal 
cord vasculature and not with macrophages. von Willebrand factor (vWF), blue; ED2, rat 
mature macrophage antigen, red. (b) Pgp does not co-localize with astrocytes. Glial fibrillary 
acidic protein (GFAP), blue. Scale bars = 100 µm. 
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 For subsequent studies, we elected to examine spinal cord Pgp expression via immunoblot 
analysis. Mice and rats express two distinct Pgp gene products, Mdr1a and Mdr1b, both of 
which are expressed in the CNS, though the Mdr1a isoform more predominantly so (198). To 
verify the efficacy of the anti-Pgp antibody for immunodetection in western blots, we 
performed SDS-PAGE on total protein samples from uninjured spinal cord tissue harvested 
from mdr1a/b-/- mice (Fig. 3.5) as well as mdr1a-/- rats (Fig. 3.6) (double mdr1a/b knockout 
rats were not available at the time of this study). mdr1 knockout animals exhibited normal 
phenotypes, and were indistinguishable from wild-types. We observed multiple non-specific 
bands on immunoblots for both mouse and rat samples (Fig. 3.7, arrowheads), most likely as a 
result of the high concentration of the primary antibody (1:100) used for immunodetection. Pgp 
was identified as the prominent band migrating to ~170 kDa, which was conspicuously absent 
in spinal cord tissue lysates from mdr1 knockout animals (Figs. 3.5, 3.6). Pgp 
immunoreactivity often appeared as a diffuse band, an observation which is likely attributed to 
variable states of glycosylation, as Pgp is normally heavily glycosylated (10-15 kDa of 
glycosylation) on its N-terminal domain (203). 
 
Figure 3.5.  P-glycoprotein is absent in spinal cords of mdr1a/b-/- mice. Representative 
immunoblot of total protein extract from spinal cord tissue of uninjured wild-type and mdr1a/b 
knockout mice. Immunoreactivity against Pgp is conspicuously absent in samples from 
knockout mice. Immunoreactivity in upper band (indicated by arrowhead) is due to non-
specific binding. 
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Figure 3.6.  P-glycoprotein is absent in spinal cords of mdr1a-/- rats. Representative 
immunoblot of total protein extract from spinal cord tissue of uninjured wild-type and mdr1a 
knockout rats. Pgp immunoreactivity is absent in samples from knockout rats. 
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Figure 3.7.  P-glycoprotein immunoblots exhibit multiple non-specific bands. Pgp 
immunoreactivity in protein samples from spinal cord tissue of (a) uninjured wild-type and 
mdr1a/b knockout mice, and (b) uninjured wild-type and mdr1a knockout rats. HeLa cell lysate 
is a positive control for human MDR immunoreactivity. Arrowheads indicate non-specific 
bands. Band of Pgp immunoreactivity (170 kDa) is labeled at left. 
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 We next investigated the temporal and spatial expression profile of Pgp within the injured 
spinal cord. Pgp expression levels at 72 hours, 7 days, 4 months, and 10 months post-SCI were 
quantified and compared to uninjured, age-matched controls via immunoblot analysis. We 
observed that Pgp expression was significantly higher within the lesion site of injured animals, 
compared with thoracic cord tissue of uninjured controls, at all time points from 72 hours to 10 
months post-SCI (Fig. 3.8). At 3 days post-injury, expression of the transporter protein was 
nearly three-fold greater than that of uninjured controls, and at 10 months post-SCI, levels were 
more than four-fold greater. These findings corroborate our gene expression data (Fig. 3.1), 
providing further evidence that Pgp expression is increased in the spinal cord injury site in both 
the acute and chronic phases of injury. 
 Previous studies in our lab have revealed that BSCB dysfunction following SCI is 
sustained into the chronic phase of injury; moreover, this barrier dysfunction spreads to spinal 
cord regions centimeters away from the T10 lesion site in the rat. This progressive spread of 
BSCB failure is characterized by reduced expression of adherens junction proteins and 
increased vascular permeability to large molecules, such as immunoglobulin G (IgG) and 
albumin (unpublished studies performed by Dr. Raymond Grill). One major goal of our 
laboratory is to develop a more comprehensive understanding of vascular pathology following 
injury to the spinal cord. The previously reported deficits in BSCB function have described 
components of passive BSCB failure—leakiness or increased permeability to small and large 
molecules due to increased passive paracellular and transcellular diffusion (177). However, it 
has not previously been investigated whether SCI also induces changes in active transport at the 
BSCB. The pathological changes in the properties of the BSCB are widely thought to solely 
encompass passive changes that enhance barrier permeability. An overarching goal of the 
current study is to investigate whether deficits in the BSCB following SCI extend to alterations 
in active transport as well.  
 We evaluated whether there were progressive, spatial changes in Pgp expression patterns 
following SCI by examining protein levels in spinal cord regions several segments removed 
from the initial site of injury. We found that Pgp expression was significantly increased within 
the cervical enlargement (C6-C7) of the spinal cord at 7 days, 4 months, and 10 months post-
SCI (Fig. 3.9). Furthermore, Pgp expression was increased in the lumbar enlargement (L3-L4) 
of the spinal cord at 4 months and 10 months following injury (Fig. 3.10). Thus, the 
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Figure 3.8.  P-glycoprotein expression is increased in the spinal cord lesion site during 
acute and chronic spinal cord injury. Pgp expression levels in T10 spinal cord tissue were 
quantified by immunoblot analysis and normalized to β-actin. Representative immunoblots are 
shown below the graph (U, Uninjured; S, SCI). Pgp expression is significantly increased at 3 
days [Uninjured = 1.00 ± 0.09 (n = 7); SCI = 2.92 ± 0.63 (n = 6), p = 0.0073], 7 days, 
[Uninjured = 1.00 ± 0.15 (n = 6); SCI = 1.61 ± 0.29 (n = 7), p < 0.001], 4 months [Uninjured = 
1.00 ± 0.07 (n = 5); SCI = 1.93 ± 0.27 (n = 6), p = 0.011], and 10 months [Uninjured = 1.00 ± 
0.05 (n = 8); SCI = 4.36 ± 0.67 (n = 4), p < 0.001] following SCI. All data are mean ± s.e.m. *, 
p < 0.05 versus uninjured, age-matched controls.  
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Figure 3.9.  P-glycoprotein expression is increased in the cervical spinal cord following 
spinal cord injury. Pgp expression levels in cervical spinal cord tissue were quantified by 
immunoblot analysis and normalized to β-actin. Cartoon indicates region of spinal cord tissue 
analyzed. Representative immunoblots are shown below the graph (U, Uninjured; S, SCI). Pgp 
expression is significantly increased at 7 days, [Uninjured = 1.00 ± 0.16 (n = 6); SCI = 1.89 ± 
0.15 (n = 8), p = 0.002], 4 months [Uninjured = 1.00 ± 0.11 (n = 6); SCI = 1.97 ± 0.33 (n = 6), 
p = 0.021], and 10 months [Uninjured = 1.00 ± 0.11 (n = 8); SCI = 1.61 ± 0.16 (n = 5), p = 
0.009] following SCI. All data are mean ± s.e.m. *, p < 0.05 versus uninjured, age-matched 
controls.  
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Figure 3.10.  P-glycoprotein expression is increased in the lumbar spinal cord during 
chronic spinal cord injury. Pgp expression levels in lumbar spinal cord tissue were quantified 
by immunoblot analysis and normalized to β-actin. Cartoon indicates region of spinal cord 
tissue analyzed. Representative immunoblots are shown below the graph (U, Uninjured; S, 
SCI). Pgp expression is significantly increased at 4 months [Uninjured = 1.00 ± 0.07 (n = 6); 
SCI = 2.60 ± 0.42 (n = 6), p = 0.004] and 10 months [Uninjured = 1.00 ± 0.07 (n = 6); SCI = 
1.93 ± 0.27 (n = 5), p = 0.011] following SCI. All data are mean ± s.e.m. *, p < 0.05 versus 
uninjured, age-matched controls. 
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pathological increase in Pgp expression after SCI is not merely restricted to the lesion site. 
Rather, our data suggests that increased Pgp expression is a progressive and spatially expanding 
phenomenon, which may reflect a larger, ongoing BSCB pathology secondary to SCI.  
 
Role of P-glycoprotein in Spinal Cord Riluzole Bioavailability Following Spinal Cord Injury 
 Riluzole is an FDA-approved drug for the treatment of ALS that has neuroprotective and 
anti-glutamatergic properties (88). Milane and colleagues have demonstrated that riluzole is a 
substrate of Pgp efflux (225), and that Pgp overexpression in the brain of mice expressing 
mutant human SOD1 results in reduced brain bioavailability of riluzole subsequent to systemic 
delivery (224). Riluzole is currently being investigated as an acute neuroprotective SCI 
intervention in an ongoing national clinical trial (87). The impetus to translate riluzole to the 
clinic is fueled by several preclinical studies demonstrating its ability to improve histological 
and functional outcome in animal models of SCI (78-86). If our observations of increased Pgp 
expression following SCI have the functional consequence of reduced spinal cord riluzole 
levels, similar to that observed by Milane and colleagues (224), these findings would be highly 
clinically relevant.  We therefore sought to examine whether spinal cord riluzole bioavailability 
is altered following SCI, and if so, whether Pgp mediates this phenomenon.  
 In a pharmacokinetics study, Milane et al. (306) showed that following i.p. delivery, the 
extent of brain penetration of riluzole is directly proportional to plasma riluzole levels in wild-
type mice at a dosing concentration of 10 mg/kg (306), establishing the brain/plasma riluzole 
concentration ratio as an effective indicator of plasma-to-brain riluzole penetration. The same 
group has also demonstrated increased brain/plasma ratios of riluzole in mdr1a knockout mice 
(225), and reduced brain/plasma ratios in mSOD1 mice with increased brain Pgp expression 
(224). These experiments highlight the vital role of Pgp activity at the blood-brain barrier in 
determining plasma-to-brain penetration of riluzole. We therefore designed an experiment 
modeled on those previous studies, in order to examine whether the plasma-to-spinal cord 
penetration of riluzole is altered following SCI. Three weeks following SCI, rats were treated 
with a single systemic (i.p.) bolus of riluzole, and drug concentrations in spinal cord and 
plasma samples were quantified. We found that the spinal cord/plasma ratio of riluzole was 
significantly decreased in rats 3 weeks after SCI versus uninjured controls (Fig. 3.11). 
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Figure 3.11.  Spinal cord riluzole bioavailability is decreased 21 days after SCI. (a) 
Schematic illustrating experimental timeline. Three weeks following SCI, animals received a 
single i.p. bolus of riluzole (RLZ). Two hours later, riluzole concentrations in whole spinal cord 
tissue and in plasma were measured by HPLC. Spinal cord riluzole concentrations were 
normalized to plasma concentrations to determine the spinal cord/plasma ratio. (b) Spinal cord 
riluzole levels were significantly reduced in animals three weeks post-SCI (74.1 ± 5.20%, n = 
7) versus uninjured controls (100 ± 9.21%, n = 7, p = 0.031). (c) Raw riluzole concentrations in 
plasma and spinal cord tissue were significantly decreased in injured rats compared to 
uninjured controls. Plasma: Uninjured = 100 ± 4.95%; SCI = 69.7 ± 6.66; p = 0.003. Spinal 
cord: Uninjured = 100 ± 5.19; SCI = 52.3 ± 6.00; p < 0.001. All data are mean ± s.e.m., 
expressed as percent of control values. *, p < 0.05 versus uninjured, age-matched controls.  
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 We also examined raw plasma concentrations of riluzole, in order to determine whether the 
pharmacokinetics of riluzole were altered following SCI. Plasma riluzole levels were also 
significantly reduced in injured rats (Fig. 3.11c). We speculate that this observation might be 
due to pathological alterations in drug metabolism or excretion during this time point of sub-
acute SCI. Milane and colleagues showed that mdr1a-/- mice exhibited higher plasma riluzole 
levels (following i.p. injection), presumably due to a reduced biliary excretion rate (306); in 
contrast, our observed reduction in plasma levels may be explained by increased excretion of 
riluzole from the plasma compartment because of injury-induced up-regulation of Pgp in the 
liver. Because the degree of spinal cord riluzole penetration is determined solely by plasma 
bioavailability (and alterations in blood-spinal cord barrier transport), the spinal cord/plasma 
concentration ratio is a more accurate representation of plasma-to-spinal cord riluzole 
penetration than raw spinal cord riluzole levels alone (306). Thus, the reduction that we have 
observed in drug plasma bioavailability of injured rats is not sufficient to explain the more 
pronounced reduction in raw spinal cord riluzole levels (Fig. 3.11c). Based on the significant 
reduction in spinal cord/plasma riluzole ratios following injury, we conclude that there is a 
reduced degree of plasma-to-spinal cord riluzole penetration into the spinal cord, compared to 
uninjured controls, by three weeks after SCI. 
 To assess whether this phenomenon might be mediated by Pgp, we utilized mdr1a 
knockout rats for a subsequent assessment of spinal cord riluzole bioavailability after SCI. 
Because mdr1a-/- rats do not express Pgp at the blood-brain barrier (307) or the BSCB (Fig. 
3.6), they are an ideal tool with which to study spinal cord Pgp function in a rat SCI model7.  
                                                          
7
 There is a wealth of evidence in the literature that mdr1a is the predominant isoform of Pgp expressed 
at the blood-brain barrier under normal conditions (203). Moreover, a comparison of Pgp transport 
activity between mdr1a and  mdr1a/1b knockout mice reveals that the loss of both gene products does 
not substantially affect the brain disposition of systemically-delivered drugs compared to the loss of 
Mdr1a alone (295); thus, the majority of Pgp function at the blood-brain barrier is most likely normally 
mediated through the Mdr1a isoform. Despite this, we have observed up-regulation of mdr1b gene 
expression during acute and chronic SCI (TABLE 3.1 & Fig. 3.1). Expression of mdr1b has been shown 
to be up-regulated by neuroinflammatory conditions (245, 297); thus, it is conceivable that the 
development of resistance to riluzole in the injured spinal cord may be at least partially mediated by the 
Mdr1b gene product. We chose to utilize the mdr1a-/- rat for these studies—despite the availability of 
single- and double mdr1 knockout mouse lines—largely because of the distinct behavioral and 
pathophysiological differences between mouse and rat models of SCI (6, 60). Only mdr1a knockout rats 
were available for purchase from Sage Labs at the time these experiments were performed. 
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Ten days after SCI was performed on wild-type and mdr1a-/- rats, we administered a single i.p. 
bolus of riluzole then examined spinal cord and plasma riluzole concentrations via HPLC (Fig. 
3.12). We found that normalized spinal cord/plasma riluzole levels were significantly decreased 
in wild-type rats following injury (p = 0.002), but that there was no detectable difference in 
drug levels between KO injured and uninjured groups (p = 0.375). Notably, normalized spinal 
cord/plasma riluzole levels were significantly higher in KO rats, than in WT rats, 10 days post-
SCI (p = 0.006). These findings illustrate a critical role for Pgp function in the development of 
spinal cord drug resistance to riluzole following SCI. 
 We also evaluated plasma riluzole concentrations (Fig. 3.13). There was no significant 
difference in plasma riluzole levels between uninjured wild-type rats (100 ± 5.83%) and injured 
wild-type rats (104 ± 4.74%, p = 0.479). There was also no significant difference in plasma 
riluzole levels between uninjured wild-type rats and mdr1a-/- rats (89.3 ± 2.13%, p = 0.577). 
This was an unexpected finding, in light of the observations of Milane et al. that mdr1a-/- mice 
exhibited higher plasma riluzole levels compared to wild-type mice after i.p. injection (306). 
However, our observation is likely explained by the fact that the Mdr1b isoform is expressed at 
normal levels in the liver of mdr1a-/- rats (Fig. 3.14); thus, Mdr1b function probably plays a 
compensatory role in the excretion of riluzole from the plasma in the absence of Mdr1a. 
 There appeared to be a slight decrease, but no significant difference, in plasma riluzole 
levels of mdr1a-/- rats following injury (KO SCI = 75.2 ± 5.04 %, p = 0.258). Compared with 
our observations of decreased plasma riluzole levels at 3 weeks after injury, the lack of effect 
of SCI on plasma drug levels at 10 days after injury suggests that there may be a time-
dependent effect on riluzole pharmacokinetics in wild-type rats. Interestingly, we observed a 
significant effect of genotype on plasma riluzole levels between injured groups (but not 
between uninjured groups); riluzole plasma levels were significantly lower in mdr1a-/- rats 
compared to wild-type rats. This finding suggests that mdr1a knockout rats probably have 
enhanced metabolism or clearance of riluzole compared to wild-types at 10 days post-SCI, 
although investigation as to the possible mechanism(s) underlying this requires further study. 
 In conclusion, we have found that spinal cord/plasma ratios of systemically-delivered 
riluzole were significantly higher in mdr1a-/- rats compared to wild-type rats after SCI (Fig. 
3.12). Curiously, we did not observe an increase in raw riluzole spinal cord concentrations in  
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Figure 3.12.  Spinal cord riluzole bioavailability is decreased 10 days after spinal cord 
injury in wild-type but not mdr1a-/- rats. Abbreviations: WT, wild-type; KO, mdr1a 
knockout; U, uninjured; S, 10 days post-SCI. (a) Schematic illustrating experimental timeline. 
Ten days following SCI, animals received a single i.p. bolus of riluzole (RLZ). Two hours later, 
riluzole concentrations in T10 spinal cord tissue and in plasma were measured by HPLC. 
Spinal cord riluzole concentrations were normalized to plasma concentrations to determine the 
spinal cord/plasma ratio. (b) Normalized spinal cord riluzole levels were significantly reduced 
in WT rats with SCI (81.6 ± 3.54%, n = 9) versus WT uninjured controls (100 ± 8.73%, n = 10, 
p = 0.002). There was no significant effect of injury on spinal cord/plasma riluzole ratios in KO 
rats (KO uninjured = 95.8 ± 6.94%, n = 6; KO SCI = 97.8 ± 6.91%, n = 7, p = 0.375). 
Normalized riluzole levels were significantly higher in injured KO rats compared to injured 
WT rats (p = 0.006). All data are mean ± s.e.m., expressed as percentage of wild-type, 
uninjured controls. *, p < 0.05. 
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Figure 3.13.  Plasma riluzole concentrations are decreased in injured mdr1a-/- rats 
compared to injured wild-type rats. Abbreviations: WT, wild-type; KO, mdr1a knockout; U, 
uninjured; S, 10 days post-SCI. Plasma riluzole levels were significantly reduced in KO rats 
with SCI (75.2 ± 5.04%) versus WT rats with SCI (104 ± 4.74%, p = 0.002). WT uninjured = 
100 ± 5.83%; KO uninjured = 89.3 ± 2.13%). All data are mean ± s.e.m., expressed as 
percentage of wild-type, uninjured controls. *, p < 0.05. 
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Figure 3.14.  mdr1a-/- rats express Mdr1b in the liver. “Western blots showing undetectable 
levels of Mdr1a protein in the brain and small intestine (S. Intestine) of knockout (KO) rats. In 
the liver sample, the band with a size that was apparently similar to that of the Mdr1a protein in 
KO rats may represent the up-regulated Mdr1b protein because of the cross-reactivity of the 
antibody. The weak potential Mdr1b protein was detected in the kidney of KO rats as well but 
not as strongly as in liver.” Quoted from Xiaoyan Chu, Zuo Zhang, Jocelyn Yabut, Sarah 
Horwitz, John Levorse, Xiang-qing Li, Lei Zhu, Harmony Lederman, Rachel Ortiga, John 
Strauss, Xiaofang Li, Karen A. Owens, Jasminka Dragovic, Thomas Vogt, Raymond Evers, 
and Myung K. Shin, Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout 
Rats Generated by Zinc Finger Nucleases, Mol Pharmacol February 2012 81:220-227. 
Reprinted with permission (307).  
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uninjured mdr1a-/- rats compared to wild-type rats (Fig. 3.15), which may be attributable to 
compensatory activity of another drug efflux transporter. Despite this, our finding that spinal 
cord riluzole delivery is significantly diminished following SCI in wild-type but not mdr1a-/- 
rats provides compelling support for the central role of Pgp in mediating post-SCI spinal cord 
drug resistance. 
 
 
 
 
Figure 3.15.  Raw spinal cord riluzole concentrations are decreased 10 days after spinal 
cord injury in wild-type but not mdr1a-/- rats. Abbreviations: WT, wild-type; KO, mdr1a 
knockout; U, uninjured; S, 10 days post-SCI. Spinal cord riluzole levels were significantly 
reduced in WT rats with SCI (66.2 ± 2.84%) versus WT uninjured controls (100 ± 10.18%, p < 
0.001). There was no significant effect of injury on spinal cord/plasma riluzole ratios in KO 
rats (KO uninjured = 93.8 ± 4.49%; KO SCI = 100.2 ± 5.94%, p = 0.767). Raw spinal cord 
riluzole levels were significantly higher in injured KO rats compared to injured WT rats (p = 
0.004). All data are mean ± s.e.m., expressed as percentage of wild-type, uninjured controls. *, 
p < 0.05. 
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CHAPTER 4 
Characterization of Inflammation in the Injured Spinal Cord 
& 
The Effects of Licofelone Treatment on P-glycoprotein 
Expression and Riluzole Bioavailability 
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Background 
 Increased P-glycoprotein expression is a hallmark of diseases such as cancer, and it has 
recently been shown to occur in a number of neurological diseases as well. Multidrug 
resistance caused by heightened Pgp-mediated drug efflux attenuates the efficacy of therapeutic 
drugs indicated to treat these diseases, and overcoming this phenomenon is a highly desirable 
goal. Because pharmacological Pgp inhibition is not a viable therapeutic solution to overcome 
drug resistance (300), a more desirable strategy is to prevent Pgp overexpression by 
pharmacologically targeting the molecular mechanisms that up-regulate it (234). There is a 
wealth of evidence that inflammation drives pathological increases in Pgp expression. For 
example, prolonged (hours) exposure to TNF-α and endothelin-1 increase Pgp expression and 
activity in brain capillary endothelial cells (308). Other inflammatory mediators, such as IL-1β, 
as well as substances such as LPS, have been shown to have differential effects on Pgp 
expression in various in vitro and in vivo models of central- and peripheral nervous system 
inflammation (198). Because of the complex nature of inflammatory response, and the diversity 
of results observed in various dose-dependent and context-dependent models, the exact nature 
of inflammatory regulation of Pgp expression is still relatively unclear. 
 Potschka and colleagues have gained much insight into the pathological up-regulation of 
Pgp via COX signaling in rodent models of seizure (See Fig. 1.10) (187). In addition to their 
work, a variety of recent studies have substantiated the role of COX signaling in driving Pgp 
up-regulation in experimental models of cancer (238-241, 309). Thus, there appears to be a 
growing body of evidence showing that pro-inflammatory COX signaling is important for 
driving pathological Pgp overexpression in various diseases, and that inhibiting this pathway 
can enhance therapeutic drug delivery. In Potschka’s model, it is not indicated exactly how the 
COX-dependent up-regulation of Abcb1 gene expression occurs at the transcriptional level, 
though the author speculates that the transcription factor NF-kB is a likely candidate based on 
evidence that brain COX-2 activity can induce NF-kB activation (245, 246). More recently, 
other groups have published findings that NF-kB does indeed promote increased Pgp 
expression in a kainic acid-induced seizure model (310), and that NF-kB mediates increased 
transcription of Mdr1b in cerebral LPS-induced inflammation (245, 297). Thus, it appears 
likely that pro-inflammatory COX signaling acts via NF-kB activation to promote up-
regulation of Pgp in neuroinflammatory diseases. Interestingly, the parallel pro-inflammatory 
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5-LOX branch of oxidative AA metabolism is an upstream activator of NF-kB activation as 
well (311-313). Furthermore, it has been shown that inhibiting 5-LOX activity blocks NF-kB 
activation during cerebral ischemia (314). Given the intimate relationship between COX and 5-
LOX signaling (155, 315), one might speculate that these two pro-inflammatory signaling 
pathways may act via a common mechanism to promote Pgp up-regulation in the diseased 
CNS. 
 We have observed increased Pgp expression within the spinal cord at acute (72 hours, 7 
days) and chronic (4 months, 9 months) time points after injury (See Chapter 3). Given the 
large amount of evidence supporting a role for inflammation in driving Pgp up-regulation, we 
became interested in whether inflammation could also be detected within the injured spinal 
cord at each of these time points. Because there has historically been much interest in the role 
of inflammation in acute SCI, a number of studies have investigated the presence of COX- and 
5-LOX pathway components within the injured spinal cord at early time points (121, 141). In 
contrast, relatively little is known about whether inflammatory signaling persists beyond a 
period of several weeks post-SCI. This unexplored question is largely attributed to the fact that 
the chronically-injured spinal cord has historically been a subject of relatively little study. 
Because COX and 5-LOX are both known to contribute to destructive SCI secondary 
pathology, and because of evidence that COX signaling drives Pgp overexpression in 
neuroinflammatory conditions (as well as indirect evidence that 5-LOX signaling may do the 
same), we evaluated whether components of these two pathways are expressed at acute and 
chronic time points following SCI, mirroring the time points at which we have previously 
detected increased Pgp expression. We also sought to develop a deeper understanding of the 
metabolic processes at work in the far chronically-injured spinal cord, as there is very little 
known about the molecular processes shaping SCI pathology during this time frame. 
 We have shown that Pgp confers resistance to riluzole uptake in the spinal cord during the 
sub-acute phase of SCI (See Chapter 3). Previous studies have shown that pharmacological 
COX inhibition down-regulates Pgp-mediated drug resistance in clinically relevant models of 
seizure and cancer (236, 238, 241). Therefore, our next goal in this study was to assess the 
efficacy of anti-inflammatory drug treatment to 1) abrogate Pgp overexpression and 2) enhance 
delivery of systemically-administered riluzole to the injured spinal cord tissue. There are 
undesirable side effects associated with the clinical use of COX inhibitors; namely, high 
incidence of gastrointestinal side effects, as well as the shunting of AA into the parallel, pro-
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inflammatory 5-LOX pathway, resulting in an antagonized inflammatory response. In order to 
circumvent these undesirable side effects of selective COX inhibition, for this study we elected 
to instead utilize the dual COX/5-LOX inhibitor, licofelone, for its superior anti-inflammatory 
properties and improved GI tolerance in humans.  
 
Specific Aims 
1. Several studies have shown that pro-inflammatory signaling drives pathological Pgp 
overexpression (238-240, 244, 309, 310). Here, we have demonstrated that spinal cord 
expression of Pgp is increased during the acute and chronic phases of SCI. Therefore, 
we aimed to assess the presence of components of pro-inflammatory COX and 5-LOX 
pathways at time points at which we have observed increased Pgp expression—72 
hours, 7 days, 4 months, and 10 months following SCI.  
2. Furthermore, the biochemical environment of the chronically-injured spinal cord has 
not previously been well characterized. In order to supplement our understanding of the 
pathological changes occurring in chronic SCI, we sought to characterize the long-term 
metabolic alterations in the chronically-injured cord via a metabolomic analysis of 
spinal cord tissue 9 months following SCI. 
3. We have demonstrated that Pgp mediates a SCI-induced decrease in riluzole 
bioavailability in the weeks following injury. Other groups have shown that treatment 
with anti-inflammatory COX inhibitors is an effective strategy to attenuate up-
regulation of Pgp and enhance CNS delivery of therapeutic drugs that are Pgp substrates 
(236, 238, 241). Licofelone is a dual COX/5-LOX inhibitor with improved GI 
tolerability in humans, as well as enhanced anti-inflammatory properties compared to 
COX inhibitors. Therefore, we aimed to evaluate the efficacy of licofelone to attenuate 
Pgp overexpression and enhance spinal cord riluzole bioavailability following SCI. 
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Results 
Assessment of COX/5-LOX Enzymes and Pro-Inflammatory Mediators in the Acutely-Injured 
Spinal Cord  
 Previous studies in our laboratory have revealed substantial increases in expression of 5-
LOX and production of the CysLTs in the spinal cord lesion site at 24 hours post-SCI (Fig. 
4.1). In order to evaluate whether the COX and 5-LOX pro-inflammatory signaling pathways 
are up-regulated at additional acute time points following injury, particularly those during 
which we have observed Pgp up-regulation (Figs. 3.8-3.10), we performed immunoblot 
analysis of T10 spinal cord tissue at 72 hours and 7 days post-SCI. At 72 hours, we observed 
significantly increased expression of all three enzymes (Fig. 4.2), the most dramatic of which 
being a nearly five-fold increase in COX-2 expression. At 7 days post-injury, we only detected 
a significant (three-fold) increase in COX-2 expression, and no change in COX-1 or 5-LOX 
versus uninjured controls (Fig. 4.3). 
 
Figure 4.1.  5-lipoxygenase expression and cysteinyl leukotriene production are increased 
24 hours following spinal cord injury. (a) Top: 5-LOX immunoreactivity (red) is virtually 
undetectable in the thoracic spinal cord tissue of uninjured controls (left panel), but is markedly 
increased in the T10 lesion site of rats 24 hours post-SCI (right panel), especially in the gray 
matter. Bottom: Plane of view for fluorescent images is indicated by the blue line (horizontal 
plane) in the cartoon. Image provided courtesy of Dr. Raymond Grill. Scale bar = 200 µm. (b) 
Cysteinyl leukotrienes are increased more than two-fold in the spinal cord lesion site compared 
to uninjured controls 24 hours post-SCI. *, p < 0.05. ELISA data provided courtesy of Dr. 
Meredith Moore.  
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Figure 4.2.  Expression of cyclooxygenase-1/-2 and 5-lipoxygenase is increased in the 
spinal cord lesion site 72 hours after spinal cord injury. Protein expression levels are 
normalized to β-actin and expressed as a percentage of uninjured control expression levels. 72 
hr post-SCI, there is significantly increased expression of COX-1 (Uninjured = 100 ± 5.79%, n 
= 6; SCI = 271 ± 19.0%, n = 8, p < 0.001), COX-2 (Uninjured = 100 ± 8.06%, n = 6; SCI = 474 
± 53.9%, n = 8, p < 0.001), and 5-LOX (Uninjured = 100 ± 5.49% n = 6; SCI = 308 ± 35.4%, n 
= 8, p < 0.001) in the T10 lesion site. Representative immunoblots pictured for COX-1 and 
COX-2 are from the same sample. All data are mean ± s.e.m. *, p < 0.05 versus uninjured 
controls.  
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Figure 4.3.  Expression of cyclooxygenase-2 is increased in the spinal cord lesion site 7 
days after spinal cord injury. Protein expression levels are normalized to β-actin and 
expressed as percentage of uninjured control expression levels. 7 days post-SCI, there is 
significantly increased expression of COX-2 (Uninjured = 100 ± 46.8%, n = 6; SCI = 300 ± 
63.0%, n = 6, p = 0.029), but not COX-1 (Uninjured = 100 ± 32.6%, n = 6; SCI = 134 ± 24.7%, 
n = 7, p = 0.418) or 5-LOX (Uninjured = 100 ± 10.8%, n = 6; SCI = 111 ± 15.4%, n = 8, p = 
0.561) in the T10 lesion site. Representative immunoblots pictured for COX-1 and COX-2 are 
from the same sample. All data are mean ± s.e.m. *, p < 0.05 versus uninjured controls.  
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Assessment of Inflammation in the Chronically-Injured Spinal Cord  
 Because the spinal cord biochemical environment after a period of 1-2 months post-SCI 
has received relatively little attention compared to the acutely-injured spinal cord, it is 
unknown whether inflammation is present during the chronic phase of injury. Two goals of the 
current study were to 1) examine whether COX/5-LOX activity is detectable in the injured 
spinal cord at several months post-injury, and 2) develop a more comprehensive understanding 
of the cytotoxic biochemical processes at work in the chronically-injured spinal cord 
environment. A previous study in our laboratory (performed by Dr. Raymond Grill) has 
provided novel evidence of pro-inflammatory AA metabolism within the spinal cord during the 
chronic period of injury. Specifically, this study has revealed increased expression of the 
cysteinyl leukotriene receptor 1 within the dorsal horn of the lumbar spinal cord 4 months 
following spinal contusion injury at T10 (Fig. 4.4). This is an intriguing finding when 
compared to our observations of increased Pgp expression in the lumbar spinal cord at 4 
months post-SCI (Fig. 3.10), and raises the question of whether pro-inflammatory 5-LOX 
signaling in the lumbar spinal cord may contribute to this component of BSCB pathology.  
 
 
Figure 4.4.  Increased expression of the cysteinyl leukotriene receptor 1 four months after 
spinal cord injury. Immunofluorescent labeling for the cysteinyl leukotriene receptor 1 
(CysLTR1, green) in the dorsal horn of the lumbar spinal cord. Inset in (a) indicates field of 
view (red-bounded square). Dashed line in (a) indicates boundary of gray and white matter in 
dorsal horn. (a) Spinal cord section from naïve, uninjured, age-matched control animal. (b) 
Spinal cord section from animal 4 months post-SCI. Arrowheads indicate cells exhibiting 
increased CysLTR1 expression. Image provided courtesy of Dr. Raymond Grill. 
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Additional investigations in our lab (performed by Dr. Raymond Grill) have shown that at 4 
months post-SCI, 5-LOX expression within the spinal cord near the lesion site appears to be 
closely associated with the vasculature (Fig. 4.5). This observation may hold interesting 
implications for BSCB pathology at far chronic time points. 
 
 
Figure 4.5.  5-lipoxygenase expression is localized to the spinal cord vasculature 4 months 
after spinal cord injury. Immunofluorescent labeling of 5-LOX (red) and the endothelial cell 
marker, rat endothelial cell antigen-1 (RECA-1, green) in thoracic spinal cord tissue of rats 4 
months after SCI. 5-LOX immunoreactivity appears to be ensheathing the capillary endothelial 
cells. 5-LOX was undetectable in age-matched, uninjured controls (data not shown). Scale bar 
= 60 µm. Image provided courtesy of Dr. Raymond Grill. 
 We used ELISA to measure levels of the major AA-derived mediators, PGE2 and LTB4, 
within spinal cord tissue of rats at the far chronic time point of nine months post-SCI. PGE2 
levels were undetectable in the spinal cord of uninjured, age-matched controls (n = 3) but 
increased to 87.1 ± 4.91 pg/ml in the lesion site of chronic SCI animals (n = 3) (p < 0.001, Fig. 
4.6a). LTB4 levels were similarly undetectable in uninjured controls (n = 6) but were 
significantly increased in T10 spinal cords of chronic SCI rats (n = 6) (10.6 ± 1.67) (p < 0.001, 
Fig. 4.6b).  
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Figure 4.6.  Increased levels of prostaglandin E2 and leukotriene B4 in the spinal cord 9 
months after spinal cord injury. Prostaglandins and leukotrienes are present in the lesion site 
of spinal cords nine months following SCI. PGE2 levels (a) and LTB4 levels (b) in T10 spinal 
cord segments of age-matched, uninjured controls (undetectable) and animals 9 mo post-SCI 
(black bars). PGE2 (87.1 ± 4.91 pg/ml, n = 3) and LTB4 (10.6 ± 1.67 pg/ml, n = 6). *, p < 0.001 
versus uninjured controls. All data are mean ± s.e.m.  
 
Metabolomic Profiling of the Chronically-Injured Spinal Cord 
 To gain a more complete understanding of the biochemical environment within the 
chronically-injured spinal cord, metabolomic profiling was performed for T10 spinal cord 
tissue from far chronic (9 months) post-SCI animals (n = 8) and uninjured, age-matched 
controls (n = 9). A total of 257 metabolites were identified in spinal cord samples, from the 
Metabolon library comprising 2,400 named molecules. Tissue expression levels of 126 of these 
compounds were altered in chronic SCI samples (TABLE 4.1). Metabolites belonged to diverse 
molecular classes (e.g., amino acids, nucleotides, and lipids), and hierarchical clustering 
revealed multiple clusters of biochemicals similarly altered in SCI tissue (Fig. 4.7-4.8). For  
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Class Sub-class Biochemical Name 
Fold Change 
(SCI + VEH / 
Uninjured) 
p Value 
Amino acid 
Glycine, serine and threonine 
metabolism 
glycine −1.35 < 0.001 
homoserine −1.18 0.0780 
betaine 2.22 < 0.001 
Alanine and aspartate metabolism 
alanine 1.19 0.0236 
aspartate −1.22 0.0091 
N-acetylaspartate (NAA) −2.38 < 0.001 
asparagine −1.47 0.0557 
Glutamate metabolism 
glutamate −1.45 < 0.001 
glutamine 1.06 0.0982 
gamma-aminobutyrate (GABA) −1.33 0.0650 
N-acetylglutamate −1.33 0.0220 
N-acetyl-aspartyl-glutamate 
(NAAG) −1.79 < 0.001 
Lysine metabolism 
2-aminoadipate 1.38 0.0040 
N6-acetyllysine 1.47 0.0014 
Phenylalanine & tyrosine metabolism tyrosine 1.15 0.0581 
Valine, leucine and isoleucine 
metabolism 
isoleucine 1.40 < 0.001 
leucine 1.45 < 0.001 
valine 1.40 0.0036 
Cysteine, methionine, SAM, taurine 
metabolism 
taurine 1.52 0.0012 
S-adenosylhomocysteine (SAH) −1.43 0.0012 
methionine 1.18 0.0260 
N-acetylmethionine 2.53 < 0.001 
2-hydroxybutyrate (AHB) 1.65 < 0.001 
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Urea cycle; arginine-, proline-, 
metabolism 
citrulline 1.55 0.0158 
trans-4-hydroxyproline 2.05 < 0.001 
Creatine metabolism creatine −1.16 0.0314 
Butanoate metabolism 2-aminobutyrate 1.72 0.0035 
Glutathione metabolism glutathione, oxidized (GSSG) 3.19 < 0.001 
cysteine-glutathione disulfide 3.19 < 0.001 
Carbohydrate 
Fructose, mannose, galactose, starch, 
and sucrose metabolism 
maltose 1.61 0.0062 
mannose 2.77 < 0.001 
mannose-6-phosphate 2.57 < 0.001 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
glycerate 1.37 0.0313 
glucose-6-phosphate (G6P) 2.53 < 0.001 
glucose 2.73 < 0.001 
fructose-6-phosphate 2.29 < 0.001 
3-phosphoglycerate −1.35 0.0195 
1,3-dihydroxyacetone 2.22 < 0.001 
lactate 1.23 < 0.001 
Nucleotide sugars, pentose metabolism 
arabitol −1.64 0.0033 
ribulose 1.40 0.0433 
arabinose −5.26 < 0.001 
Cofactors and 
vitamins 
Ascorbate and aldarate metabolism dehydroascorbate 1.86 0.0388 
Nicotinate and nicotinamide metabolism 
nicotinamide 1.32 0.0292 
nicotinamide adenine 
dinucleotide (NAD+) 1.45 < 0.001 
Pantothenate and CoA metabolism 
pantothenate 1.69 < 0.001 
phosphopantetheine 1.12 0.0459 
coenzyme A −2.56 < 0.001 
3'-dephosphocoenzyme A −2.78 < 0.001 
Pyridoxal metabolism pyridoxal 2.17 < 0.001 
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Riboflavin metabolism 
flavin adenine dinucleotide (FAD) 1.42 0.0036 
riboflavin (Vitamin B2) 1.78 < 0.001 
Tocopherol metabolism alpha-tocopherol −1.43 < 0.001 
Energy 
Krebs cycle malate 1.28 < 0.001 
Oxidative phosphorylation acetylphosphate −1.28 0.0788 phosphate −1.25 < 0.001 
Lipid 
Medium chain fatty acid 
caproate (6:0) 1.81 0.0526 
pelargonate (9:0) −1.11 < 0.001 
Long chain fatty acid 
oleate (18:1n9) −1.23 0.0204 
cis-vaccenate (18:1n7) −1.43 < 0.001 
arachidate (20:0) −1.18 0.0658 
eicosenoate (20:1n9 or 11) −1.89 0.0016 
dihomo-linoleate (20:2n6) −1.49 0.0755 
arachidonate (20:4n6) −1.32 0.0776 
Fatty acid, monohydroxy 13-HODE + 9-HODE 1.93 0.0051 
Fatty acid, dicarboxylate 2-hydroxyglutarate −1.69 < 0.001 
Eicosanoid 15-HETE 1.89 0.0013 
Endocannabinoid 
oleic ethanolamide −1.96 < 0.001 
palmitoyl ethanolamide −2.22 < 0.001 
Fatty acid metabolism (also BCAA 
metabolism) propionylcarnitine 1.42 0.0682 
Carnitine metabolism 
acetylcarnitine 1.24 0.0648 
myristoylcarnitine −1.56 0.0791 
palmitoylcarnitine −1.75 0.0236 
stearoylcarnitine −1.47 0.0812 
oleoylcarnitine −2.08 0.0078 
Glycerolipid metabolism choline phosphate −1.14 0.0076 glycerophosphoethanolamine 1.18 0.0558 
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glycerol −1.20 0.0164 
glycerol 3-phosphate (G3P) 1.41 0.0514 
glycerophosphorylcholine (GPC) 2.09 < 0.001 
Ketone bodies 3-hydroxybutyrate (BHBA) 1.50 < 0.001 
Lysolipid 
2-docosahexaenoyl GPE −1.27 0.0929 
2-palmitoyl GPC −1.52 0.0442 
1-stearoyl GPC −1.37 0.0754 
2-stearoyl GPC −1.45 0.0306 
1-oleoyl GPC −1.52 0.0168 
2-oleoyl GPC −1.35 0.0032 
1-docosahexaenoyl GPC −1.69 0.0263 
2-docosahexaenoyl GPC −1.61 0.0286 
1-
palmitoylglycerophosphoinositol −2.63 0.0015 
1-stearoylglycerophosphoinositol −2.33 0.0314 
1-
arachidonoylglycerophosphoinosi
tol 
−2.13 0.0011 
Monoacylglycerol 1-oleoylglycerol (1-monoolein) −2.04 < 0.001 
2-oleoylglycerol (2-monoolein) −1.79 0.0049 
Sphingolipid palmitoyl sphingomyelin 1.60 < 0.001 
stearoyl sphingomyelin −1.39 0.0342 
Mevalonate metabolism 3-hydroxy-3-methylglutarate −2.56 < 0.001 
Sterol/Steroid 
cholesterol −1.15 0.0011 
7-alpha-hydroxycholesterol 1.77 0.0011 
7-beta-hydroxycholesterol 1.46 0.0034 
24(S)-hydroxycholesterol −1.85 < 0.001 
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Nucleotide 
Purine metabolism, 
(hypo)xanthine/inosine containing 
xanthosine 1.25 0.0451 
inosine −1.06 0.0368 
Purine metabolism, adenine containing 
adenosine −1.96 0.0033 
adenosine 2'-monophosphate (2'-
AMP) 1.74 < 0.001 
adenosine 3'-monophosphate (3'-
AMP) 1.62 0.0035 
adenosine 5'-monophosphate 
(AMP) −1.23 0.0198 
Purine metabolism, guanine containing guanosine −1.89 < 0.001 
Purine metabolism, urate metabolism urate 1.64 < 0.001 
Pyrimidine metabolism, cytidine 
containing 
cytidine 1.27 < 0.001 
2'-deoxycytidine 2.49 < 0.001 
uracil 1.54 0.0017 
5,6-dihydrouracil −1.20 0.0852 
Peptide 
Dipeptide derivative homocarnosine −1.37 
< 0.001 
anserine 1.83 0.0369 
gamma-glutamyl 
gamma-glutamylglycine −1.33 0.0197 
gamma-glutamylmethionine 1.33 0.0481 
gamma-glutamylglutamate −1.43 < 0.001 
gamma-glutamylglutamine 1.28 0.0275 
gamma-glutamylphenylalanine −1.16 0.0969 
gamma-glutamylalanine 1.42 0.0012 
Xenobiotics 
Benzoate metabolism hippurate 1.32 0.0514 
Chemical glycolate (hydroxyacetate) 1.35 0.0708 
Food component/Plant stachydrine 1.51 0.0109 
homostachydrine 1.64 0.0052 
Sugar, sugar substitute, starch erythritol −1.30 0.0434 
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TABLE 4.1.  Spinal cord metabolites with altered concentrations in chronic spinal cord-
injured rats versus uninjured, age-matched controls. Abbreviations: 13-HODE + 9-HODE, 
13- and 9-hydroxyoctadecadienoic acid; 15-HETE, 15-hydroxyeicosatetraenoic acid; GPE, 
glycerophosphoethanolamine; GPC, glycerophosphocholine; SCI + VEH, chronically-injured, 
vehicle-treated8. p values are versus uninjured, age-matched controls. Bolded p values < 0.05 
(104 metabolites); non-bolded p values < 0.10 (22 metabolites). 
                                                          
8
 Chronic SCI animals were treated either with licofelone or vehicle; there were no untreated animals in 
this chronic study. 
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Figure 4.7.  Metabolites increased in the chronically-injured spinal cord. Heat map 
illustrates the change in levels of 64 metabolites with increased expression in chronic SCI 
animals versus uninjured, age-matched controls. Increases (yellow) and decreases (blue) in 
concentration, relative to the median metabolite level, are represented by various shades of 
intensity (see color scale). Metabolites are arranged by hierarchical clustering, with 
representative cluster highlighted (a). Scale bar (upper left) indicates Pearson correlation 
coefficient (r). Colored bars indicate super class of each metabolite (amino acids, 
carbohydrates, cofactors and vitamins, energy metabolites, lipids, nucleotides, peptides, and 
xenobiotics). The names of representative pro-inflammatory and pro-oxidative metabolites are 
shown in pink lettering. 
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Figure 4.8.  Metabolites decreased in the chronically-injured spinal cord. Heat map 
illustrates the change in levels of 62 metabolites with decreased expression in chronic SCI 
animals versus uninjured, age-matched controls. Increases (yellow) and decreases (blue) in 
concentration, relative to the median metabolite level, are represented by various shades of 
intensity (see color scale). Metabolites are arranged by hierarchical clustering, with 
representative clusters highlighted (b-c). Scale bar (upper left) indicates Pearson correlation 
coefficient (r). Colored bars indicate super class of each metabolite (amino acids, 
carbohydrates, cofactors and vitamins, energy metabolites, lipids, nucleotides, peptides, and 
xenobiotics). The names of representative anti-inflammatory metabolites are shown in green 
lettering. 
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example, one cluster of glycolytic intermediates were similarly increased in SCI samples (Fig. 
4.7a, r = 0.88, p < 0.05), and two large clusters of lipid metabolites were similarly decreased in 
SCI samples (Fig. 4.8b, r = 0.72, p < 0.05; Fig. 4.8c, r = 0.53, p < 0.05). These analyses reveal 
alterations in multiple metabolic pathways within the chronically-injured spinal cord.  
 Evaluation of metabolites increased in chronic SCI revealed that several were strong 
indicators of oxidative stress conditions (pink lettering, Fig. 4.7). These included oxidized 
glutathione (+3.19 fold), cysteine-glutathione disulfide (+3.19 fold), dehydroascorbate (+1.86 
fold), and 13- and 9-hydroxyoctadecadienoic acid (+1.93 fold) (p < 0.05, Fig. 4.9a). 
Additionally, chronic SCI tissue contained significantly depleted levels of anti-oxidant and 
anti-inflammatory metabolites (green lettering, Fig. 4.8), such as alpha-tocopherol (-1.43 fold) 
and 24(S)-hydroxycholesterol (24-OH-Chol) (-1.85 fold) (p < 0.05, Fig. 4.9b). 
 
Effect of Licofelone on Inflammation and Oxidative Stress Following Spinal Cord Injury 
 In conjunction with our metabolomic characterization of chronically-injured spinal cords, 
we also examined the effects of 28-day licofelone treatment on the spinal cord metabolic 
profile of animals with chronic (8 months) SCI. We detected changes in 26 named metabolites 
in spinal cord tissue of chronic SCI animals treated with licofelone (n = 9), compared to 
vehicle-treated SCI animals (TABLE 4.2). Hierarchical clustering revealed clusters, primarily 
composed of lipids and carbohydrates, that increased with licofelone treatment (Fig. 4.10). 
Among these were anti-inflammatory and anti-oxidative compounds, including 15-
hydroxyeicosatetraenoic acid (15-HETE) (+1.42 fold), 24-OH-Chol (+1.25 fold), chiro-inositol 
(+1.51 fold), inositol 1-phosphate (+1.22 fold), and homocarnosine (+1.14 fold) (p < 0.05, Fig. 
4.10b). Interestingly, the only metabolite that decreased with licofelone treatment (−2.44 fold) 
was the bile acid taurocholate (TABLE 4.2 & Fig. 4.10a), a pro-inflammatory bile acid that 
enhances NF-kB activation (316).  
 In order to evaluate the ability of licofelone to inhibit production of PGE2 within the 
injured spinal cord, we used ELISA to quantify PGE2 levels in injured rats treated with either 
vehicle or licofelone (Fig. 4.11). At 24 hours after injury, PGE2 levels within the lesion site 
were significantly higher than levels in the thoracic spinal cord of uninjured animals (p < 
0.001). Furthermore, this spike in PGE2 was completely abolished in rats that were treated with  
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Figure 4.9.  Metabolomic analysis reveals oxidative stress and inflammation in the 
chronically-injured spinal cord. Box plots illustrate changes in abundance of select 
metabolites within spinal cord tissue of uninjured controls (white) and rats 9 mo post-SCI 
(gray). For each metabolite, all concentration values have been re-scaled to have a median 
value equal to 1 for all groups. Box legend: + inside box represents mean value, bar inside box 
represents median value, upper and lower box boundaries represent 75th percentile and 25th 
percentile, respectively, upper and lower whiskers represent maximum and minimum of 
distribution, circles represents extreme data points. (a) Several metabolites significantly 
increased in chronic SCI spinal cords are associated with oxidative stress. (b) Levels of anti-
inflammatory and anti-oxidative metabolites are decreased in chronic SCI cords. 
Abbreviations: 24-OH-Chol, 24(S)-hydroxycholesterol; α-Toco, alpha-tocopherol, GSSG, 
oxidized glutathione; Cys-S-SG, cysteine-glutathione disulfide; DHA, dehydroascorbate; 13- + 
9-HODE, 13-hydroxyoctadecadienoic acid and 9-hydroxyoctadecadienoic acid. *, p < 0.05 
versus uninjured controls. 
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Class Sub-class Biochemical Name 
Fold Change 
(SCI + LIC /  
SCI + VEH) 
p Value 
Amino acid Alanine and aspartate metabolism aspartate 1.10 0.0471 
Carbohydrate 
Aminosugars metabolism erythronate 1.18 0.0287 N-acetylneuraminate 1.22 0.0421 
Fructose, mannose, galactose, starch, 
and sucrose metabolism maltose 1.28 0.0417 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
glucose 1.27 0.0633 
lactate 1.11 0.0223 
Nucleotide sugars, pentose metabolism arabitol 1.59 0.0030 
ribose 1.47 0.0836 
Energy Krebs cycle citrate 1.16 0.0877 
Lipid 
Long chain fatty acid 
margarate (17:0) 1.22 0.0077 
cis-vaccenate (18:1n7) 1.26 0.0183 
behenate (22:0) 1.20 0.0615 
Eicosanoid 15-HETE 1.42 0.0328 
Bile acid metabolism taurocholate −2.44 0.0625 
Glycerolipid metabolism glycerol 1.13 0.0090 
Inositol metabolism 
myo-inositol 1.20 0.0704 
chiro-inositol 1.51 0.0224 
inositol 1-phosphate (I1P) 1.22 0.0163 
Sterol/Steroid 
cholesterol 1.06 0.0081 
7-alpha-hydroxycholesterol 1.26 0.0209 
7-beta-hydroxycholesterol 1.19 0.0930 
24(S)-hydroxycholesterol 1.25 0.0013 
Nucleotide Purine metabolism, urate metabolism allantoin 1.20 0.0709 
Peptide Dipeptide glycylglycine 1.24 0.0625 Dipeptide derivative homocarnosine 1.14 0.0071 
Xenobiotics Sugar, sugar substitute, starch erythritol 1.30 0.0755 
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TABLE 4.2.  Changes in levels of spinal cord metabolites of chronically-injured rats 
treated with licofelone. Abbreviations: 15-HETE, 15-hydroxyeicosatetraenoic acid; SCI + 
LIC, injured, licofelone-treated; SCI + VEH, injured, vehicle-treated. p values are versus 
chronic SCI, vehicle-treated group. Bolded p values < 0.05 (16 metabolites); non-bolded p 
values < 0.10 (22 metabolites). 
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Figure 4.10.  Changes in the spinal cord metabolic profile of chronically-injured rats 
following 28-day licofelone treatment. (a) Heat map showing 26 metabolites that exhibit 
changes in chronic SCI, licofelone-treated animals (SCI + L), compared to chronic SCI, 
vehicle-treated animals (SCI + V). Metabolites are arranged by hierarchical clustering. Scale 
bar (upper left) indicates Pearson correlation coefficient (r). Colored bars indicate super class 
of each metabolite (e.g., amino acids, carbohydrates). Increases (yellow) and decreases (blue) 
in concentration, relative to the median metabolite level, are represented by various shades of 
intensity (see color scale). (b) Box plots illustrating changes in levels of select compounds 
within the chronic SCI, vehicle-treated (white) or licofelone-treated (gray) groups. For box plot 
legend, see Figure 4.9. Abbreviations: 15-HETE, 15-hydroxyeicosatetraenoic acid; 24-OH-
Chol, 24(S)-hydroxycholesterol; 7-β-OH-Chol, 7-beta-hydroxycholesterol; I1P, inositol 1-
phosphate. *, p < 0.05 versus chronic SCI, vehicle-treated group. 
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Figure 4.11.  Elevated prostaglandin E2 production within the acutely-injured spinal cord 
is eliminated by licofelone treatment. ELISA quantification of prostaglandin E2 levels within 
the spinal cord lesion site of animals treated with either vehicle or licofelone at 3 hours after 
injury, then again at 18 hours after injury. Uninjured (43.2 ± 4.67 pg/ml; n = 6); SCI + vehicle 
(405 ± 47.4 pg/ml; n = 6); SCI + licofelone (16.9 ± 6.87 pg/ml; n = 6). All data are mean ± 
s.e.m. *, p < 0.05.  
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licofelone starting at 3 hours post-injury (p < 0.001). This data illustrates the efficacy of 
licofelone to prevent injury-induced production of prostaglandin E2, which has previously been 
shown to drive brain Pgp overexpression in rodent seizure models (235). Because licofelone 
inhibits both COX and 5-LOX, we also used ELISA to quantify leukotriene B4 levels in rat 
spinal cord tissue using the same treatment paradigm. However, the calculated LTB4 levels in 
spinal cord tissue for all three groups fell below the sensitivity limit of the assay [Uninjured 
(6.93 ± 1.13 pg/ml; n = 6); SCI + vehicle (7.90 ± 2.56 pg/ml; n = 6); SCI + licofelone (5.02 ± 
1.66 pg/ml; n = 6)]. Thus, we cannot draw any conclusions about the effects of licofelone 
treatment on LTB4 levels following SCI from this data. 
 
 Effect of Licofelone on P-glycoprotein Expression and Spinal Cord Riluzole Bioavailability 
Following Spinal Cord Injury 
 Pekcec et al. showed that brain Pgp overexpression following seizure is mediated by PGE2, 
and that antagonizing the EP1 receptor was sufficient to increase therapeutic efficacy of the 
anti-convulsant drug phenobarbital in rodents following seizure (235). Because we have shown 
that licofelone is effective at decreasing PGE2 levels in the acutely-injured spinal cord (Fig. 
4.11), we next wanted to evaluate whether treatment with licofelone could abrogate the effects 
of SCI on spinal cord Pgp expression and thereby increase riluzole bioavailability. In order to 
increase the clinical relevance of our experimental paradigm, we chose to focus our subsequent 
studies on the effects of licofelone treatment during the acute phase of SCI. 72 hours post-SCI 
was selected as an optimal time point for evaluating these outcome measures because of two 
main contributing factors. First, our overall goal is to enhance the spinal cord bioavailability 
and therapeutic efficacy of riluzole, a neuroprotective compound that likely exerts the greatest 
therapeutic benefit early after SCI. Therefore, we reasoned that positive results with licofelone 
treatment would hold more clinical relevance if observed as early as possible after injury. 
Secondly, previous studies in our laboratory have demonstrated that peak BSCB permeability 
to the protein albumin occurs between 48 and 72 hours post-SCI (Fig. 4.12). Accordingly, we 
hypothesized that 72 hours post-SCI would be a more ideal time point for the assessment of 
Pgp expression and function, as it is past the peak of BSCB leakiness and might eschew some 
of the complications arising from increased passive diffusivity at the BSCB during earlier time 
points. 
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Figure 4.12.  Time course of blood-spinal cord barrier permeability to albumin during 
acute spinal cord injury. Albumin (~68 kDa) is a large blood-borne molecule that is normally 
restricted from passing through the BSCB into the spinal cord tissue. The albumin-binding dye 
Evans Blue (EB) is therefore a useful tool for the assessment of BSCB permeability to large 
molecules following injury to the spinal cord. (a) EB was delivered i.v. to rats at various time 
points following spinal contusion injury. 30 minutes later, rats were transcardially perfused 
with saline, and spinal cords were harvested. Extravasation of EB from T10 spinal cord tissue 
was quantified by fluorometric measurement at 620 nm. Compared to uninjured controls (100 ± 
2.38%), EB extravasation was significantly higher in rats 1-3 days following SCI (24 h post-
SCI = 264 ± 59.5%; 48 h post-SCI = 348 ± 14.3%; 72 h post-SCI = 290 ± 105%). Furthermore, 
EB extravasation remained increased for up to one week after injury, though not statistically 
significant (5 d post-SCI = 195 ± 21.4%; 7 d post-SCI = 160 ± 26.1%). Based on this data, the 
peak BSCB permeability to albumin following traumatic SCI appears to occur at about 48 
hours post-injury. All data are mean ± s.e.m. and presented as percentage of uninjured controls. 
*, p < 0.05 versus uninjured controls. (b) Photo illustrating gross anatomy of spinal cord tissue 
of uninjured rat (top) and rat 48 hours post-SCI (bottom), following systemic delivery of EB 
dye, and subsequent transcardial perfusion. Spinal cords of uninjured rats appear white because 
intact BSCB function prevents the entry of the albumin-EB complex into the spinal cord 
parenchyma. In contrast, vascular leakage of albumin-EB at 48 hours post-SCI is apparent in 
the spinal cord parenchyma, both within the epicenter of injury (arrowhead), as well as several 
millimeters rostral and caudal to the lesion site. Data provided courtesy of Dr. Raymond Grill.  
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 Animals were treated with either licofelone (100 mg/kg) or vehicle via the clinically-
relevant oral route beginning at 3 hours post-SCI, then once daily for 3 days. At 72 hours, 
immunoblotting revealed that T10 Pgp expression was significantly increased in the injured, 
vehicle-treated group compared to uninjured controls (Fig. 4.13). This increase is reflective of 
that observed previously (Fig. 3.8). Importantly, we observed that T10 Pgp expression was 
significantly lower in the injured, licofelone-treated group versus that of the injured, vehicle-
treated group. This finding demonstrates that pathological Pgp overexpression within the 
injured spinal cord can indeed be attenuated by oral treatment with licofelone. Our results also 
corroborate those of previous studies, which have demonstrated that antagonism of the 
COX/PGE2 signaling axis is effective in reducing Pgp overexpression in other neurological 
disease models.  
 We next examined whether licofelone treatment exhibited an effect on spinal cord riluzole 
bioavailability at this same time point. Animals were treated with licofelone or vehicle 
beginning at 3 hours after injury, then once daily for 3 days. All three groups (both SCI groups 
as well as uninjured controls) also received riluzole (i.p.) during the same dosing schedule. At 
72 hours post-injury, spinal cord/plasma ratios of riluzole were assessed (Fig. 4.14). We found 
that normalized spinal cord riluzole levels were slightly decreased in SCI compared to 
uninjured controls, though this difference is not statistically significant (p = 0.201). We have 
previously demonstrated that normalized spinal cord riluzole levels are significantly decreased 
in T10 spinal tissue at 10 days post-SCI (Fig. 3.12), as well as in whole spinal cords at 21 days 
post-SCI (Fig. 3.11). In light of these observations, the lack of a statistically significant 
decrease in normalized riluzole levels at 72 hours after SCI might be attributed to increased 
BSCB permeability observed at 3-7 days post-SCI, an observation supported both in our 
laboratory (Fig. 4.12) and by other groups (189). Notably, we observed that normalized spinal 
cord riluzole levels of licofelone-treated animals at 72 hours post-SCI were significantly higher 
versus vehicle-treated animals (Fig. 4.14). Together with the observation that licofelone 
treatment attenuates Pgp overexpression at 72 hours post-SCI (Fig. 4.13), the finding that 
licofelone can also enhance the spinal cord uptake of riluzole supports our hypothesis that pro-
inflammatory signaling drives Pgp-mediated spinal cord drug resistance following SCI. These 
results suggest a new therapeutic avenue for enhancing the therapeutic efficacy of riluzole, a 
drug that is currently being evaluated in an ongoing clinical trial as a neuroprotective 
intervention for acute SCI. 
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Figure 4.13.  Licofelone treatment attenuates P-glycoprotein overexpression 72 hours 
following spinal cord injury. Immunoblots of T10 spinal cord samples from rats 72 hours 
post-SCI. Pgp expression levels are normalized to β-actin and expressed as a percentage of 
uninjured controls (100 ± 9.01%, n = 8). Pgp levels in the lesion site of injured, vehicle-treated 
rats are significantly higher than uninjured controls (SCI + vehicle = 306 ± 34.4%, n = 10, p < 
0.001). Pgp levels of injured, licofelone-treated rats are significantly reduced versus injured, 
vehicle-treated rats (SCI + licofelone = 198 ± 26.4%, n = 15, p = 0.008), but are still 
significantly higher than uninjured levels (p = 0.022). Representative immunoblots are pictured 
below graph. All data are mean ± s.e.m. *, p < 0.05.  
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Figure 4.14.  Licofelone treatment enhances spinal cord riluzole bioavailability 72 hours 
after spinal cord injury. Animals were treated with riluzole alone, or riluzole and licofelone, 
beginning 3 hours after SCI and again once daily for three days. Normalized spinal cord 
riluzole levels were reduced (although not significantly so) in the riluzole-treated group 72 
hours after injury (81.1 ± 4.53%, n = 6) versus uninjured controls (100 ± 4.24%, n = 7, p = 
0.201). Normalized spinal cord riluzole levels were significantly enhanced in injured animals 
treated with riluzole + licofelone (124 ± 13.8%, n = 8) versus the injured, riluzole-treated group 
(p = 0.017). Additionally, the increase in spinal cord/plasma riluzole ratio in animals treated 
with riluzole + licofelone approached statistical significance compared to uninjured controls (p 
= 0.092). All data are mean ± s.e.m., expressed as percentage of uninjured controls. *, p < 0.05. 
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 We also evaluated whether there was differential plasma riluzole bioavailability in these 
groups (Fig. 4.15). Interestingly, we observed that although the raw spinal cord riluzole 
concentrations in both SCI groups were almost identically lower than uninjured controls (Fig. 
4.15a), the plasma bioavailability of riluzole in the licofelone-treated group was substantially 
lower than both uninjured controls and injured, riluzole-treated animals (Fig. 4.15b). From this 
data, we have drawn two conclusions: 1) Because there is no injury-associated effect on plasma 
riluzole bioavailability at 72 hours (See pink bar in Fig. 4.15b), the observed decrease in 
plasma riluzole bioavailability in the licofelone-treated group must be attributed to licofelone 
treatment; 2) Though there is no difference in raw spinal cord riluzole concentrations between 
SCI groups (Fig. 4.15a), the reduction in plasma levels in the licofelone-treated group indicates 
that licofelone enhances plasma-to-spinal cord delivery of riluzole, and suggests that a higher 
systemic dose of riluzole may increase spinal cord drug delivery further. Because of these 
observations, we speculate that at this acute time point following SCI, licofelone acts to 
enhance clearance of riluzole from the plasma and to promote increased delivery of riluzole 
from the plasma to the spinal cord tissue.  
 Up-regulation of Abcb1 transcription at the blood-brain barrier can also occur as a result of 
drug treatment via activation of the pregnane X receptor, a ligand-activated nuclear receptor 
(317). Therefore, it is possible that, independent from the effects of SCI-associated 
inflammation on Pgp expression, treatment with riluzole during the acute phase of injury might 
also alter spinal cord Pgp expression levels, and consequently the spinal cord uptake of riluzole. 
We therefore performed a subsequent experiment to rule out this possibility. Beginning 3 hours 
after injury, rats were treated with vehicle alone, riluzole alone, or riluzole and licofelone, once 
daily for three days. Immunoblot analysis of Pgp expression revealed no significant effect of 
riluzole treatment on Pgp expression within the lesion site at 72 hours post-SCI (Fig. 4.16). In 
contrast, spinal cord Pgp expression in rats treated with both riluzole and licofelone was 
significantly lower than those of vehicle-treated and riluzole-treated groups. Because repeated 
treatment with riluzole does not significantly affect Pgp expression levels during this acute  
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Figure 4.15.  Effects of injury and licofelone treatment on raw spinal cord and plasma 
riluzole concentrations. Abbreviations: RLZ, riluzole; RLZ + LIC, riluzole + licofelone. (a) 
Compared to raw spinal cord riluzole concentrations of uninjured control rats (100 ± 4.25%), 
both SCI groups displayed statistically significant decreases (SCI + RLZ = 74.4 ± 8.70%, p = 
0.022; SCI + RLZ + LIC = 74.5 ± 7.86%, p = 0.016) that were almost identical (p = 0.988). (b) 
In contrast, there was no significant reduction in plasma riluzole concentrations in the injured, 
riluzole-treated group (93 ± 13.2%) compared to uninjured controls (100 ± 3.39%, p = 0.640). 
However, injured rats treated with riluzole and licofelone displayed significantly reduced 
plasma riluzole levels (64.9 ± 9.81%) compared to uninjured controls (p = 0.036) as well as 
injured, riluzole-treated animals (p = 0.049). All data are mean ± s.e.m., expressed as 
percentage of uninjured controls. *, p < 0.05.  
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Figure 4.16.  Repeated riluzole treatment does not affect spinal cord P-glycoprotein 
expression. Immunoblots of T10 spinal cord samples from rats 72 hours following SCI. Protein 
expression levels are normalized to β-actin and expressed as percentage of injured, vehicle-
treated (VEH) levels (100 ± 15.4%, n = 8). Pgp levels in the lesion site of riluzole (RLZ)-
treated rats are not significantly different than vehicle-treated (RLZ = 91.8 ± 8.83%, n = 9, p = 
0.598). Injured rats treated with both RLZ and licofelone (LIC) have significantly reduced Pgp 
expression (RLZ + LIC = 59.5 ± 7.19%, n = 9) compared to the vehicle-treated group (p = 
0.036) and also compared to the riluzole-treated group (p = 0.039). Representative 
immunoblots are pictured below graph. All data are mean ± s.e.m. *, p < 0.05 versus SCI + 
VEH.  
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period of SCI, we conclude that the reduced riluzole bioavailability observed in injured, 
riluzole-treated rats (Fig. 4.14) is not attributed to the effects of riluzole treatment itself, but 
rather can only be due to pathological mechanisms induced by injury. 
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CHAPTER 5 
Effect of Licofelone Treatment on Functional Recovery 
Following Spinal Cord Injury in the Rat 
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Background 
 At present, there are no proven effective therapeutic interventions that can significantly 
improve functional recovery in SCI patients. To date, a large number of preclinical studies have 
identified neuroprotective compounds that, if administered to experimental animals in the 
minutes to hours following injury, can improve functional recovery. Several of these promising 
neuroprotective compounds have been translated to clinical trials over the last few decades; 
unfortunately, all have failed to show a robust, statistically significant improvement in 
functional outcome of human patients. Therefore, a major goal of current SCI research is to 
identify robust interventions that retain this neurological efficacy when translated to the clinic. 
 The central principle underlying therapeutic neuroprotection for acute SCI is the desire to 
attenuate the destructive biochemical cascades that are set into motion immediately upon injury 
to the spinal cord. Thus, an ideal neuroprotective intervention must be delivered as soon as 
possible after SCI, in order to quickly attenuate the toxic biochemical processes of secondary 
injury, minimize the expansion of cell death and tissue degeneration, and therefore maximize 
preservation of neurological function (318). To minimize delay of treatment, the drug should be 
administered systemically (intravenously or orally), rather than via invasive and time-intensive 
surgical delivery (77). An ideal therapy should also exhibit high “translational potential”, 
meaning that it should fall under one of the following categories: 1) an already FDA-approved 
drug, or 2) a drug that has either undergone extensive evaluation for safety and efficacy in 
human clinical use or 3) exhibits high potential to be translated to human trials, based on 
preclinical studies (77). In this way, the time to translation “from bench to bedside” would be 
minimal, and years of delay before FDA approval could be avoided. 
 Riluzole is an anti-glutamatergic compound that is FDA-approved as an oral therapy for 
ALS. Currently, riluzole is under evaluation as an acute SCI intervention in a Phase I clinical 
trial through the North American Clinical Trials Network (NACTN) (87). The translation of 
riluzole to clinical trials was largely a result of preclinical evidence suggesting that it provides 
neuroprotection when delivered 15-30 minutes following injury (77, 78, 82), and was greatly 
facilitated by its status as an FDA-approved drug. However, subsequent experimental studies in 
clinically relevant animal models, in which the initial delivery of the drug was delayed to a 
more clinically realistic time point of 2 hours post-injury, reported that riluzole treatment did 
not provide any neurological or histological benefits (81). It is reasonable to conclude from 
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these findings that riluzole may exert therapeutic efficacy for SCI only if administered during a 
crucial window of efficacy very early after injury. Despite the lack of experimental data 
supporting any neuroprotective effect of riluzole when delivered at a more clinically relevant 
time frame following SCI, the current clinical trial seeks to evaluate the efficacy of riluzole in 
human SCI patients, with an initial therapeutic window extending up to 12 hours following 
injury (87). It is, then, plausible that this trial may fail to observe any significant neurological 
improvement in patients receiving riluzole several hours after SCI. 
 Based on our evidence that increased Pgp expression and activity during acute SCI results 
in reduced spinal cord bioavailability of systemically-delivered riluzole (See Chapters 3 & 4), 
we speculate that there is a time-dependent loss of efficacy of treatment due to Pgp up-
regulation within the injured spinal cord. This injury-induced mechanism could potentially 
explain the observation that riluzole’s efficacy diminishes as the therapeutic window is delayed 
(81). Moreover, this mechanism might also underlie the failure of neuroprotective drugs 
previously seen in SCI clinical trials. If this is the case, then identifying a route to overcoming 
Pgp-mediated drug resistance in the acutely-injured spinal cord is a therapeutic goal of high 
priority.  
 
Specific Aims 
1. Our results thus far have shown that: 1) Spinal cord riluzole bioavailability is decreased 
during the acute and sub-acute phases of SCI [See Chapter 3], and 2) Licofelone 
treatment enhances riluzole delivery to the injured spinal cord [See Chapter 4]. Because 
of the ability of licofelone treatment to enhance spinal cord riluzole delivery, we sought 
to examine whether, following SCI in rats, combined treatment of licofelone and 
riluzole would result in enhanced neurobehavioral outcome compared to riluzole 
treatment alone.  
2. Licofelone is a new generation anti-inflammatory drug that inhibits COX-1 and -2 as 
well as 5-LOX (159). Previous research studies have indicated that COX and 5-LOX 
pro-inflammatory signaling pathways both contribute to the pathophysiology of SCI, 
and that pharmacologically inhibiting either of these branches improves functional 
recovery in rodent models of SCI (121, 136, 142, 144). For these reasons, the potential 
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efficacy of NSAIDs for SCI treatment has been recently discussed (77). We speculated 
that licofelone may hold promise as a neuroprotective treatment for acute SCI based on 
two reasons. First, there is evidence that dual inhibition of both pathways has a 
synergistic anti-inflammatory effect, as COX inhibition can shunt AA to 5-LOX 
metabolism, thus increasing inflammation (153, 319). Second, licofelone use is 
associated with a lower incidence of GI complications in patients compared to classical 
COX inhibitors such as naproxen (320), thus making it a more attractive candidate for 
clinical use than classical NSAIDs. We therefore evaluated whether licofelone 
treatment following SCI in rats could improve functional recovery. 
 
Results 
Basso, Beattie, and Bresnahan Open Field Locomotor Scale 
 We assessed whether licofelone, alone or in combination with riluzole, could improve 
locomotor outcome in rats over a six-week period following SCI. In order to evaluate rodents’ 
neurological recovery following a clinically-relevant drug dosing schedule, we reproduced the 
time course of treatment utilized in the current NACTN riluzole SCI trial (87), in which 
riluzole treatment is initiated in patients ≤12 hours post-SCI, then continued for 14 days. 
Following SCI, rats were treated with: 1) vehicle (VEH), 2) riluzole (RLZ), 3) licofelone (LIC), 
or 4) licofelone and riluzole (LIC + RLZ), beginning at 3 hours following injury, then again 
once daily until post-injury day 14 (DPI 14). Beginning on DPI 1, motor recovery was assessed 
using the BBB Open Field Locomotor Scale, a sensitive assessments allowing quantification of 
multiple aspects of hindlimb motor function in rats (280). BBB scores were assessed on post-
operative days 1, 2, 3, 5, 7, 10, 14, 21, 28, 35, and 42. Average BBB scores for all treatment 
groups at each time point are displayed in tabular format in TABLE 5.1 and graphically in 
Figure 5.1.  
 Beginning on DPI 14, BBB scores of the SCI + LIC group and the SCI + LIC + RLZ group 
were significantly greater than those of the SCI + vehicle group. This effect was observed 
consistently at each time point from DPI 14 until the last measured time point, DPI 42. In 
contrast, the SCI + RLZ group scores were not significantly greater than the SCI + vehicle 
group scores at any point during this study. We also failed to detect any significant difference 
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   Baseline  Day 1  Day 2  Day 3  Day 5  Day 7 
Uninjured 
  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0 
VEH 
  21.0 ± 0.0  0.3 ± 0.1  1.3 ± 0.3  1.9 ± 0.3  4.5 ± 0.7  5.6 ± 0.9 
RLZ 
  21.0 ± 0.0  0.6 ± 0.1  1.8 ± 0.6  1.9 ± 0.7  4.6 ± 1.1  5.9 ± 1.1 
LIC 
  21.0 ± 0.0  0.9 ± 0.2  2.1 ± 0.7  4.8 ± 1.0  6.9 ± 0.6  7.8 ± 0.7 
RLZ + LIC 
  21.0 ± 0.0  0.7 ± 0.2  2.9 ± 0.7  3.6 ± 0.7  6.5 ± 0.6  7.9 ± 0.4 
 
                         
 
  
Day 10  Day 14  Day 21  Day 28  Day 35  Day 42 
Uninjured 
  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0  21.0 ± 0.0 
VEH 
  6.6 ± 0.8  7.8 ± 0.4  8.5 ± 0.3  8.8 ± 0.4  9.0 ± 0.3  9.1 ± 0.5 
RLZ 
  8.2 ± 0.7  9.3 ± 0.6  10.0 ± 0.7  10.2 ± 0.6  10.4 ± 0.6  10.4 ± 0.7 
LIC 
  9.3 ± 0.9  9.9 ± 0.9  10.7 ± 0.6  11.3 ± 0.6  11.6 ± 0.7  12.1 ± 0.7 
RLZ + LIC 
  9.0 ± 0.2  9.8 ± 0.2  10.2 ± 0.2  10.8 ± 0.3  11.4 ± 0.3  12.1 ± 0.4 
 
 
TABLE 5.1.  BBB open field locomotor scores. Average hindlimb BBB scores at time points before (baseline) and after injury. Uninjured, n 
= 17; SCI + Vehicle (VEH), n = 9; SCI + Riluzole (RLZ), n = 7; SCI + Licofelone (LIC), n = 9; SCI + Riluzole + Licofelone (RLZ + LIC), 
n = 10. All data are mean ± s.e.m. 
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Figure 5.1.  BBB scores. Average hindlimb BBB scores at time points before (Pre) and after injury. All data are mean ± s.e.m. *, p < 0.05 
versus injured, vehicle-treated animals. 
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between BBB scores of the licofelone-treated group and the licofelone-and-riluzole-treated 
group at any time point during this study.  
 
Photobeam Activity System 
 The PAS is a sensitive assessment of multiple measures of gross and fine locomotor 
activity. During the 20-minute testing period, animals’ movements were recorded by the PAS 
computer, and the following parameters were tabulated: distance traveled, speed of movement, 
time at rest, fine movement, ambulatory movement, number of rears, and time spent rearing. 
Each of these activity parameters reflects different aspects of locomotor function and/or ability. 
For example, an increased speed of movement and/or distance traveled by an animal indicates a 
heightened overall level of activity; conversely, increased time spent at rest might indicate a 
state of increased pain or a relative difficulty moving (321). Rearing, in which an animal stands 
up on its hindlimbs, utilizes not only hindlimb muscles but also trunk muscles for maintenance 
of posture. It has therefore been suggested that the extent of rearing by animals with SCI is a 
useful parameter for studying the effects of treatments on postural maintenance that may be 
relevant to human patients (322). 
 Distance, Speed, and Rest Time:  Total distance traveled by all animals over the 20-
minute testing period is displayed graphically in Figure 5.2.  All SCI groups covered a 
significantly lower distance versus uninjured controls (p < 0.05) at all time points following 
injury. Similarly, the speed of movement of all SCI groups was significantly reduced versus 
uninjured controls at all time points point-injury (Fig. 5.3), but there was no significant 
difference in speed between injured groups. Lastly, we examined the time spent resting during 
the 20-minute testing period (Fig. 5.4). We detected statistically significant increases in resting 
time compared to uninjured controls for the following comparisons: SCI + VEH at DPI 14, -35, 
and -42; SCI + RLZ + LIC at DPI 14; and RLZ at DPI 21. At DPI 42, time spent at rest by the 
SCI + LIC group was significantly lower than that of the SCI + VEH group. 
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Figure 5.2.  Total distance of movement. Total distance (cm) traveled by rats during the 20-
minute testing period. All data are mean ± s.e.m.  
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Figure 5.3.  Average speed of movement. Average speed (cm/s) of rats’ movement during the 
20-minute testing period. All data are mean ± s.e.m.  
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Figure 5.4.  Total time spent at rest. Average resting time (s) by rats during the 20-minute 
testing period. All data are mean ± s.e.m. *, p < 0.05 versus SCI + VEH. 
 
133 
 
 Fine and Ambulatory Movement:  Animals’ total fine movement over the 20-minute 
testing period is displayed in Figure 5.5a. The amount of fine movement observed in SCI 
groups was higher than that of uninjured controls at every assessed time point after injury, 
though statistical significance was only achieved for the following comparisons: SCI + VEH at 
DPI 21, -28, -35, and -42; SCI + RLZ at DPI 14 and -35; SCI + LIC at DPI 7, -21, -35, and -42; 
SCI + RLZ + LIC at DPI 7, -21, -35, and -42. There were no significant differences between 
injured groups at any time point. For ambulatory movement (Fig. 5.5b), all SCI groups 
exhibited significantly reductions versus uninjured controls at all time points post-injury.  
There were no treatment-dependent effects on ambulatory movement between SCI groups. 
 Rearing:  The total number of rearing events exhibited by each group is displayed in 
Figure 5.6a. At each time point from DPI 7 through DPI 35, total rearing events exhibited by 
each injured group are significantly lower than that of uninjured controls; however, at DPI 42 
only the SCI + VEH group is significantly lower than controls. At DPI 42, number of rearing 
events of the SCI + LIC + RLZ group was significantly higher than in the SCI + VEH group. 
Total time spent rearing is displayed in Figure 5.6b. Total rearing time is significantly reduced 
at DPI 7, -14, -21, and -28 for all SCI groups versus uninjured controls. At DPI 35, only SCI + 
RLZ + LIC exhibited significantly reduced rearing time versus controls, and there were no 
significant differences detected between groups at DPI 42.  
 Despite the wealth of activity data assessed here, we conclude that the only robust and 
significant result of this study was the improvement in BBB scores exhibited by both 
licofelone-treated groups from DPI 14 to -42. Though there were two significant effects of 
licofelone treatment on activity parameters at DPI 42 (Figs. 5.4 & 5.6a), it is doubtful that these 
slight improvements are functionally meaningful. In contrast, the more than three-point 
improvement in BBB scores that we have observed in licofelone-treated rats has a large degree 
of functional significance (See Chapter 6).  
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Figure 5.5.  Total fine and ambulatory movement. Total fine movement (a) and ambulatory 
movement (b) during the 20-minute testing period. All data are mean ± s.e.m.  
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Figure 5.6.  Total rearing events and time spent rearing. Total number of rearing events (a) 
and total time (s) spent in the rearing posture (b) during the 20-minute testing period. All data 
are mean ± s.e.m. *, p < 0.05 versus SCI + VEH. 
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CHAPTER 6 
Conclusions, Translational Significance, and Future Directions 
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Potential Roles for Other ABC Transporters in the Injured Spinal Cord 
 In the current study, we have shown that P-glycoprotein is only one among several ABC 
transporters that undergo differential expression following SCI. Our microarray results (TABLE 
3.1) indicate that several genes belonging to the ABC transporter family are also significantly 
increased or decreased within the spinal cord lesion site at 7 days after injury. Aside from 
abcb1, among the genes that we have found to be up-regulated by injury were abcb4 (+6.07-
fold, p < 0.001), abcb7 (+2.06-fold, p = 0.006), abcc3 (+2.14-fold, p < 0.001), and abcg1 
(+3.36-fold, p < 0.001). Of these, abcc3, the gene encoding Multidrug resistance-associated 
protein 3 (Mrp3), is the only member which has been described in the literature as exhibiting 
drug transport activity; thus, it is not implausible that increased expression of Mrp3 may also 
contribute to spinal cord drug resistance following traumatic SCI.  
 ABC transporter genes that were down-regulated following injury included abca5 (-2.59-
fold, p = 0.002), abcb6 (-1.71-fold, p < 0.001), abcb9 (-3.91-fold, p < 0.001), abcc2 (-13.92-
fold, p < 0.001), abcc6 (-3.44-fold, p = 0.008), abcc8 (-3.00-fold, p < 0.001), abcd2 (-5.54-fold, 
p < 0.001), abcd3 (-1.55-fold, p < 0.001), and abcg2 (-1.62-fold, p = 0.010). Of these, abcc2 
(mrp2) is of particular interest in terms of drug transport. The Mrp2 gene product is 
functionally similar to Pgp; it is expressed on the luminal membrane of brain capillary 
endothelial cells, where it transports a wide variety of compounds, including drugs susceptible 
to multidrug resistance as well as endogenous organic anions (9). Pgp and Mrp2 have some 
overlapping activity; for example, up-regulated Pgp functions in a compensatory role for anti-
epileptic drug transport in rats deficient in Mrp2 (323). To date, there have been no reports 
describing an affinity of Mrp2 for riluzole, so whether reduced activity of this transporter may 
influence riluzole disposition, e.g., in the current study, remains to be determined. 
 In contrast, the gene product of abcg2, Breast cancer resistance protein (Bcrp), was 
recently shown by Milane et al. to transport riluzole at the blood-brain barrier in mice (324). 
Though much less is known about the regulation of Bcrp expression compared to that of Pgp, 
this group also demonstrated that repeated riluzole treatment led to increased Bcrp efflux 
activity and decreased brain riluzole levels in mdr1a-/- mice (324), implying that Bcrp can be 
up-regulated at the blood-brain barrier by drug treatment. Here, we have shown that repeated 
riluzole treatment does not alter Pgp expression in the injured spinal cord, but we did not assess 
Bcrp levels. Therefore, we cannot rule out the possibility that enhanced Bcrp expression in the 
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spinal cord lesion site, following repeated riluzole treatment, may contribute to reduction of 
spinal cord riluzole levels. Interestingly, Milane and colleagues did not observe any differences 
in Bcrp expression or function in mice expressing the mutant human G86R SOD1 isoform 
(224), despite their observations of increased Pgp expression and activity in this model. This 
disparity suggests that the pathological mechanisms driving Pgp overexpression in neurological 
disease do not necessarily also regulate Bcrp expression in the same way. We have observed a 
1.62-fold decrease in abcg2 expression one week following injury within the spinal cord lesion 
site, compared to a 10-fold increase in abcb1 expression. Based on this data, it is obvious that 
the pathological processes within the injured spinal cord do not modulate expression of these 
two transporters in equal ways. It has recently been shown that Bcrp and Pgp act in concert to 
diminish drug delivery in brain cancer (325); thus, it is not inconceivable that a similar 
mechanism might be observed in SCI. Whether Bcrp and other drug transporters negatively 
influence spinal cord drug delivery following SCI remains an important question for future 
study. Active drug transport at the blood-brain/-spinal cord barriers is not entirely understood, 
as it is an extraordinarily complex system comprised of multiple, tightly regulated family 
members that often exhibit functional redundancy (182). Thus, the pathological consequences 
of SCI may very well include altered expression and activity of multiple drug transporters, with 
potential to alter the CNS disposition of a multitude of bioactive drugs. Future studies are 
needed to examine the roles of other drug transporter proteins in the injured spinal cord and the 
extent to which they might also contribute to multidrug resistance. 
 Given the broad functional diversity of the ABC transporter family members, it is 
conceivable that some of these proteins, which carry out biological functions other than drug 
transport, may function in roles that otherwise influence SCI pathology. The most dramatically 
up-regulated of the ABC transporter genes that we observed at 7 days post-SCI (apart from 
abcb1) was abcb4, which encodes Mdr2, a phosphatidylcholine transporter that plays a crucial 
role in the liver, transporting hepatic phospholipids into the bile. It is known that Mdr2 is 
expressed in the brain at low levels, but its function in the CNS is unknown (326). 
Additionally, abcg1, encoding the White1 transporter, is important for cholesterol homeostasis, 
suggesting possible implications for the regulation of myelination following SCI. The abcd2 
gene, which encodes the adrenoleukodystrophy-related protein (Aldrp), is expressed in 
peroxisomal membranes. Aldrp plays a vital function in the transport of very long-chain fatty 
acids (VLCFA) during normal fatty acid oxidation (326). In the metabolic disease 
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adrenoleukodystrophy (ALD), dysfunction of abcd1 and abcd2 results in accumulation of 
VLCFA, causing lipotoxicity-induced, demyelinating inflammation of the brain (299). 
Interestingly, it has recently been shown that this lipotoxic effect of VLCFA accumulation is 
mediated through 5-LOX activity and enhanced production of the pro-inflammatory CysLTs 
and LTB4 (327). Perhaps the substantial down-regulation of abcd2 observed here at 7 days 
post-SCI may impart a similar VLCFA-mediated lipotoxic effect via increased production of 
leukotrienes. These are only speculations, and there is a limit to the information that can be 
gleaned from a study of differential gene expression within such a complex pathophysiological 
system. Regardless, our array data may provide important clues into the multifaceted 
pathological response of ABC transporter family members to SCI, and serve as a useful starting 
point toward the design of further investigations of the potentially injurious (or 
neuroprotective) influences of these proteins within the injured spinal cord. 
  
P-glycoprotein Expression Patterns in the Injured Spinal Cord 
 We have shown that Pgp immunoreactivity in the uninjured spinal cord is restricted to 
blood capillary endothelial cells (Figs. 3.2, 3.3). This finding is consistent with the vast 
majority of previously published accounts (203). Only one group has repeatedly reported Pgp 
expression on the cell membranes of astrocyte end-foot processes (301-304). However, whether 
Pgp has a functional role in astrocytes or other cells in the brain parenchyma, under normal or 
disease conditions, is not known. We have not extensively examined cellular distribution of 
Pgp immunoreactivity following SCI in this study, but we did observe that Pgp expression 
remained localized to spinal cord vasculature at one week post-SCI (Fig. 3.4). Thus, it is 
reasonable to assume that our immunoblot quantification of Pgp levels is an accurate 
representation of Pgp expression in capillary EC membranes at the BSCB. 
 Here, we have reported increased Pgp expression within the spinal lesion site from as early 
as 72 hours post-injury, up to 10 months after injury (Fig. 3.8). Due to the practical limitations 
of these experimental studies, we have only assessed protein expression levels at four acute and 
chronic time points: 72 hours, 7 days, 4 months, and 10 months post-SCI. We have not 
examined earlier time points, so it is possible that Pgp up-regulation may occur even earlier 
than 72 hours within the injured spinal cord. Similarly, we have not examined Pgp expression 
at time points between one week and four months. During this substantial time window, the 
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BSCB is generally thought to regain most of its functional integrity; however, some reports 
have demonstrated prolonged BSCB permeability for months following injury (177, 189). In 
the context of the sparse and incomplete information that has been gained about BSCB function 
during the sub-acute and chronic phases of SCI, it will be interesting to see whether future 
investigations reveal a relationship between the temporal dynamics of BSCB leakiness and the 
expression patterns of selective transport systems such as Pgp. Characterizing the relationship 
between “passive” barrier dysfunction (e.g., loss of tight junctional integrity) and differential 
regulation of “active” barrier function (i.e., Pgp up-regulation) will increase our understanding 
of how changes in BSCB properties contribute to outcome following traumatic injury to the 
spinal cord. Certainly, further studies are warranted in order to gain a more complete 
understanding of the temporal regulation of expression of Pgp (and possibly other drug 
transporters) within the spinal cord lesion site. 
 Similarly, another question of high interest is whether the delayed increases in cervical and 
lumbar Pgp expression that we report here (Figs. 3.9, 3.10) mirror a progressive spatial spread 
of passive BSCB deficits. Previous studies in our laboratory have identified increased BSCB 
permeability to large molecules such as albumin and IgG that is detectable 1 cm rostral to the 
lesion site 1 month after contusion injury at T10, as far rostral as the brainstem by 8 months 
post-SCI, and as far caudal as the lumbar cord by 9 months post-SCI (unpublished data; 
experiments performed by Dr. Raymond Grill). Our laboratory has also shown that this 
progressive barrier dysfunction correlates with reduced vascular expression of the adherens 
junction protein, vascular endothelial (VE)-cadherin (unpublished data). Together, these 
observations provide compelling evidence for a temporal and spatial spread of passive BSCB 
dysfunction. In this study, we have detected increased Pgp expression in cervical (C6-C7) 
spinal cord tissue as early as one week after injury; this alteration appears to be sustained for as 
long as 10 months (Fig. 3.9). We have also made similar observations in lumbar spinal cord 
tissue at 4 and 10 months post-SCI (Fig. 3.10). We have not evaluated Pgp expression in other 
areas of the spinal cord or brainstem in this project, but we plan to investigate this possibility in 
future studies. If SCI is followed by a progressive spread of increased vascular Pgp expression, 
similar to the spread in passive BSCB dysfunction that we have previously observed, there may 
be important implications for drug delivery in the chronic phase of SCI. Further study is also 
needed to investigate whether the active and passive components of BSCB pathology are 
distinct, or whether they might be driven by common molecular mechanisms. If the latter is 
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true, simultaneously targeting both of these aspects of BSCB dysfunction by antagonizing a 
common signaling network may be a desirable therapeutic goal. 
 
Functional Significance of P-glycoprotein Up-regulation  
 P-glycoprotein is an incredibly promiscuous drug transporter with an affinity not only for 
endogenous substrates, but also for xenobiotic compounds. How—and why—Pgp has evolved 
to recognize such a large variety of substrates is an intriguing philosophical question. Some 
insight might be gained by examining the biochemical basis for the transporter’s ability to 
recognize such a large variety of structurally disparate compounds. Aller and colleagues (199) 
recently elucidated the crystal structure of Pgp in the presence and absence of bound substrate. 
They found that the transporter possesses a large substrate binding domain, which contains 
multiple hydrophobic, aromatic, and polar residues (Fig. 6.1). Unique subsets of these residues’ 
side chains make contact with different drug compounds within the binding pocket, thereby 
forming the basis for the protein’s substrate poly-specificity (199).  
  Most Pgp substrates are small and hydrophobic, and consequently exhibit an increased 
tendency to partition into the cell membrane (328). It is therefore easy to appreciate the 
evolutionary advantage gained by stationing such a highly promiscuous and efficient efflux 
system at a biological barrier that is susceptible to transcellular diffusion of potentially toxic 
molecules. These properties endow Pgp with an unparalleled ability to protect the various 
sensitive tissues at which it is expressed (e.g., the CNS (329), the testes (204), and even the 
developing fetus (205)) from exposure to harmful compounds in the blood. ABC transporters 
are ancient, and these proteins are expressed in organisms as distant from humans as bacteria. 
Each member of this very diverse family has some type of specialized active transport activity, 
but only the MDR (ABCB), MRP (ABCC), and BCRP (ABCG) family members confer 
multidrug resistance in humans. One perplexing philosophical question, therefore, is why Pgp 
evolved the ability to recognize such a large variety of synthetic drugs that do not occur in 
nature. It is difficult to speculate as to why Pgp evolved substrate poly-specificity before the 
advent of modern medicine. It is likely that Pgp originated from related ABC transporters that 
functioned in the transport of endogenous substrates (a function that Pgp also retains), and that  
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Figure 6.1.  Drug-binding residues of P-glycoprotein. QZ59-RRR and QZ59-SSS are two 
stereoisomers of cyclic hexapeptide inhibitors. (A) Crystal structures of drug-bound Pgp 
substrate binding pockets. Binding of each of these drugs, as well as the Pgp substrate drug 
verapamil, within the Pgp substrate binding domain involve associations with unique subsets of 
amino acid side chains (B) within the binding pocket. Figure from: Structure of P-
Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Stephen G. Aller, 
Jodie Yu, Andrew Ward, Yue Weng, Srinivas Chittaboina, Rupeng Zhuo, Patina M. Harrell, 
Yenphuong T. Trinh, Qinghai Zhang, Ina L. Urbatsch, and Geoffrey Chang. Science 27 March 
2009: 323 (5922), 1718-1722. Reprinted with permission (199). 
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at some point during evolutionary history, Pgp gained an increased substrate promiscuity that 
conferred the organism(s) expressing it with a biological advantage. This advantage lies in its 
ability to “adapt” its binding site to accommodate a diverse variety of substrates, thus providing 
barrier defense against new and previously unencountered substances. In this way, Pgp activity 
is analogous to that of the cytochrome P450 (CYP) class of enzymes, which perform oxidative 
breakdown of substances in a diverse range of organisms from bacteria to humans. There is an 
incredible range of CYP family members and isoforms, and like Pgp, they act on diverse 
substrates including a large number of synthetic xenobiotics. It is easy to understand the 
evolutionary advantage of enzymes with such labile binding sites in the context of 
detoxification of exogenous, potentially harmful substances. 
 It is these same qualities of Pgp, however, that often prevent therapeutic levels of blood-
borne drugs from reaching the CNS, unless such high doses are used that peripheral side effects 
may be experienced (182). Similarly, the up-regulation of Pgp expression following repeated 
drug treatment is probably a protective response that evolved in order to more efficiently 
protect the organism against a repetitive barrage of toxic insults. Others have shown that up-
regulation of Pgp can be driven by inflammation and oxidative stress—molecular processes 
that are principally associated with disease and injury. Pgp up-regulation might therefore serve 
as an endogenous protective response. In neurological disease and trauma, it is plausible that 
blood-brain/-spinal cord barrier up-regulation of Pgp could be spurred in part by passive 
deficits in blood-CNS barrier integrity. The resulting increase in extravasation of circulating 
substances through the barrier would lead to accumulation of toxic blood-borne compounds and 
endogenous metabolites; thus, an increase in efflux transport activity at the blood-CNS 
interface would function to protect the CNS tissue by contributing to clearance of toxic 
metabolites.  
 
Dual Modulation of the Blood-Spinal Cord Barrier by Anti-Inflammatory Therapy 
 It seems logical to assume that increased paracellular flow of substances from the 
circulating blood into the CNS would effectively increase delivery of systemic drugs to the 
CNS. Paradoxically, however, increased passive permeability of the blood-CNS barriers may 
not necessarily assure drug permeability, and in some cases may actually reduce brain drug 
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concentrations. Marchi and colleagues showed that osmotic blood-brain barrier disruption 
caused increased serum protein extravasation and reduced levels of free phenytoin (an anti-
epileptic drug) in the brain (330), an effect likely attributed to increased drug-protein binding. 
A similar effect may occur in SCI, where vasogenic edema resulting from BSCB opening may 
increase sequestration of drug molecules by extravasated albumin in the injured spinal cord 
tissue. If this is the case, it is possible that passive BSCB dysfunction, in addition to alterations 
in active transport, also contribute to reduced efficacy of systemically-delivered therapeutic 
drugs. 
 It is interesting to consider the possible contributions of inflammation to both passive and 
active aspects of BSCB function following traumatic injury to the spinal cord. Extensive work 
by Potschka and colleagues has implicated the COX-2/PGE2/EP1 signaling axis as key in 
driving Pgp overexpression at the blood-brain barrier following seizure activity (235, 236, 
244). In light of our observations that licofelone is effective in attenuating BSCB Pgp levels 
during acute SCI (Fig. 4.13), it is highly likely that similar regulatory mechanisms of Pgp 
expression are at work in both pathologies. This is not altogether surprising, as it is well known 
that neuroinflammation drives multiple pathophysiological mechanisms that contribute to the 
progression of CNS disease. It is well established that inflammation modulates opening of the 
blood-brain barrier (331); likewise, following SCI and peripheral nerve injury, inflammatory 
mediators promote BSCB permeability (72, 178, 332, 333). Thus, treatment with anti-
inflammatory drugs such as licofelone may serve a double purpose in improving BSCB 
function after SCI, by both preventing inflammation-driven up-regulation of drug efflux 
transport via Pgp, and attenuating inflammatory-mediated opening of the BSCB. Previous work 
by other groups has demonstrated that treatment with the COX inhibitors ibuprofen and 
indomethacin reduces edema and BSCB permeability following SCI (124, 127). Though we 
have not yet addressed whether licofelone treatment can also improve aspects of passive BSCB 
function, we intend to evaluate this possibility in future studies in our laboratory.  
 Previous reports have shown that the COX and 5-LOX signaling pathways are critical 
factors shaping the pathological molecular processes and influencing functional outcome 
during acute SCI (121, 142, 144, 246). It is these observations that have fueled our laboratory’s 
interest in simultaneous COX/5-LOX inhibition as a means not only to target Pgp up-
regulation, but also to combat other aspects of SCI pathophysiology and potentially improve 
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functional outcome. We have shown that licofelone completely abolishes the sharp increase in 
PGE2 production observed 24 hours after injury (Fig. 4.11). However, our failure to detect 
quantifiable levels of LTB4 is a caveat that undermines the argument for a therapeutic role for 
5-LOX inhibition in these studies. One possible explanation is that LTB4 production may only 
occur very early after injury, and fall to baseline (uninjured) levels by 24 hours after SCI. This 
possibility is supported by the work of Moreland and colleagues (141), in which peak LTB4 
production was observed within the first 4 hours post-SCI in rabbits and returned to control 
levels by 24 hours. An alternative approach would be to evaluate the effects of licofelone on 
CysLT production, given that we have previously observed a marked elevation in CysLT levels 
24 hours post-SCI (Fig. 4.1).  
 We have shown that acute licofelone treatment is efficacious in partially abrogating the up-
regulation of Pgp by SCI (Fig. 4.13), providing strong support for the inflammatory modulation 
of Pgp expression within the injured spinal cord. Potschka’s group have revealed COX-
mediated PGE2 signaling to be a major factor promoting Pgp expression in the epileptic brain 
(187), and more recently other groups have reported similar findings in cancer cells (238, 241, 
309). We have hypothesized the likelihood of a comparable regulatory mechanism in SCI, 
given the common pathological cascades (e.g., inflammation, oxidative stress, excitotoxicity) 
that are exhibited in these diseases. In the absence of a systematic study comparing Pgp levels 
following COX inhibition versus combined COX/5-LOX inhibition in spinal cord-injured rats, 
it is difficult to speculate whether licofelone treatment would be more efficacious than a COX 
inhibitor such as ibuprofen. It is also known that oxidative stress drives Pgp up-regulation in 
brain capillary ECs (334). We have shown that expression of all three enzymes—COX-1, 
COX-2, and 5-LOX—is increased 72 hours after injury (Fig. 4.2), so it is feasible that 
licofelone’s effect on Pgp expression at this time point is partially due to blocking the oxidative 
stress produced by COX- and 5-LOX- metabolism of AA. Certainly, more mechanistic studies 
are needed to investigate this possibility. 
 
Novel Evidence of Inflammation and Oxidative Stress in Chronic Spinal Cord Injury 
 Inflammation plays a major role in shaping the pathophysiology of acute SCI. During the 
hours-to-days following the initial impact to the spinal cord, the inflammatory response 
contributes to disruption of vascular integrity (72), formation of the glial scar (100), 
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cytotoxicity (98), and sensitization of neural pathways (30). In contrast, relatively few studies 
have undertaken the task of characterizing the molecular milieu of the spinal cord beyond one 
to two months post-injury. Recently, studies have reported the presence of infiltrating 
peripheral immune cells and activated microglia within the spinal cord up to 1 year post-SCI 
(69, 70). These findings raise the possibility that neuroinflammation might not simply be a 
transient phenomenon, but may rather continue into the chronic phase of injury, fueling 
ongoing pathological processes that plague SCI patients with long-standing injuries, such as 
neuropathic pain. 
 In the current study, we have provided novel evidence of both pro-inflammatory AA 
metabolism and oxidative stress within the chronically-injured spinal cord. The presence of 
LTB4 and PGE2 in the spinal cord lesion site 9 months after injury (Fig. 4.6) is compelling 
evidence that the inflammatory response is not simply a phenomenon confined to the earlier, 
acute phase of injury. Rather, our results have demonstrated that pro-inflammatory signaling 
through COX and 5-LOX pathways is also present in the chronically-injured spinal cord. 
Furthermore, using a high-throughput metabolomic screen (Figs. 4.7-4.9 & TABLE 4.1), we 
have shown that the chronically-injured spinal cord contains elevated levels of oxidative stress 
markers and a depletion of endogenous anti-oxidative and anti-inflammatory compounds. This 
included elevated levels of the major indicators of cellular ROS damage, oxidized glutathione 
(335), cysteine-glutathione disulfide (336), and dehydroascorbate (337). Chronic SCI tissue 
also possessed increased levels of 13-HODE and 9-HODE, markers of oxidative stress and 
lipid peroxidation (338). Additionally, chronically-injured spinal cords contained decreased 
levels of the antioxidant alpha-tocopherol, which plays an especially important role in 
protecting the highly sensitive CNS from pathological lipid peroxidation (339). These are 
significant findings, due to the existing deficiency in knowledge of the molecular environment 
within the chronically-injured spinal cord. Our observations of neuroinflammation and 
oxidative stress in the far chronic period will contribute to understanding of the pathological 
mechanisms that shape the myriad adverse conditions, including neuropathic pain, that are the 
hallmark of the chronic phase of SCI.  
 Ours is the first study featuring a metabolomic profile of chronically-injured spinal cord 
tissue. In this report, we have placed an emphasis on the metabolic alterations indicative of 
oxidative stress and inflammation in the cord, because of their previously identified role in 
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promoting up-regulation of P-glycoprotein (214). However, our metabolomic screen has 
illuminated a large number of additional metabolic alterations in various other biochemical 
pathways (Figs. 4.7, 4.8 & TABLE 4.1). Our metabolomic results reveal chronic alterations in 
nucleotide metabolism, reductions in levels of several metabolites associated with 
neurotransmission, decreased phospholipid levels, and alterations in cholesterol metabolism, 
among many other changes. We have also detected increases in glycolytic intermediates in the 
chronically injured spinal cord, such as glucose (+2.73 fold), glucose-6-phosphate (+2.53 fold), 
and fructose-6-phosphate (+2.29 fold). In view of our results of chronically increased Pgp 
expression, we anticipate that enhanced glycolysis in the chronically injured spinal cord may 
reflect an increased need for energy to fuel active transport systems, as has been previously 
described in multidrug-resistant tumors (340). Lending support to this idea, a recent metabolic 
profiling study has shown increased glycolysis and phospholipid turnover in drug resistant 
tumor cells (341). As a side note, the possible relationship between increased glycolytic flux 
and heightened active transporter activity may also be worth considering in another form of 
neurotrauma, traumatic brain injury (TBI), which is often accompanied by brain 
hyperglycolysis (342). Though Pgp-mediated drug resistance has not yet been characterized in 
TBI, injury-associated resistance to pharmacotherapy has previously been observed (343).  
 Our observations of chronic inflammation in the injured spinal cord also led us to 
investigate the effects of dual COX/5-LOX inhibition in the chronic phase of SCI. We observed 
that months-delayed licofelone treatment resulted in statistically significant increases in a 
number of compounds that exhibit anti-inflammatory and anti-oxidative properties (Fig. 4.10 & 
TABLE 4.2). However, the precise mechanism by which licofelone mediates this effect is 
unclear, as AA metabolism is a complex cascade with a plethora of molecular targets. Based on 
the wide range of metabolic pathways enhanced by licofelone, it is possible that licofelone may 
activate a “master regulator” of the antioxidant response such as nuclear factor erythroid-2-
related factor-2 (Nrf2), which induces transcription of multiple protective anti-oxidant genes 
(344). Due to experimental constraints, we did not evaluate the effect of licofelone treatment on 
prostaglandin and leukotriene production in the chronically-injured spinal cord. However, we 
intend to investigate this in future studies, as the eicosanoids have been shown to play a 
significant role in the development and maintenance of neuropathic pain (345, 346), a condition 
that afflicts a substantial percentage of individuals with chronic SCI (276).  
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Implications of P-glycoprotein-Mediated Drug Resistance in Spinal Cord Injury 
 One might anticipate that a lack of Pgp efflux activity at the BSCB would result in 
enhanced spinal cord drug delivery under normal (non-disease state) conditions. An interesting 
finding of this study is that uninjured mdr1a-/- rats did not exhibit greater spinal cord riluzole 
penetration compared to uninjured wild-type rats (Fig. 3.12). This is in contrast to Milane’s 
observation that mdr1a-/- mice showed 1.4-fold higher brain uptake of riluzole than mdr1a+/+ 
mice (225). The most logical explanation for this discrepancy is that the rat may possess some 
degree of compensatory riluzole efflux due to activity of other drug transporters, such as Bcrp. 
Further analysis will be needed to substantiate this possibility. Regardless, our observation that 
loss of Pgp is sufficient to abolish an injury-induced decrease in spinal cord riluzole uptake, is a 
very strong piece of evidence showing that Pgp is responsible for the reduction in blood-to-
spinal cord riluzole delivery that we have observed following SCI. 
 Also interesting is our finding that mdr1a-/- rats with SCI have significantly lower plasma 
levels of riluzole than their injured, wild-type counterparts (Fig. 3.13). Following i.p. drug 
delivery, clearance of drug from the plasma is regulated to a large extent by active transport-
mediated excretion of drug by the liver and kidneys into the bile and urine, respectively. 
Importantly, Pgp activity is involved in both of these aspects of drug clearance (347, 348). In 
the liver, Pgp transports drugs from the hepatocytes into the bile, and in renal epithelial cells 
the transporter acts in a similar role of drug transport to the urine. One might therefore expect 
healthy mdr1a-/- rats to exhibit reduced drug clearance from the plasma due to loss of hepatic 
and renal Pgp function. Our results show that this is not the case, and suggest that 
compensatory drug transport activity might also serve to explain the lack of significant 
difference in plasma drug levels between uninjured wild-type and knockout rats. However, the 
sizeable SCI-induced reduction in riluzole plasma levels of mdr1a-/- rats, but not wild-type rats, 
is somewhat puzzling. In their characterization of the mdr1a-/- rat, Chu et al. showed that these 
animals retain strong expression of what is presumably the Mdr1b gene product in the liver, but 
only faint expression in the kidney (Fig. 3.14) (307). Perhaps, then, this closely related isoform 
becomes up-regulated following SCI in the absence of Mdr1a function. Though the current 
study has not addressed Mdr1a/1b expression in the liver, kidneys, or intestines, Chu et al. also 
reported a five-fold increase in mdr1b expression in the liver, and a two-fold decrease of mdr1b 
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expression in the kidney of male mdr1a knockout rats, compared to wild-type animals9. Taken 
together with experimental evidence that Mdr1b efflux activity can increase in response to 
inflammation (245), it seems quite plausible that increased liver Mdr1b function may explain 
the augmented drug plasma clearance in mdr1a-/- rats with systemic inflammation resulting 
from SCI (31).  
 We chose riluzole for these studies because of the obvious clinical relevance of examining 
post-SCI drug resistance using a drug that is currently in clinical trials. However, studies in the 
mdr1a-/- rat are very likely complicated by our use of riluzole to measure Pgp activity, since 
this drug is also a substrate for the Bcrp efflux transporter. Hence, it is possible that 
compensatory Bcrp activity at the BSCB, intestines, liver, and kidneys of the mdr1a-/- rat may 
obfuscate the interpretation of these results to some degree. Chu et al. did not detect any change 
in abcg2 expression in the liver, kidneys, intestine, or brain of the male mdr1a-/- rat, though the 
reported expression patterns are those of healthy, uninjured rats (307). Areas of ongoing 
investigation in our laboratory will include the characterization of Mdr1b and Bcrp expression 
in the liver, kidney, intestine, and spinal cord of wild-type and mdr1a-/- rats in response to SCI. 
However, to determine the exact contribution of Pgp-mediated transport to the development of 
spinal cord drug resistance after SCI, future studies would necessitate the use of drugs that are 
“pure” Pgp substrates, such as the opioid-receptor antagonist loperamide.  
 Curiously, we have also observed a significant reduction in plasma riluzole levels 72 hours 
post-SCI in (wild-type) rats treated with licofelone in combination with riluzole, but not in rats 
treated with riluzole alone (Fig. 4.15). Despite this considerable drop in plasma drug levels, 
raw spinal cord concentrations of riluzole are not decreased. The net effect of these factors is a 
significantly higher normalized spinal cord riluzole bioavailability compared to riluzole-treated 
injured rats as well as uninjured controls (Fig. 4.14). This implies two actions of licofelone. 
First, licofelone enhances the plasma-to-spinal cord penetration of riluzole, presumably by 
partial attenuation of Pgp up-regulation (Fig. 4.13). Second, licofelone also enhances the 
plasma clearance of riluzole. How the latter might occur is a subject of speculation that might 
be better addressed by assessing expression patterns of efflux transporters (Pgp, Bcrp) in the 
                                                          
9
 The mdr1a knockout rats characterized by Chu et al. were Wistar Hannover rats and the mdr1a 
knockout rats utilized in the present study were Sprague Dawley. Thus, differences in genetic 
background could conceivably contribute to different pharmacokinetics between the strains used in our 
study and those used previously. 
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liver and kidneys of rats following SCI, with and without licofelone treatment. However, as 
there is no difference from control drug plasma levels in the injured, riluzole-alone group, it 
seems unlikely that the effect observed in the licofelone group would be due to licofelone’s 
modulatory effect on transporter-mediated excretion of riluzole. Perhaps instead, licofelone 
enhances drug metabolism in the liver, possibly through a CYP-mediated mechanism. 
Alternatively, it is possible that the high dose of licofelone (100 mg/kg) used in this study 
induces an up-regulation in liver enzymes underlying this observation. Whatever the 
mechanism, a reduction in plasma drug levels is an unexpected result of licofelone therapy that 
is counterproductive to the goal of this study—to enhance therapeutic delivery of drugs such as 
riluzole while achieving efficacy with lower doses. Hence, this is a very important question that 
will be addressed in future investigations in our laboratory. 
 
Licofelone as a Neuroprotective Agent 
 We have shown that treatment with licofelone, beginning at 3 hours post-injury and 
continued for two weeks, is sufficient to improve functional outcome following SCI. This 
conclusion is based on the improvement in BBB scores that we observed in rats treated with 
either licofelone alone, or both licofelone and riluzole, versus rats treated with vehicle alone 
(Fig. 5.1 & TABLE 5.1). We are confident that the improvement in BBB scores we have 
observed with licofelone treatment (3.0-point improvement in both licofelone-treated groups 
versus vehicle-treated group) is robust and meaningful, because of the conservative statistical 
analytic methods used to interpret the effects of treatment, as well as the functional significance 
corresponding to the observed behavioral improvements.  
 Dr. Stephen W. Scheff, a researcher at the University of Kentucky, has presented an 
argument for the use of appropriate statistics in analysis of BBB data, suggesting that 
parametric statistical analysis may often be appropriate (349). However, rather than promoting 
one specific analytical method over another, Scheff emphasizes that a cautious interpretation of 
BBB data, using a statistical comparison best suited to the distribution of data, as well as 
judicious choice of post hoc analysis, is crucial. After all, most studies utilizing an outcome of 
BBB locomotor scores are chiefly interested in assessing the efficacy of potential SCI 
treatments, and because of the researcher’s vested interest in identifying effective therapies, it 
is best to take a more cautious approach to data analysis. Scheff concludes his argument by 
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emphasizing that “investigators [should] choose to be more conservative in their choice of post 
hoc statistics in order that only those difference that are strongly revealed can be identified as 
appropriate avenues for further investigation in SCI experiments.” 
 We have therefore taken a conservative approach to statistical analysis of BBB data in this 
study and utilized the Kruskal-Wallis test for single time point comparisons of nonparametric 
data, followed by a Dunn’s post test to determine significant effects of treatment at each 
individual time point. We feel that a nonparametric analysis is generally more appropriate for 
cautious interpretation of BBB data. This is chiefly because the BBB locomotor rating scale is 
comprised of ordered (ranked) data, with no numerical values between individual scores, and 
with the improvement between points on the scale not being numerically equal (e.g., the 
functional difference between a 0 and a 2 is unequal to the functional difference between a 17 
and a 19). Importantly, our BBB data was not normally distributed in this study, making the 
choice of a nonparametric statistical test appropriate in this case.  
 It is important to remark on the significance of the extent of hindlimb functional 
improvement we have observed in licofelone-treated animals. At the end of this study, vehicle-
treated SCI rats exhibited an average BBB score of 9.1 ± 0.5 (mean ± s.e.m.). The distribution 
of individual animals’ scores on DPI 42 is displayed in Figure 6.2. Vehicle-treated rats were 
scored between 7 (n = 2) and 11 (n = 1), with the most frequent score being 10 (n = 3) on DPI 
42. A BBB score of 10 is characterized by occasional (≤50% of the time) weight supported 
plantar stepping, with no forelimb (FL)-hindlimb (HL) coordination (See APPENDIX B). These 
scores are consistent with those of previous studies. Other groups have reported similar time 
courses of locomotor recovery in vehicle-treated rats following the same moderate spinal 
contusion injury paradigm (parameters = 150 kdynes, 1 s dwell) (See Fig. 5.1) (350, 351). Of 
the vehicle-treated group, 4 of 8 exhibited any plantar stepping, and only one exhibited frequent 
(50-94% of the time) stepping10. Additionally, only one rat from this group showed any FL-HL 
coordination.  
                                                          
10
 There were originally nine rats in the SCI + vehicle group, but one of the rats died between DPI 35 
and -42, thus only eight animals were assessed on DPI 42. Similarly, one of the riluzole-treated rats died 
between DPI 35 and -42, thus DPI 42 scores reflect six animals in the riluzole group. 
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Figure 6.2.  Distribution of individual BBB scores on post-injury day 42. Data is presented 
as the number of animals in each treatment group receiving each score on day 42 post-injury. 
BBB scores represent an average rating for both hindlimbs of one subject. BBB scores 
associated with plantar stepping are contained within the gray shaded area; gradient shading 
indicates stepping frequency, with consistent plantar stepping beginning at 14. Blue shaded 
area illustrates the range of BBB scores associated with forelimb-hindlimb coordination; 
gradient shading indicates frequency of coordination, with consistent coordination beginning at 
14.  
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 Average BBB scores of riluzole-treated animals were slightly higher, and ranged between 
8 (n = 1) and 13 (n = 1). The most frequently observed DPI 42 score for this group was 11 (n = 
2), which corresponds to frequent (50-94%) to consistent (95-100% of the time) weight 
supported plantar stepping without coordination. Only one out of seven riluzole-treated rats 
achieved frequent coordination. The time course of locomotor recovery observed in our riluzole 
group is remarkably similar to that reported by Mu et al. (81), who treated with riluzole at 2 
and 4 hours after injury, then once daily for one week; at 42 DPI, the authors reported an 
average BBB score of about 12 for their riluzole-treated animals.  
 In contrast, rats treated with both licofelone and riluzole had noticeably higher DPI 42 
BBB scores, ranging from 10 (n = 1) to 14 (n = 2); rats treated with licofelone alone exhibited a 
greater range of locomotor function, ranging from 9.5 (n = 1) to 16 (n = 1). Importantly, 89% (8 
of 9) of the licofelone group, and 100% (10 of 10) of the licofelone + riluzole group exhibited 
plantar stepping. This is a clear functional advantage compared to 50% of the vehicle group, 
and 67% of the riluzole group, that displayed plantar stepping. Also notable is the proportion of 
animals per group that exhibited coordination (12.5% of vehicle, 50% of riluzole, 67% of 
licofelone, 80% of licofelone + riluzole). The only animals to exhibit both consistent stepping 
and consistent coordination in this study were animals that received licofelone. Furthermore, 
both licofelone-treated groups exhibited significantly improved BBB scores beginning at DPI 
14 (Fig. 5.1 & TABLE 5.1), and sustained throughout the end of the study. Because of these 
observations, we assert that licofelone treatment, both alone and in conjunction with riluzole, 
confers significant neuroprotection that is sustained well after discontinuation of treatment.  
 The vast majority of the animals at the end of this study fell within one of two categories: 
1) the period which Basso et al. termed the “intermediate recovery phase” (BBB score between 
8 and 12), defined as the period of functional recovery following SCI in which rats have 
established plantar placement of the hindpaws and display various levels of coordinated FL-HL 
movement; or 2) the “late recovery phase” (BBB score between 13 and 21), in which finer 
aspects of locomotor function, such as toe clearance, limited paw rotation during swing, and 
improved balance, are regained (280) (TABLE 6.1). Only two rats, both of which were in the 
vehicle-treated group, remained in the “early recovery phase”, scoring below 8 on DPI 42. 
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Treatment Group Early Recovery Phase (n) 
Intermediate 
Recovery Phase (n) 
Late Recovery 
Phase (n) 
Vehicle 25% (2) 75% (6) - 
Riluzole - 83% (5) 17% (1) 
Licofelone - 56% (5) 44% (4) 
Licofelone + Riluzole - 60% (6) 40% (4) 
TABLE 6.1.  Percentage of animals in each phase of recovery on DPI 42, by treatment 
group. Phases of recovery following SCI are defined in:  A Sensitive and Reliable Locomotor 
Rating Scale for Open Field Testing in Rats, D. Michele Basso, Michael S. Beattie, Jacqueline 
C. Bresnahan, Journal of Neurotrauma. February 1995: 1-21. (280) 
 
 Stepping and coordination are very important aspects of locomotor functional recovery in 
rat models of SCI. The region of the BBB scale pertaining to differences in stepping and 
coordination frequency is associated with functionally important milestones in the overall 
recovery of locomotor ability. For example, the three-point separation between a BBB score of 
9 (plantar placement with weight support in stance only or dorsal stepping, with no plantar 
stepping) and 12 (frequent to consistent plantar stepping and occasional FL-HL coordination) 
corresponds to a much more functionally significant improvement than, say, the difference 
between a score of 1 (slight movement of one or two joints) and 4 (slight movement of all three 
joints) (APPENDIX B). An animal with a BBB score of 9 can support its body weight, and, at 
best, may exhibit bouts of disjointed, uncoordinated dorsal stepping. In contrast, an animal with 
a BBB score of 12 possesses a higher degree of motor control, and shows substantially 
improved regulation of muscles and joints involved in the normal biomechanics of coordinated 
stepping. Thus, the improvements in BBB scores conferred by licofelone treatment at the end 
of this study are not only statistically significant, but moreover, are associated with 
physiologically important functional gains that dramatically enhance overall locomotor ability. 
Moreover, though we have limited our assessment to a 6-week period following injury, 
recovery of function in licofelone-treated animals did not appear to plateau by 6 weeks post-
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SCI. Thus, it is possible that the improvement in locomotor recovery conferred by licofelone 
treatment could continue beyond this time point, leading to an even better functional outcome. 
 In the current study, we have also utilized the photobeam activity system to evaluate 
additional measures of locomotor function and overall activity at multiple time points after 
injury. Among the parameters assessed by the PAS were distance and speed of locomotion, 
time spent resting, fine and ambulatory movement, and rearing. Rearing is thought to be a 
particularly useful indicator of clinically relevant physiological functions, like postural control, 
that are important for upright walking in human patients (322). Other readouts of the PAS (e.g., 
extent of ambulatory movement, total distance, speed, and rest time) reflect the ease with which 
an animal can freely move about. For example, increased distance and speed of movement 
during the testing period might be observed in an animal with better control of stepping and 
coordination compared to an animal with a lower level of locomotor control; the latter animal 
might expend more energy dragging its hindlimbs or compensating for uncoordinated, 
inefficient stepping, and spend more time resting to recover. However, factors such as 
increased time spent resting without any movement may also be attributed to various factors 
such as pain state (321), so activity data must be interpreted judiciously.  
 Though we analyzed multiple different aspects of overall activity in this study, we only 
detected two statistically significant effects of treatment on activity parameters. First, we 
observed that the licofelone-treated group spent significantly less time at rest than the vehicle-
treated group on DPI 42 (SCI + vehicle = 154 ± 22.6 s; SCI + licofelone = 51 ± 11.9 s, p < 
0.05) during the 20-minute testing period (Fig. 5.4). Though this effect was only significant on 
DPI 42, the total resting time of the licofelone group was consistently lowest and closest to that 
of uninjured controls compared to all other treatment groups from DPI 14 to -42. This 
observation may indicate that licofelone treatment enhances the ability to locomote, or the ease 
of locomotion, in rats recovering from SCI. Secondly, we observed that rats treated with both 
licofelone and riluzole exhibited significantly more rearing during the testing period than did 
injured, vehicle-treated rats (SCI + vehicle = 2.6 ± 1.5; SCI + licofelone = 6.4 ± 1.5, p < 0.05) 
(Fig. 5.6a). This may be indicative of improved muscle control in the trunk in rats treated with 
licofelone and riluzole, contributing to an enhanced ability to rear up on hindlimbs, a functional 
measure that may correlate to postural control in human SCI patients. Other than these two 
results, our PAS data did not reveal any statistically significant effects of treatment.  
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 Notably, we have failed to detect any significant improvements in locomotor function in 
riluzole-treated animals during this study. These results are consistent with previous findings, 
which did not detect any improvement in behavior in animals treated with riluzole beginning at 
2 hours post-SCI and continued for one week (81). In fact, the only studies reporting positive 
effects of riluzole treatment on functional outcome have utilized a treatment window of 15-30 
minutes post-SCI (77, 78, 82). Taken together, these results suggest that riluzole may exert 
therapeutic efficacy for SCI only if administered very early after injury. If this is the case, the 
lack of therapeutic efficacy at later treatment windows may be due to enhanced efflux transport, 
as we have reported in this study (See Chapters 3 & 4). However, it is also plausible that the 
dose of riluzole used in this study is simply inefficient to confer enough neuroprotection to 
translate into significant functional improvement. Despite the ability of licofelone to enhance 
blood-to-spinal cord delivery of riluzole (Fig. 4.14), we have detected no significant difference 
between locomotor scores of licofelone-treated and licofelone-and-riluzole-treated groups in 
this study. Thus, more systematic studies are needed to optimize factors such as dose and 
treatment schedule, in order to more thoroughly assess the therapeutic potential of combined 
treatment with licofelone and riluzole for acute SCI.  
 Several studies have reported neuroprotective efficacy of NSAIDs, when administered 
prior to experimental SCI (119, 123-128), at the time of injury (129-132, 135), or after a short 
delay period (e.g., 15 min post-SCI) (121). Unfortunately, there are very few published reports 
of improved behavioral outcome following a clinically relevant treatment window with COX 
inhibitors. Two recent studies have reported beneficial effects of delayed, sustained ibuprofen 
treatment for improving functional recovery in rats after SCI. Fu et al. (136) reported a ~2.0-
point increase in BBB scores, along with improved performance in other locomotor 
assessments, in rats treated with 60 mg/kg/d ibuprofen (osmotic pump) beginning at 7 days 
after spinal contusion injury and continuing for one month (SCI + vehicle ≈ 13.5, SCI + 
ibuprofen ≈ 15.5). Similarly, Wang and colleagues (352) reported increased BBB scores (SCI + 
vehicle ≈ 7.7, SCI + ibuprofen ≈ 9.4) in rats treated with 70 mg/kg/d ibuprofen (osmotic pump) 
beginning at 3 days post-SCI and continuing for one month. That both of these studies have 
reported statistically significant gains in locomotor function following a days-long delay in 
treatment with ibuprofen, is exciting. These findings suggest that a delayed window of efficacy 
may exist when targeting the pro-inflammatory COX arm of the secondary injury cascade 
following SCI. However, neither of these studies evaluated gastric mucosal erosion following 
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the extended course of ibuprofen treatment, despite the known deleterious GI side effects of 
long-term NSAID use. Because of the improved GI tolerance of licofelone (320), as well as the 
evidence showing that antagonism of 5-LOX signaling supports functional improvement in 
preclinical SCI studies (142, 144, 145), it would therefore be interesting to evaluate whether 
simultaneous COX/5-LOX inhibition would exhibit neuroprotective efficacy following delayed 
treatment similar to that used in the aforementioned ibuprofen studies.  
 Ultimately, it is difficult to compare our results to these two reports, as there are 
considerable differences in experimental design, type and severity of injury, and time course of 
treatment. However, the three-point improvement in BBB scores that we have observed with 
licofelone is a robust and significant finding that has never before been shown in experimental 
studies of anti-inflammatory therapies. We have used a clinically relevant SCI model, a spinal 
contusion/compression injury that approximates the type of human SCI most often observed in 
the clinic (4). Furthermore, we have demonstrated significant and sustained functional recovery 
following a clinically relevant delay in treatment (3 hours post-SCI) via the clinically relevant 
oral route with licofelone, a drug that has successfully passed Phase III clinical trials and is safe 
in humans. For these reasons, we conclude that licofelone exhibits high translational potential 
as a treatment to improve functional recovery following SCI.  
 The central question of how licofelone works within the spinal cord to supply this 
neuroprotective efficacy will be among the most important future areas of investigation. We 
have not yet examined histological outcome measures—such as lesion size, neuronal and glial 
cell counts, white matter tract sparing, extent of myelination, or BSCB structural alterations—
in the rats utilized for the current study. All of these parameters are important contributors to 
neurological outcome following SCI, and assessing them will be critical for developing a 
mechanistic model of how licofelone might confer enhanced functional outcome. Though 
licofelone has not been studied in published reports of neurological trauma, some insight as to 
the molecular basis for its neuroprotective properties might be gained from studies of rodent 
models of Huntington’s disease (162, 163). In these preclinical studies, licofelone treatment 
enhanced oxidative defenses and reduced levels of anti-inflammatory compounds in the brain, a 
finding similar to what we have observed in chronic SCI (Fig. 4.10 & TABLE 4.2). The authors 
also observed reduction in the size of chemically-induced striatal lesions with licofelone 
treatment, which corresponded to enhanced functional outcome. It is possible that the anti-
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inflammatory and anti-oxidative properties of this drug may exhibit a similar effect on the 
spinal cord lesion site in our model. Further studies are needed to evaluate this possibility and 
better characterize the biochemical and cellular changes within the injured spinal cord that 
result from licofelone treatment. 
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Overall Translational Significance of this Study 
 
I.  P-glycoprotein overexpression causes spinal cord drug resistance following SCI 
 There is currently no proven effective treatment for SCI, so the vast majority of SCI 
patients face a lifetime of paralysis, intractable pain, and other complications (263). We have 
identified an important pathophysiological mechanism arising early after SCI that imparts the 
spinal cord with resistance to a wide variety of drugs, thus establishing a major, previously 
unknown barrier to effective therapeutic intervention for SCI. This finding holds important 
implications not only for the acute delivery of neuroprotective drugs immediately after SCI, but 
also for the long-term clinical management of pain and muscle spasticity in chronic SCI 
patients. We propose that overcoming Pgp-mediated drug resistance, thereby enhancing spinal 
cord bioavailability of systemically-administered neuroprotective drugs after SCI, will provide 
a significant therapeutic advantage to patients who otherwise have very little hope for 
functional recovery. 
 The neuroprotective drug riluzole is currently being evaluated in a Phase I clinical trial as 
an intervention for SCI, with daily delivery for 14 days subsequent to injury (87). Our 
observations of increased Pgp expression and diminished spinal cord riluzole bioavailability 
during the acute phase of SCI strongly support the existence of Pgp-mediated drug resistance in 
the injured spinal cord. Importantly, we have shown that licofelone treatment can enhance 
blood-to-spinal cord delivery of riluzole during acute SCI. We anticipate that this finding has 
potential to develop into a new combinatorial treatment strategy to attenuate the expression of 
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post-SCI drug resistance and improve therapeutic efficacy for riluzole, as well as a variety of 
other neuroprotective drugs.  
 Based on the data obtained in this study, we propose a working model (Fig. 6.3) in which 
Pgp expression at the BSCB is up-regulated following traumatic SCI, resulting in a reduction in 
spinal cord bioavailability of systemically-delivered drugs that are Pgp substrates. Because of 
previously established mechanisms of Pgp up-regulation in other neurological disease models, 
we hypothesize that this process is driven by pro-inflammatory COX signaling. We have shown 
that acute treatment with the dual COX/5-LOX inhibitor licofelone is sufficient to both 
attenuate Pgp overexpression and enhance blood-to-spinal cord delivery of riluzole during the 
acute phase of SCI.  
 Importantly, this work has defined a new combinatorial mechanism with applications to 
human disease beyond SCI research. Pgp overexpression is a recognized obstacle to effective 
treatment of neurological diseases such as ALS (224) and epilepsy (222), as well as multiple 
types of cancer (353). The ability to target the molecular signaling pathways driving Pgp up-
regulation with licofelone is therefore a highly useful strategy with potential to impact any 
pathological condition in which Pgp activity reduces efficacy of drug treatment. 
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Figure 6.3.  Working model of P-glycoprotein-mediated drug resistance in the injured 
spinal cord. (a) Under normal conditions, Pgp is expressed on the luminal surface of 
endothelial cells lining blood vessels at the BSCB. Blood-borne drug molecules must diffuse 
through the endothelial cell in order to enter spinal cord tissue. However, the drug efflux 
transport activity of Pgp pumps drugs back into the bloodstream at a discrete rate, thus limiting 
spinal cord drug concentrations. (b) Following SCI, pro-inflammatory COX signaling within 
the damaged spinal cord tissue drives Pgp overexpression at the BSCB. This increased Pgp 
expression and drug transport activity results in diminished drug delivery to the spinal cord. 
Treating rats with the dual COX/5-LOX inhibitor licofelone after SCI attenuates spinal cord 
Pgp overexpression, thus enhancing spinal cord drug delivery and efficacy of treatment. 
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II.  Licofelone treatment promotes significant neurological recovery following SCI 
 Inflammation is a major factor involved in shaping outcome during the early, acute phase 
of traumatic SCI, and there is much evidence that pro-inflammatory COX and 5-LOX activity 
are key among the adverse pathological processes negatively affecting functional outcome 
following SCI. Antagonizing the COX-2 (119) or 5-LOX (142, 144) pathways independently 
has led to modest reductions in the pathological and behavioral deficits following SCI. 
However, the therapeutic potential of combined COX and 5-LOX inhibition to improve 
functional outcome following SCI has not previously been assessed. 
 We have shown that, in a clinically relevant model of spinal contusion/compression injury, 
oral licofelone treatment significantly and robustly improves hindlimb locomotor function in 
rats, starting from two weeks after injury. Furthermore, we have demonstrated that this 
functional improvement is sustained following cessation of treatment, for up to four weeks. We 
have utilized a clinically relevant delayed treatment window (beginning at 3 hours after injury), 
thus our findings display high translational potential for movement to clinical trials.  
 Furthermore, our findings indicate that licofelone is more effective as a neuroprotective 
intervention for acute SCI than riluzole, a drug which is currently undergoing clinical trials as a 
promising SCI intervention. Thus, licofelone holds great promise as a stand-alone therapeutic 
intervention to improve functional recovery following SCI. 
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APPENDIX B 
Basso, Beattie, and Bresnahan Open Field Locomotor Scale 
& 
Definition of Terms Used in the BBB Scale 
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THE 21-POINT BASSO, BEATTIE, BRESNAHAN LOCOMOTOR RATING SCALE 
AND OPERATIONAL DEFINITIONS OF CATEGORIES AND ATTRIBUTES 
0 No observable hind limb (HL) movement 
1 Slight movement of one or two joints, usually the hip and/or knee 
2 Extensive movement of one joint or extensive movement of one joint and slight movement 
of one other joint 
3 Extensive movement of two joints 
4 Slight movement of all three joints of the HL 
5 Slight movement of two joints and extensive movement of the third 
6 Extensive movement of two joints and slight movement of the third 
7 Extensive movement of all three joints of the HL 
8 Sweeping with no weight support or plantar placement of the paw with no weight support 
9 Plantar placement of the paw with weight support in stance only (i.e., when stationary) or 
occasional, frequent, or consistent weight supported dorsal stepping and no plantar 
stepping 
10 Occasional weight supported plantar steps, no forelimb (FL)-HL coordination 
11 Frequent to consistent weight supported plantar steps and no FL-HL coordination 
12 Frequent to consistent weight supported plantar steps and occasional FL-HL coordination 
13 Frequent to consistent weight supported plantar steps and frequent FL-HL coordination 
14 Consistent weight supported plantar steps, consistent FL-HL coordination; and 
predominant paw position during locomotion is rotated (internally or externally) when it 
makes initial contact with the surface as well as just before it is lifted off at the end of 
stance or frequent plantar stepping, consistent FL-HL coordination, and occasional dorsal 
stepping 
15 Consistent plantar stepping and consistent FL-HL coordination; and no toe clearance or 
occasional toe clearance during forward limb advancement; predominant paw position is 
parallel to the body at initial contact 
16 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe 
clearance occurs frequently during forward limb advancement; predominant paw position 
is parallel at initial contact and rotated at lift off 
17 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe 
clearance occurs frequently during forward limb advancement; predominant paw position 
is parallel at initial contact and lift off 
18 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe 
clearance occurs consistently during forward limb advancement; predominant paw position 
is parallel at initial contact and rotated at lift off 
19 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe 
clearance occurs consistently during forward limb advancement; predominant paw position 
is parallel at initial contact and lift off; and tail is down part or all of the time 
20 Consistent plantar stepping and consistent coordinated gait; consistent toe clearance; 
predominant paw position is parallel at initial contact and lift off; tail consistently up; and 
trunk instability 
21 Consistent plantar stepping and coordinated gait, consistent toe clearance, predominant 
paw position is parallel throughout stance, consistent trunk stability, tail consistently up 
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DEFINITIONS OF TERMS USED IN THE BBB LOCOMOTOR RATING SCALE 
Slight:   Partial joint movement through less than half the range of joint motion 
Extensive:  Movement through more than half of the range of motion 
Sweeping:  Rhythmic movement of HL in which all three joints are extended, then fully flex 
and extend again; animal is usually sidelying, the plantar surface of paw may or may not 
contact the ground; no weight support across the HL is evident 
No Weight Support:  No contraction of the extensor muscles of the HL during plantar 
placement of the paw; or no elevation of the hindquarter 
Weight Support:  Contraction of the extensor muscles of the HL during plantar placement of 
the paw, or elevation of the hindquarter 
Plantar Stepping:  The paw is in plantar contact with weight support then the HL is advanced 
forward and plantar contact with weight support is reestablished 
Dorsal Stepping:  Weight is supported through the dorsal surface of the paw at some point in 
the step cycle 
FL-HL Coordination:  For every FL step an HL step is taken and the HLs alternate 
Occasional:  Less than or equal to half; ≤50% 
Frequent:  More than half but not always; 51-94% 
Consistent:  Nearly always or always; 95-100% 
Trunk Instability:  Lateral weight shifts that cause waddling from side to side or a partial 
collapse of the trunk 
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